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Testicular cancer is a common tumour of younger men and although chemotherapy 
is effective, tumour-specific immune responses may be important. Previous work 
from our group demonstrated that patients have activated T cells in blood and 
functional responses to MAGE proteins.  
I analysed the phenotype, checkpoint expression and function of T cells within blood 
from patients with seminoma or non-seminomatous tumours. No differences in T cell 
subsets were seen compared to healthy donors but CD27- B cells were increased 
and CD16 was reduced on CD56Dim NK cells. A distinctive pattern of immune 
checkpoint expression was observed with increased expression of Tim-3, LAG-3 and 
CTLA-4. This suggests some degree of T cell exhaustion although functional 
analysis showed broad cytokine responses after mitogenic stimulation. However, 
small numbers of T cells that were spontaneously producing IL-17, IL-21 or IL-10 
were found, indicating baseline T cell stimulation. 
In order to investigate novel approaches to identify and isolate MAGE-specific T cells 
I utilized cytokine secretion. This showed that TNF-α production was the most 
sensitive assay and, combined with CD107a, identified strong MAGE responses in 
two donors. Using a matrix of peptide pools I was able to isolate and define a 
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CHAPTER I.  INTRODUCTION 
 
General introduction of Cancer and Testicular Cancer 
The Hallmarks of Cancer 
 
The WHO predicts that cancer will become the leading cause of death globally within 
the next few years (de Martel et al., 2020). Cancer arises from the development of 
transformed cells that develop a range of phenotypic properties (Cooper, 2000). 
These have been characterised by Pecorino (2012) as disturbed pattern of growth, 
survival in limited serum and anchorage independence.  
 
Fig. 1-1. The biological hallmarks of cancer.  
Adapted from Hanahan and Weinberg, 2017, Cancer Medicine 
In 2000, through fine analysis, Hanahan and Weinberg defined six hallmarks of most, 
if not all, cancers (Pecorino, 2012). They proposed that the essence of 
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carcinogenesis relied on the acquisition of several molecular characteristics. These 
were acquirement for growth signal autonomy, evasion of growth inhibition and cell 
death signals, unlimited replication, angiogenesis, and the properties of invasion and 
metastases (Hanahan & Weinberg, 2011). An update of these initial report was 
published in 2017 and included a range of additional properties such as deregulating 
cellular energetics and metabolism and avoiding immune destruction  (Hanahan et 
al., 2000). Notably, this included the evasion of host immune defences.  In this thesis 
I undertook an analysis of the immune response against testicular cancer, a disease 
for which the clinical outlook has improved dramatically in recent years and for which 
tumour-specific immune responses may play an important role.  
Testicular Germ Cell Tumours (TGCT)  
The incidence of testicular Cancer  
 
Testicular germ cell tumours (TGCT) are a relatively infrequent cases representing 
approximately 1% of worldwide malignancies in males. The clinical outlook has 
improved greatly in recent years such that these now represent only  0.1% of cancer 
mortality (Khan & Protheroe, 2007). The highest incidence rates are observed in 
Northern European countries with 12.2 cases per 100,000 men. In contrast, Asian 
and African males are less affected with only less than 0.7 cases found in 100,000 
men population. It seems that racial difference affects genetic susceptibility (Chia et 
al., 2010). Although small numbers of TGCT cases appeared to affect those elderly 
with ages around 80 years, this affected vast majority of those whose ages ranged 
from 25-35 years (Garner et al., 2005). Of note, despite the great clinical outlook, 
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the incidence of TGCT over time, especially in developed countries, and has doubled 
over the past 40 years (Oldenburg et al., 2013). 
Testicular cancer has a very high cure rate with 5-year survival rate was reported to 
reach over 96%  when treated at an early stage (Stage I) (Hayes-Lattin, 2009). 
Seminoma, in particular, was often reported to demonstrate the most excellent 
outlook with survival rate ranges from 97-100% when diagnosed at stage I (Albers 
et al., 2015).  
Classification of Testicular Germ Cell Tumours (TGCT)  
 
Germ cell tumours are a heterogenous group of neoplasms that develop primarily in 
the gonads. And to less frequent cases, they might also develop from specific 
extragonadal sites along the midline, the pineal gland, mediastinum, retropritoneum 
and sacrum (Reuter, 2005). The migration route of the primordial germ cells to the 
genital ridge is thought to be the main cause of such a particular distribution  (Pereda 
et al., 2006). In males, about 98% of all testicular neoplasms are testicular germ cell 
tumours (TGCT) (Ghazarian et al., 2015).  
It was not until 1946 that Friedmann and Moore proposed that TGCT can be 
classified into 4 categories namely seminoma (germinoma) and embryonal 
carcinomas, with the subgroups of choriocarcinoma, teratoma and teratocarcinoma 
(Mostofi, 1980; Pugh &Parkinson, 1981). Dixon and Moore (1952) refined this 





2) Embryonal carcinoma 
3) Teratoma 
4) Teratoma with embryonal carcinoma, choriocarcinoma, and sarcoma 
5) Choriocarcinoma 
This classification was further simplified by the World Health Organization (WHO) 
and this is most often used these days. According to the WHO 2016 version TGCT 
are divided into three major groups as detailed below (Table 1-1): 
Table 1-1. Main Histological Types of TGCT Based on WHO Classification 
Noninvasive germ cell neoplasia     
  
Germ cell neoplasia in situ (GCNIS; previously termed intratubular germ cell neoplasia 
unclassif ied, IGCNU) 
  Gonadoblastoma        
            
Germ cell tumours derived from GCNIS       
  Seminoma       
  Nonseminoma (non seminomatous germ cell tumours)   
    Embryonal carcinoma       
    Teratoma       
    Yolk Sac       
    Choriocarcinoma and other trophoblastic tumours   
            
Germ cell tumours unrelated to GCNIS       
  Childhood tumours       
    Teratoma (prepubertal type)       
    Yolk Sac tumour (prepubertal type)     
  Spermatocytic tumour (median of  diagnosis is about 50 years of  age)  




Seminoma and nonseminoma are by far the most common histological subtypes of 
TGCT (Bahrami et al., 2007a) and were the subject of my thesis. The relative 
incidence and histological appearances of these two subtypes are discussed and 
contrasted below. 
a) Seminoma 
1. Classical seminoma  
Classical seminoma affects males after their first decade of age and 
culminates between 35-45 years. This is the most common subtype of TGCT 
which contibutes to approximately 50% of TGCT cases (Meyts, et al., 2016) . 
Large proportion of seminoma is commonly found to constitute mixed TGCT. 
Less than 10% of patients showed extension pattern of seminoma to the 
spermatic cord or epididymis is observed and involvement and approximately 
2% of cases involved both testes (Albers et al., 2011) . 
 
2. Spermatocytic seminoma 
Spermatocytic seminoma arises exclusively in the testis.  It has no ovarian 
equivalent. This affects typically males in their 50-60 but younger patients with 
this subtype of TGCT were also observed (Pins, 2010). Unlike classical 
seminoma whose incidence contributes to around 50% of all TGCT cases, 
spermatocytic seminoma only account for 1-2% (Jha et al., 2018). The cell 
origin of spermatocytic seminoma appears to be more differentiated 
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compared to that of seminoma (Raiss et al., 2011), equipped with capability 
of spermatogenesis (Bostwick et al., 2006).  
b) Teratoma 
Teratoma tumours are histologically characterised by the presence of typically at 
least a germinal layer of endoderm, mesoderm and ectoderm. Those arise only from 
1 of the 3 germ layers are termed as monodermal teratoma (L. Cheng et al., 2017). 
Pure teratoma mostly affects children while adults tend to be affected by mixed 
teratoma. While pure teratoma only accounts for 2-3% of all TGCT cases, teratoma-
contained mixed TGCT represent almost 50% of the cases.  It is interesting to note 
that these tumours in prepubertal patients are typically diploid with, often, 
chromosome 12p loss, whereas in postpubertal patients the tumours are aneuploid 
and contain isochromosome 12p (Rescorla, 2012).  
 
c) Yolk sac carcinoma  
Yolk sac carcinoma is the most common TGCT in pediatric population which 
incidence represent approximately 80% of prepubertal TGCT with age of onset is at 
1.5 years in average and 17-40 years old in postpubertal (Bahrami et al., 2007b). 
While in prepubertal males this tumour is always seen as a pure yolk sac, in 
postpubertal this is admixed with other types of germ cell tumours. Yolk sac 
carcinoma differentiate from the embryonic yolk sac to allantois and end in the 





Choriocarcinoma often present more as clinical systemic symptoms rather than an 
abnormal terticular mass. This is an infrequent tumour although when it is admixed 
with other subsets of testicular tumours its incidence rises up to 10% of all TGCT 
cases.  Like majority types of TGCT, choriocarcinoma tends to affect younger male 
population (Bahrami et al., 2007b).  
 
e) Embryonal carcinoma, with or without teratomatous elements 
Embryonal carcinoma is a relatively common testicular germ cell tumour after 
puberty (Lanzkowsky, 2011). 10% are pure embryonal tumours, and a substantial 
number of tumours will have a mixed embryonal component (Dicken & Billmire, 
2012). 
The testis as an immune privileged site  
 
The concept of immune privilege is thought to reflect the observation that some 
organs such as brain and retina (Forrester & Xu, 2012) require protection from the 
immune surveillance to suppress immune-mediated tissue damage. In addition to 
brain and retina as immune privilege sites, the testis is also believed to be one of 
such site. An additional reason in support of this was the observation that no 
lymphatic drainage was found within the tissue. However, this thought was 
subsequently challenged by the discovery of afferent lymphatic vessels. To prevent 
immune cells from such entering through these afferent lymphatic vessels the testis 
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is anatomically surrounded by a specific zone called the blood-testis barrier (BTB) 
(Cheng & Mruk, 2012). The BTB lies between adjacent Sertoli cells in the 
seminiferous tubules. Furthermore, this compartmentalizes the tubules into an 
adluminal area, where meiosis, spermiogenesis and spermiation may take place, 
and basal compartments –where spermatogonial cell division followed by 
differentiation to preleptotene spermatocytes occur (Jiang et al., 2014). The BTB 
hence forms an immunological barrier that protects meiotic and postmeiotic cells 
from circulating blood and external insults (Kaur et al., 2014). 
The BTB is formed as a response toward gonadotropic stimulation and the presence 
of zygotene-pachytene primary spermatocytes in the pubertal period. This formation 
occurs during the process of spermatogenesis. The BTB is made up of cellular 
junctions such as adhesion junctions, tight junctions (TJs) and gap junctions (GJs). 
Interestingly, in men in whom the junctional proteins are impaired due to an inherited 
dysfunction the immune responses against meiotic and postmeiotic cells can ensue 
and this causes spermatogenetic failure and infertility (de Kretser et al., 2015).  
Cancer Antigens 
 
Proteins that act as antigens for tumour responses in T-cell immunity can be divided 
into four major groups, based on their expression profile. 
1) Differentiation antigens 
These proteins are expressed in tumour cells and also in those normal cells from 
which the tumour develops (Vigneron, 2015). For example, the term ‘melanoma 
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differentiation antigens’ (MDAs) defines proteins that are present in melanoma as 
well as melanocytes, from which this tumour develops (Davis et al., 2019). Of 
interest, many MDA proteins work to mediate melanin production and this is 
presumably a reflection of the most characteristic feature of this cell. MDA protein, 
such as gp100 (gp100209–217) or  tyrosinase (tyr369-377), often contain peptide epitopes 
recognized by T-cells (Overwijk & Restifo, 2000). 
2) Cancer/testis antigens 
The term Cancer/testis antigens (CTAg) describes a family of proteins whose role in 
tumour immunity reflects their pattern of expression (Yao et al., 2014). CTAg 
expression is observed in many different subtypes of malignant tumour but these 
proteins are largely not expressed in healthy somatic cells, except in testis and 
placenta (Fratta et al., 2011). Due to the immune privileged nature of germ cells it 
seems that the immune response does not gain access to sites of CTAg expression. 
This restricted pattern of expression, as well as the potential to reinforce immune 
responses when on somatic tissue, renders CTAg an ideal target for tumour 
immunotherapy (Song et al., 2012). 
CTAgs are expressed in many subtypes of tumours and serological responses 
against the antigens have been identified.  Results from screening of patients’ sera 
suggests that  they are highly antigenic. So far, More than 200 CTAgs have been 
molecularly charactized, including MAGE, NY-ESO-1, GAGE, AKAP3, SSX, and 
LAGE (Song, et al., 2016).  
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3) Overexpressed antigens 
These proteins are broadly expressed in the normal tisues as well as in tumours. 
However, their expressions in tumours are greatly elevated compared to that of 
normal tissues. They, hence, are capable of inducing immunological responses. 
Antigens such as sperm protein 17 (sp17) (Schutt et al., 2017), preferentially 
expressed antigen of melanoma (PRAME) (Hermes et al., 2016), squamous antigen-
rejecting tumour (SART-3), and p15 , which are greatly expressed in melanoma and 
various types of tumours are just few examples of overexpressed antigens that have 
been well-characterized (Gjerstorff et al., 2015).  
 
 4) Tumour-specific antigens 
Cancer arises due to acquisition of somatic mutations (Stratton et al., 2009). These 
mutations lead to coding changes in expressed proteins. When a novel peptide 
derived from these changed proteins coupled then presented by HLA molecules then 
these are termed neoantigens (Jiang et al., 2019). In melanoma, neoantigens such 
as β-catenin is described as a result of either point mutation or translocation-based 
gene fusions like that of the low-density lipid receptor with GDP L-fucose (Stratton 
et al., 2009) . 
Expression pattern and Biological function of Cancer/Testis Antigens 
 
The present study focused on the immune response to Cancer/Testis Antigens 
(CTAgs). As alluded to above, these antigens are tumour proteins whose expression 
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is highly restricted to germ cells and cancer cells. As such, they represent a valid 
protein target for immune therapy (Whitehurst, 2014).  
A classification of cancer has been made, based on the frequency of CTAg 
expression (Krishnadas et al., 2013) : 
1) CTAg-rich tumours which melanoma and ovarian cancer .  
2) CTAg-intermediate including breast cancer, bladder cancer, and 
prostate cancer 
3) CTAg-poor including colorectal cancer, and lymphoma/leukemia 
Unlike most auto-antigens, CTAgs are highly immunogenic (Caballero & Chen, 
2009). This has been widely attributed to the immune-privileged properties of the 
testis that arise from the fact that Sertoli cells restrict immune cell access into 
functional spermatozoa and seminal fluid (Kaur et al., 2014). At a physical level this 
is mediated by the BTB, whilst the molecular basis includes secretion of activin A, 
granzyme B, FAS ligands and transforming growth factor (TGF-β) (Meinhardt & 
Hedger, 2011). 
Immunological targeting of CTAgs would be expected to be minimally toxic to 
somatic tissue. Indeed, since CTAgs are normally expressed solely in immune 
privileged testicular tissue where human leukocyte antigen (HLA) class I molecules 
expression is also lacking, the immune response is not stimulated. In addition, the 
presence of the BTB in the testis may help them to stay protected from the exposure 
to the immune recognition mechanism (Mital et al., 2011).  
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Despite the fact that the number of studies regarding the expression of CTAgs in the 
thymus is relatively small, CTAgs-specific T cells appear to have the potential to 
underpin the robust nature of immune responses against CTAgs in cancer patients. 
The biological function of the CTAg proteins in tumour development remains poorly 
understood (Fratta et al., 2011). It is most probably that they play an essential role 
in cellular transformation and p53 function inhibition or chromatin organisation 
(Marcar, et al., 2010). MAGE A3 has been reported to play a role in cell cycle 
regulation. In addition its expression has been associated with impaired treatment 
outcomes following taxane-based chemotherapy for gastric cancer (Xie et al., 2016).  
In addition to the MAGE family, GAGE-7 has also been shown to have a role in 
cellular transformation (Fratta et al., 2011). GAGE-7C expression was thought to be 
causing cell resistance to FAS-mediated apoptosis (Caballero & Chen, 2009). 
Of note, multiple CTAgs may be expressed in a single tumours at various 
magnitudes. MAGE A-1, MAGE A-3, NY-ESO-1, SSX-2 and SSX-4 appear to be 
more frequently expressed compared to BAGE, GAGE-A1 and SCP-1. Genes within 
a single homologous family also show this pattern and this is characteristically seen 
for members of the SSX family (Scanlan et al., 2002). 
In the previous study from our laboratory, different MAGE-A proteins were seen to 
be able to stimulate T cells responses in patients with TGCT. Seminoma 
demonstrated the highest frequency of T cell responses against MAGE-A1 antigen-
whereas mixed germ cell tumours (mGCTs) directed their responses at the highest 
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frequency toward MAGE-A3 and MAGE-A4 antigens (Pearce et al., 2017). These 
findings led me to focus my research on immune responses to the MAGE A-1/3/4 
family of proteins. 
CTAg antigens as targets for Cancer Immunotherapy 
 
Fundamental research into the mechanisms of cancer immunology has improved 
markedly in recent years and has driven improvements in immunotherapy (Yang, 
2015). Although conventional therapies, such as chemotherapy and radiotherapy, 
are the most common initial approach these modalities alone are not sufficient for 
many patients (Marshall & Djamgoz, 2018). This is particularly true for disease that 
has relapsed or undergone metastasis. Cancer immunotherapy offers a range of 
novel opportunities for cancer treatment has holds the potential to provide systemic 
and long lasting disease control (D’Errico et al., 2017).  
Immunotherapy may be delivered in several different forms. Adoptive transfer of 
autologous cells that have been expanded in the laboratory has been utilised for 
many years and shown reasonable efficacy in disorders such as melanoma (Wu et 
al., 2012). The success of allogeneic stem cell transplantation for mediating graft 
versus leukaemia is also an example of immunological response against tumours. 
(Dickinson et al., 2017) 
Cancer immunotherapy employs the specificity and the strength of the immune 
system to treat cancer. With a general aim to develop long-lasting tumour-specific 
immunologic “memory” in patients, it allows the immune rejection over the tumour 
growth or re-growth to be a lifelong protection system (Locy et al., 2018).  The 
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molecular determination of the MAGE antigens by Boon and colleagues more than 
two decades ago was a major step forward in peptide-specific therapy (Boon et al., 
1997). Nevertheless, adoptive therapy with antigen-specific T cells is technically 
demanding and carries substantial financial cost (June, 2007). As such, vaccination 
approaches are also under investigation and DNA and peptide-based approaches 
have been widely used (Butler & Hirano, 2014).  
In order to obtain a comprehensive information about immunogenicity of cancer cells 
in vivo, peptide-specific T cells has been isolated from cancer patients. For instance, 
following in vitro sitmulation with the peptides, Melan-A specific T cells were 
demonstrable in 87% of melanoma patients compared to 56% of healthy donors and 
a higher frequency was also seen in the patient group (Parmiani et al., 2002). 
In my work I aimed to identify, and potentially isolate, cancer testis antigen -specific 
T cells, especially those from the MAGE family of proteins, from the blood of men 
with seminoma. The vaccination approach relies on the knowledge of relevant 
cancer-associated epitopes and as such this would provide new reagents for 
immunotherapy. 
So far, a range of either HLA-class I-restricted or HLA-class II-restricted CTAgs have 
been identified. However, immune responses are often weak in cancer patients. In 
the past decade a total of 44 clinical trials using MAGE-A have been undertaken 
(https://clinicaltrials.gov); 16 in phase I; 13 in phase I/II; 13 in phase II and 2 in phase 
III. Many of these studies use adjuvants in order to boost immune responses. More 
recently, T-cell receptor (TCR) transduced T-cells and expanded cytotoxic T 
lymphocytes (CTLs) have been exploited in six and two trials, respectively (Zajac et 
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al., 2017). This level of interest shows that MAGE proteins are considered to highly 
offer potential as a cancer-specific antigen for immunotherapy. This supports my 
thesis aims to characterise MAGE-A-specific T cells from the blood and tumour-
infiltrating lymphocytes (TILs) of patients with testicular cancer.   
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The Interaction of Cancer and Immune system: The Concept of Immune 
surveillance Against Tumours 
 
The concept that the immune system is capable of recognising and eliminating 
tumours in the absence of therapeutic intervention has existed for almost a century 
(Pardoll, 2015). Despite this, its validity has been hard to establish. As so little was 
known regarding the nature of cellular and molecular immune recognition of cancer, 
the concept was difficult to test experimentally. However, as the field of immunology 
has developed, this concept, often termed cancer immunosurveillance, has 
gradually been acquired (Ribatti, 2015).  
 




Dunn and Schreiber (Fig. 1-2) developed the concept of “cancer immunoediting” 
which encompassed three phases (Dunn et al., 2002): 
1. The Elimination phase where tumour cells are killed by NK, CD4+ and CD8+ 
cells 
2. The Equilibrium phase which corresponds to a balanced state between 
immune and tumour cells. Only when the immune system fails to combat the 
tumour cells can the third phase be reached 
3. The escape phase that concludes with the clinically detected tumours. 
Despite the potential utility of tumour immunosurveillance, it is clear that a huge 
number of tumours still develop in the presence of an apparently functional immune 
system (Swann & Smyth, 2007).  
In mice evidence for immunosurveillance has been derived from studies of specific 
gene deleted strains. However in humans there are still those that question the 
importance of the mechanism. Patients with immunodeficiency or acquired 
immunosuppression do display an excess of cancer but these are often related to 
viral infection and a substantial increase in the common subsets of epithelial tumours 
has been difficult to demonstrate (Dunn et al., 2002). 
The importance of immune surveillance can be applied to the study of seminomas. 
Tumour-infiltrating lymphocytes (TIL) are found abundantly in seminomas and are 
believed to be of prognostic significance (Hadrup et al., 2006). Indeed, it has been 
suggested that lymphocytes are able to recognize tumour-specific peptides 
presented by MHC class I on cancer cells (Comber & Philip, 2014).  A study of 
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tumour-infiltrating lymphocytes in seminoma was performed by Hadrup and 
colleagues in 2006 and indicated that specific functional T-cell responses were 
operative which further suggested that the inflammatory infiltrate was indeed 
involved in the immunological control of the tumour (Hadrup et al., 2006).  
Introduction to major cells of the Immune system 
NK Cells  
 
Although initially NK cells were recognized as effector lymphocytes encompassing 
cytolytic functions in the innate immunity, they are now defined as a population of 
cells with a wide repertoire of activating- and inhibiting-harboring receptors that are 
well-calibrated to make sure that, while the cells are active against viral infections as 
well as tumour development, they are tolerant of their host’s healthy cells (Boudreau 
& Hsu, 2018; Orr & Lanier, 2010). Some recent studies revealed that NK cells were 
capable of mounting a form of antigen-specific memory. They, thus, exert 
sophisticated function attributable to both innate and adaptive immunity (Vivier, et 
al., 2011). 
In human NK cells are characterized as CD3−CD56+ cells. They are present in many 
peripheral tissues, most notably liver and lung, and represent around 10% of 
peripheral blood mononuclear cells (PBMCs) (Lee et al., 2017). They develop from 
a common lymphoid progenitor in the bone marrow and differentiation progresses 
via several stages (Bozzano et al., 2017). A key feature of NK cells, that 
discriminates them from T cells, is that they do not express the RAG protein and 
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therefore cannot mediate somatic recombination of their antigen receptors (Paust et 
al., 2010). As such, all of their interactions have to be mediated by proteins that are 
encoded by germline-encoded molecules (Orr & Lanier, 2010). 
 
T- and B-Lymphocytes 
 
T and B lymphocytes are small cells (8–10 microns in diameter) and each has a 
large nucleus with dense hetero-chromatin. Both, therefore, are morphologically 
indistinguishable. When they become activated, once they encounter antigenic 
stimuli, they may enlarge their sizes to accommodate their increasing cytoplasm and 
organelle numbers (Cano & Lopera, 2013). T and B lymphocytes present TCR and 
BCR, respectively, on their surfaces for antigen recognition in different specificities. 
These receptors are encoded from genes that undergo DNA recombination that 
allows the generation of a considerable amount of diversity in their repertoire 
(Nemazee, 2000). 
Both B and T lymphocytes develop from bone marrow-derived cells. However, while 
B lymphocytes stay in the site for a further process--gene rearrangement, by which 
B cell repertoire can be generated, T lymphocytes migrate to the thymus where they 
undergo maturation (Zhao et al., 2012). The earliest thymic progenitor cells are 
phenotypically characterized as  CD4lowCD8−CD3− cells which pass through some 
stages of maturation through which they become CD3−CD4−CD8− and 
CD3lowCD4+CD8+ cells. They eventually differentiate into a fully mature T cells 
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phenotypically characterized as CD3highCD4+CD8− or 
CD3highCD4−CD8+ T lymphocytes (Roifman & Grunebaum, 2013). There is also a 
subset called γδ -T lymphocyte that is generated early in this process (Cano & 
Lopera, 2013). 
As alluded previously, B cell repertoire, as a result of gene rearrangement 
processes, generate a myriad diversity of immunoglobulin (Ig) genes. This leads to 
the creation of a huge population of B cells with a broad range of specificities for 
different antigens. Cells with certain specificity of antibody anti -self require 
inactivation or removal via receptor editing mechanisms (Martin et al., 2016). 
γδ- T cells 
 
Differ to conventional T cells that harbor α and β chains on their surface, a subgroup 
of them carry distinct T cell receptors termed γ and δ chains. They are defined as γδ 
T cells and initially described in 1987. They account for around 0.5%-5% of the total 
T lymphocyte repertoire. Despite their circulating number, which is much less than 
αβ-T cells, γδ-T cells are common as intra-epithelial lymphocytes within the gut 
(Zhao et al., 2018).  
γδ-T cells, unlike αβ-T cells, recognize antigens in a non-MHC restricted manner. 
They also capable of secreting cytokines abundantly following the antigen 
recognition (Raverdeau et al., 2019). Attentions toward their potential contributions 
in tumour immunity increase. Moreover, their promising roles in the clinical trials are 
now being applied for adoptive transfers into a broad types of cancers (Nussbaumer 
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& Koslowski, 2019). In general these  studies have demonstrated that γδ-T cell 




As a subset of innate-like T lymphocytes, mucosa-associated invariant T (MAIT) 
recognize MHC-related protein 1 (MR1)-restricted stimuli (Xiao & Cai, 2017). Their 
recognition pattern is somewhat uncertain but appears to be directed primarily 
towards bacterial antigen. These populations are often localized within mucosal 
surfaces (Sundström et al., 2019) and may also be localized within tumour tissue 
(Ling et al., 2016). The cells decrease in frequency with age (van der Geest et al., 
2018)  They are able to mediate both cytotoxic and cytokine responses but their 
potential role in the control or support of malignant transformation is currently 
unclear and needs furher investigation (Garner et al., 2018).  
Introduction of Antigen Processing and Presentation 
In order to be recognized by T cells proteins must be ‘presented’ to the immune 
system by antigen presenting cells (APC). Generally there are two major pathways 
by which antigens (Ags) may gain access to presentation and so initiate an adaptive 
immune system, namely the 1) exogenous (endocytic) pathway and 2) endogenous 





Fig. 1-3. Cross presentation pathways pathways (Embgenbroich & Burgdorf, 2018).  
. 
1) Exogenous (endocytic) pathway 
In the exogenous pathway of presentation, antigens that originated external to APC 
are phagocytosed or pinocytosed prior to endosomal degradation by resident 
proteases (Mantegazza et al., 2013). Successive compartments display decreasing 
levels of pH, ranging from 6.0-6.5 at early endosomal processing to 4.5-5.0 in 
lysosomes. Proteins are fragmented into peptides of 13-18 amino acids in length 




2) Endogenous (cytosolic) pathway 
Endogenous pathways is initiated when the antigen entering the cytosol is tagged 
by a tiny protein called ubiquitin (Cruz et al., 2017). This tagging leads the processing 
of the intact proteins to yield peptides that typically 8-13 amino acids long. The event 
occurs within the proteasome. The peptides are then transported to the endoplasmic 
reticulum (ER) through ATP-dependent proteins termed TAP1 and TAP2. Prior to 
binding to the peptides and the TAPs, the MHC class I molecules, calnexin and β2m 
form a macromolecular complex in the ER (Hewitt, 2003). Finally, MHC class I 
molecules loaded with peptide are transported to the cell surface (Blum et al., 2013). 
In addition to antigen processing mechanism elaborated above, Cross Presentation 
is a term describing an alternative pathway which is considered to be pivotal in 
tumour immunity. This pathway permits the presentation of exogenous proteins on 
HLA class I molecules, a process crucial for the generation of effector CD8+ T cell 
responses (Fehres et al., 2014). A proposed mechanism for cross presentation 
includes the exchange of exogenous peptides within an endosomal compartment 
which already loaded onto HLA-class I molecules in the Endoplasmic Reticulum 
(ER).  However, the mechanism allowing transfer of proteins into the cytosol, or the 
site at which peptides are loaded onto class I MHC molecules require further 
investigations (McDonnell et al., 2010). Cross presentation can only takes place 
within specialised subsets of dendritic cells termed conventional DC (cDC) (Joffre et 
al., 2012). Therefore, in the tumour antigen vaccination strategy, DCs are seen to be 
significant as a target (Robson et al., 2010). 
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Major Histocompatibility Complex (MHC)/Human Leukocyte Antigen (HLA) 
 
As indicated above, for immune recognition by T cells peptides must be presented 
on the cell surface by the MHC (mice) or HLA (human) complex.  The HLA complex 
is located on chromosome 6 and contains many genes associated with immune 
regulation. In relation to this thesis, the most notable are the three HLA Class I genes 
(HLA-A, B and C) which present peptides to CD8+ T cells, and the three HLA Class 
II genes (HLA-DR, DQ and DP) which present peptides to CD4+ cells. The HLA 
complex is highly polymorphic and this is thought to have arisen from evolutionary 
selection for protection against infectious disease.  
HLA Class I (HLA-I) antigens are integral membrane glycoproteins that are present 
on virtually all cells. These molecules bind degraded endogenous proteins and 
present them to T cell receptor (TCR) on CD8 T cells (Cruz-Tapias et al., 2013). It is 
important to note that many human tumours express greatly reduced levels of HLA 
protein at the cell surface. This may be apparent in the expression of individual 
alleles or in the global expression of HLA class I or class II at the cell surface. These 
observations have led to speculation that progression of malignant disease could 
result from the lack/loss of recognition by CTL, allowing tumour to escape immune 







Identification of tumour-specific T cell responses in vitro using overlapping 
peptides stimulation 
 
The most commonly used approach to study antigen-specific T cells responses in 
vitro is through the application of ex vivo stimulation with relevant protein or a panel 
of overlapping synthetic peptides (Jiang et al., 2006). The former approach offers an 
advantage as it does not require a priori knowledge regarding the specific 
immunodominant epitopes in the immunogen. Using this approach, detection of 
antigen-specific T cell responses irrespective of HLA types is also possible 
(Zandvliet et al., 2010). On the other hand, since the whole protein needs to be 
internalized and processed prior to presentation on HLA molecules, this technique 
ideally requires fresh specimens and is much more effective for analysis of CD4+ 
responses. The advantage of peptide screening is that it may be pursued using 
cryopreserved samples and is very effective at eliciting CD8+ T cell responses (Jiang 
et al., 2006).  
The use of overlapping synthetic peptides (OSP) appears to be overcoming the 
drawback in the use of whole proteins. They have been widely employed to bypass 
the constraints in the requirement for degradation of intact exogenous protein 
(Maecker et al., 2001). OSP is a sensitive approach and has been broadly applied 
to elicit robust peptide-specific responses against immunodominant and 
subdominant epitopes ( Jiang et al., 2006). 
An adaptation of the OSP application is the use of overlapping long peptides that 
have been demonstrated to enable detection of weak peptide-specific responses, 
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such as against E6 and E7 from HPV. These peptides are, indeed, particularly 
effective as immunogens. They are, therefore, capable of inducing an immune 
responses in rabbits as indicated by a reduction in papillomavirus-induced lesions 
as well as suppressing the number of sites following a latent cottontail rabbit 
papilloma virus (CRPV) infection (Vambutas et al., 2005).  
Within my thesis I focussed on the use of overlapping peptides, and specific defined 
single epitope peptides, to assess the immune response against cancer testis 
antigens. This approach was taken as no MAGE proteins were available for study 
and the OLP approach offers potentially greater sensitivity and ease of use.   
Moreover, this allowed me to assess the response of both CD4+ and CD8+ T cells, 
simultaneously.  
Cytokine release as a readout for T cell functionality  
 
Intracellular cytokine analysis is commonly used as a method for detection of 
antigen-specific T cells and NK cell responses (Smith et al., 2015). IFN-γ, TNF-α, IL-
2 and GM-CSF are the common cytokines detected in these assay. 
Acting as a predominant pro-inflammatory cyokine, IFN-γ is produced by Th1 cells 
and  mature NK cells. Indeed, NK cells harbor epigenetic marks that mediate 
chromatin opening at the IFNG locus and can facilitate rapid cytokine production as 
required (Stetson et al., 2003; Mah & Cooper, 2016). NK cell activation is initiated 
by immunoreceptor tyrosine-based activating receptor motifs (ITAMs) that 
phosphorylate Src family tyrosine kinases, with subsequent activation of MAPK. 
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Ultimately transcriptional activity is altered through influence on transcription factors 
such as Fos and Jun (Schoenborn & Wilson, 2007).  
The cytokine production by previously differentiated Th1 CD4+ and CTLs cells can 
also mediated by cytokines such as IL-12 and IL-18 (Nakanishi, 2018). Specifically 
to the Th1 CD4+ T cells, the cells do not only produce IFN-γ but are also induced to 
do so in part by IFN-γ itself (Yang et al., 1999). It was reported that, in vitro, treatment 
of Th1-differentiated CD4+ T cells with the combination of IL-12 and IL-18 capable 
of eliciting IFN-γ even without prior TCR activation by antigen or antibodies against 
CD3. This suggested that cytokine-mediated T cell activation can occur without 
engagement of the T cell receptor (Munk et al., 2011).  
In the context of tumour, IFN-γ is seen as the main cytokine which functions most 
effectively to thwart the tumour growth. It, henceforward, is categorized as a pro-
inflammatory cytokine. Once the cytokine is secreted, it signals antigen-presenting 
cells (APCs) activation (Ivashkiv, 2018). Activated APCs, in turn, upregulate the 
expressions of co-stimulatory molecule CD86, IL-12 and IL18, that together promote 
Th1 differentiation. As well as activating effector cells, IFN-γ can further promote 
inflammation by suppressing the activity of T regulatory cells and other cells within 
the myeloid lineage (Kammertoens et al., 2017; Deligne et al., 2015). This will lead 
to the tumour destruction. It is now clear that indeed the presence of IFN-γ triggers 
a variety of signals by which T cells can function effectively whereas when IFN-γ 
signalling pathway is dampened the T cells’ function is diminish. This allows tumour 
growth into a persistence level (Ni & Lu, 2018). 
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In addition to IFN-γ, TNF-α is an additional strong pro-inflammatory cytokine that 
mediates its activity through the TNFR-1 and TNFR-2 receptors. TNFR-1 is 
expressed on all cell types, and possesses a death domain (DD), whereas TNFR-2 
is expressed mainly confined on immune cells and interesting has a much higher 
affinity for TNF (Yang et al., 2018). The DD mediates some of the physiological 
outcomes from which TNFR-1 and TNFR-2 can be distinguished. Downstream 
signaling via TNFR engages a range of intracellular receptors including SODD, 
TRADD, RIP and FADD (van Horssen, 2006).  
IL-2 (interleukin-2) is a key cytokine in T cell development, activation and regulation  
(Ross & Cantrell, 2018). It is made by T cells on activation and human cells also then 
express  the IL-2 receptor (CD25) such that it can mediate a paracrine effect. Three 
IL-2 receptor subunits have been identified (IL-2Rα, IL-2Rβ and IL-2Rγc) and 
together these subunits form an trimeric complex called IL-2Rαβγ with a high affinity 
(Malek & Castro, 2010). Interestingly, a transduction signal can also be trigerred 
when IL-2 binds the IL-2Rβγ receptor which occurs at an intermediate affinity (Kd- 
10-9 M) whilst  a lower affinity  of Kd- 10-8 M is observed when IL-2 binds IL-2Rα but 
this does not generate transduction signals (Jiang et al., 2016). The Janus family 
tyrosine kinase members JAK1 and JAK3 are recruited to the cytoplasmic domains 
of the IL-2R molecules and this leads to phosphorylation of the STAT family, most 
notably 1, 3 and 5. Phosphoinositide 3-kinase and MAPK-signalling pathways are 
also initiated (Jiang et al., 2016).  
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Granulocyte-macrophage colony-stimulating factor (GM-CSF) was initially 
recognized in mice through its capability of stimulating proliferation of bone marrow 
cells in vitro with specific expansion of granulocyte and macrophages colonies 
(Burgess et al., 1976). GM-CSF shows a heavy glycosylation pattern cytokine and 
stimulates progenitor cells in a concentration-dependent fashion (Ganguly et al., 
2007). 
Cytotoxicity assay   
 
Another important T cells function is cytotoxic degranulation. Cytotoxic T 
lymphocytes (CTLs) kill virally-infected or transformed cells through exocytosis of 
secretory granules or engagement of death receptors on the surface of the target 
cell (Trapani & Smyth, 2002). Cytotoxic granules carry diverse perforin and 
granzymes. The activation of perforin is initiated by the polimerization of perforin 
monomers on phospholipid membranes in a calcium-dependent manner 
(Voskoboinik et al., 2005) to form a pore that allow entry of granzymes (Janeway, et 
al., 2001) . Granzymes are serine proteases capable of inducing apoptosis in the 
target cell. Blockade of perforin function causes remarkably weakened cellular 
cytotoxicity. The sequential elimination of several target cells (‘serial killing’) is a 
feature of CTLs (Trapani & Smyth, 2002).  
The expression of CD107a (also known as Lysosome-associated membrane 
proteins-1/ LAMP-1) is seen on the cell membrane during cytotoxicity (Krzewski et 
al., 2013). This has been widely exploited by scientists as a sensitive assay to 
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assess cytotoxic activity (Betts et al., 2003) and I added CD107a into our flow 
cytometry assay to evaluate the magnification of degranulation occurred following 
antigen stimulation.  
Aims for my Thesis 
 
Given (1) the defined importance of cancer testis antigens in the immunotherapy of 
cancer, (2) their expression in testicular cancer and (3) the excellent clinical 
outcomes for this condition with modern therapy, I was interested to assess the 
immune response to cancer testis antigens in men with this tumour. This was the 
primary aim of my thesis.  
The objectives of my work were to: 
- Study the profile of T cell subsets in patients with testicular cancer 
- Assess the range of immune checkpoint expression on T cells in patients with 
testicular cancer 
- Determine if the pattern of cytokine production was modulated in this disease 
- Interrogate the immune response to CTAG proteins and attempt to identify 




CHAPTER II. MATERIALS AND METHODS 
 
Blood samples from Testicular Germ Cell Tumour (TGCT) patients and healthy 
controls 
 
Up to 36 ml of heparinised whole blood and 6 ml of clotted blood were obtained from 
TGCT patients (n=57) attending routine appointments at the cancer outpatient clinic 
at the Queen Elizabeth Hospital, Birmingham. The bloods were collected prior to 
chemotherapy treatment. Written informed consent and local ethical committee 
approval (South Birmingham research ethics committee LREC reference 
09/H1207/161) were obtained prior to sample collection.  Patients recruited in the 
study were previously confirmed to be HIV-, HBV-, and HCV- free with ages were 18 
years old or over and competent to provide full written, informed consent. The ages 
of recruited patients ranged from 20-69 years with an average age of 41 years (± SD 
12.75). The majority were at localized stages (I-II) where distant metastases were 
not observed. Follow-up blood samples were collected where possible.  A summary 
of patient and histopathological subtype of tumour is given in Table 3-1. Heparinised 
peripheral blood samples from healthy donors (n=16) were used as controls. 
 
Cell culture media and Buffer recipes  
Growth Media (GM) / LCL media  
RPMI 1640, 100 U/ml Penicillin, 100 µg/ml Streptomycin, 2 mM Glutamine, 
10% Foetal Calf Serum 
Wash buffer 




Freezing Media (FM) 
90% Foetal Calf Serum, 10% DMSO 
MACS buffer 
1 x PBS, 2% FCS, 2mM EDTA 
CSA media 
RPMI-1640, 10% FCS, 100 U/ml Penicillin, 100 µg/ml Streptomycin, 1µg/ml 
Cyclosporin A  
PBS-T 
1 x PBS, 0.05% Tween-20 
 
PBMC Isolation from Peripheral Whole Blood 
 
PBMCs were isolated from heparinised whole blood under sterile conditions by 
density gradient centrifugation. Whole blood was diluted in wash media at a ratio 
1:1. The diluted blood was layered at a ratio of 2:1 over Lymphoprep and centrifuged 
at 790xg at room temperature for 25 minutes (brake off). The lymphocyte layer was 
carefully removed with a transfer pipette into fresh RPMI media and centrifuged at 
400xg for 10 minutes at room temperature (brake on). The pellet was resuspended 
in fresh GM media, an aliquot removed for counting and the cells centrifuged at 
350xg for 5 minutes at room temperature (brake on). Cells were either used fresh or 
cryopreserved in Freezing Media for future use. 
Flow cytometry - Checkpoint panel 
 
First step was to stain the dead cells with 500 µl ef-506-Fixable Viability Dye at 4ºC 
for 30 minutes. The PBMCs were washed once with cold MACS buffer and 
centrifuged at 400xg for 5 minutes. Cell pellets were resuspended in residual 
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volume, stained with 5ul FcR block for 10 minutes on ice followed by surface staining 
with antibody cocktail (Table 2-1) for 30 minutes on ice. Cells were washed twice 
with 3 ml MACS buffer and centrifugated at 400xg for 5 minutes. Supernatant was 
discarded and cell pellet was resuspended with 200 µl for flow cytometric analysis.   
 
Table 2-1. Checkpoint Panel antibody details  
Antibody anti 
human- 
Fluorochrome Clone Manufacturer Volume/
reaction 
(µl) 
CD45 Alexa Fluor ®700 2D1 Biolegend 2.5  
CD4 APC/Fire™750 RPA-T4 Biolegend 3.5 
CD8 PerCP/Cy5.5 SK1 Biolegend 3 
CD3 FITC UCHT1 Biolegend 5 
PD-1 (CD279) Brilliant Violet 421™ EH12.2H7 Biolegend 4 
Tim-3 (CD366) PE F38-2E2 Biolegend 5 
CD223 (LAG3) PE/Cy7 11C3C65 Biolegend 5 
CD152 (CTLA-4) PE/Dazzle™594 BNI3/L3D10 Biolegend 5 
TIGIT (VSTM3) APC A1513G Biolegend 5 
Fc Blocking Solution   Biolegend 5 
Total volume    43 
 
Flow cytometry – Immune cell phenotyping panel 
 
First step was to stain the dead cells with 500 µl ef-506-Fixable Viability Dye at 4ºC 
for 30 minutes. The PBMCs were washed once with cold MACS buffer and 
centrifuged at 400xg for 5 minutes. Cell pellets were resuspended in residual 
volume, stained with 5ul FcR block for 10 minutes on ice followed by surface staining 
with antibody cocktail (Table 2-2) for 30 minutes on ice. Cells were washed twice 
with 3 ml MACS buffer and centrifugated at 400xg for 5 minutes. Supernatant was 
discarded and cell pellet was resuspended with 200 µl for flow cytometric analysis. 
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Flow cytometry was done on a BD LSR II machine and analysed using Kaluza 
software ®.   
Table 2-2. Immune Cell Population antibody panel 
Antibody anti 
human- 
Fluorochrome Clone Manufacturer Volume/
reaction 
(µl) 
CD45 Alexa Fluor ®700 2D1 Biolegend 2.5  
CD3 FITC UCHT1 Biolegend 5 
TCR Vα7.2 PE 3C10 Biolegend 4 
CD16 PerCP/Cy5.5 3G8 Biolegend 5 
CD56 (NCAM) PE/Cy7 5.1H11 Biolegend 5 
CD27 Brilliant Violet 421™ O323 Biolegend 4 
CD161 APC/Fire™750 HP-3G10 Biolegend 5 
CD19 PE/Dazzle™594  Biolegend 5 
γδ TR APC B1 Biolegend 5 
Fc Blocking Solution   Biolegend 5 
Total volume    45.5 
 
PMA/Ionomycin stimulation of PBMC from healthy donors and testicular 
cancer patients 
 
PBMCs were resuspended at 1x106 cells/ml in ImmunoCult (ImmunoCult-XF T Cell 
Expansion Medium, Stem Cell Technologies) media and either stimulated with 1x 
cell stimulation cocktail (40.5 µM Phorbol 12-Myristate 13-Acetate (PMA), 670 µM 
Ionomycin; eBiosciences) or left un-stimulated.  Cells were treated with 1x protein 
transport inhibitor cocktail (eBiosciences) and incubated at 37°C, 5% CO2 for 4 hours 
before being washed in MACS buffer.  Cells were stained with ef506 Fixable Viability 
Dye (1:1000, eBioscience) and washed in MACS buffer.  Cells were resuspended in 
the residual volume and stained with surface antibodies listed in Table 2-3a in the 
presence of 5ul FcR block (Biolegend) for 30 minutes on ice, protected from light.  
Cells were washed in MACS buffer, resuspended in residual volume and fixed in 4% 
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paraformaldehyde (Biolegend) for 30-45 minutes at room temperature, protected 
from light. Cells were centrifuged in 1x permeabilization buffer (Biolegend) at 760xg 
for 5 minutes and the cells resuspended in 100µl 1x permeabilization buffer.  Cells 
were incubated with the antibodies listed in Table 2-3b for 45 minutes at room 
temperature, protected from light. Peptides were titrated prior to use. Cells were 
washed in 1x permeabilization buffer and resuspended in a suitable volume of MACS 
buffer for analysis by flow-cytometry. 
Table 2-3. T-cell functionality flow panel antibodies 
Table 2-3a. T cell functionality flow panel antibodies – Surface staining 
Antibody anti 
human- 
Fluorochrome Clone Manufacturer Volume/
reaction 
(µl) 
CD45 Alexa Fluor ®700 2D1 Biolegend 2.5  
CD4 APC/Fire™750 RPA-T4 Biolegend 3.5 
CD8 PerCP/Cy5.5 SK1 Biolegend 3 
CD3 FITC UCHT1 Biolegend 5 
FcR Block   Biolegend 5 
Total volume    19 
 
Table 2-3b. T cell functionality flow panel antibodies – Intracellular staining 
Antibody anti 
human- 
Fluorochrome Clone Manufacturer Volume/
reaction 
(µl) 
IFN-γ PE/Dazzle™594 4S.B3 Biolegend 2.5 
IL-10 APC JES3-9D7 Biolegend 4.5 
IL-13 PE/Cy7 JES10-5A2 Biolegend 4.5 
IL-21 PE 3A3-N2 Biolegend 4.5 
IL-17a Brilliant Violet 421™ BL168 Biolegend 4 





Overlapping Peptide Stimulation 
 
The overlapping peptide stimulation was performed using either fresh or frozen 
PBMC. For the latter mentioned, acclimatization in a 5% CO2 incubator at 37ºC 
overnight was applied immediately after the cells were thawed. 
The cells were plated in round-bottomed 96-well plates at concentrations of 1-
1.5x106/150 ul/well. The overlapping peptides, MAGE A-1, MAGE A-3 and/or MAGE 
A-4 (JPT Innovative Peptide Solutions, Germany), were added separately at a final 
concentration of 1 μg/ml/well. Human antibody anti-CD28 (eBioscience) and human 
antibody anti-CD107a FITC were added to each well at a concentration of 2µg/ml 
and 1µl/test, respectively. Subsequently, incubation at 370 C, for 1-1.5 hours was 
applied to allow the T cells-peptides interactions occur. Protein Transport Inhibitor 
(PTI) was added at a concentration of 2µl/ml. Then the cells were incubated for 3-4 
hours. Cells were harvested and used for downstream assays such as “Intracellular 
cytokine staining following overlapping peptide stimulation” outlined below. 
 
Intracellular cytokine staining following overlapping MAGE-A peptide 
stimulation  
 
Peptide stimulated and control cells were harvested and washed in MACS buffer, 
then stained with ef-506-Fixable Viability Dye (1:1000) at 4ºC for 30 minutes. Cells 
were washed in MACS buffer and resuspended in the residual volume and stained 
with surface antibodies (Table 2-4a) in the presence of 5ul FcR block (Biolegend) for 
30 minutes on ice, protected from light.  Cells were washed in MACS buffer, 
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resuspended in residual volume and fixed in 4% paraformaldehyde (Biolegend) for 
30-45 minutes at room temperature, protected from light. Cells were centrifuged in 
1x permeabilization buffer (Biolegend) at 760xg for 5 minutes and the cells 
resuspended in 100µl 1x permeabilization buffer.  Cells were incubated with the 
antibodies (Table 2-4b) for 45 minutes at room temperature, protected from light. 
Cells were washed in 1x permeabilization buffer and resuspended in a suitable 
volume of MACS buffer for analysis by flow-cytometry. 
Table 2-4. MAGE-A overlapping peptide flow panel antibodies 
Table 2-4a. MAGE-A overlapping peptide flow panel antibodies – Surface staining 
Antibody anti 
human- 
Fluorochrome Clone Manufacturer Volume/
reaction 
(µl) 
CD3 Alexa Fluor ®700 UCHT1 Biolegend 2.5  
CD4 APC/Fire™750 RPA-T4 Biolegend 3.5 
CD8 PerCP/Cy5.5 SK1 Biolegend 3 
Total volume    9 
 
Table 2-4b. MAGE-A overlapping peptide flow panel antibodies – Intracellular staining 
Antibody anti 
human- 
Fluorochrome Clone Manufacturer Volume/
reaction 
(µl) 
IFN-γ PE/Dazzle™594 4S.B3 Biolegend 2.5 
TNF-a PE/Cy7 Mab11 Biolegend 4.5 
GM-CSF PE BVD2-21C11 Biolegend 4.5 
IL-2 Brilliant Violet 421™ MQ1-17H12 Biolegend 4 








Overlapping peptide-specific T cell clone generation 
 
In this study, antigen-specific T cell lines were generated from the fresh PBMC. The 
cells were resuspended in sterile T cell line (TCL) media then plated out into wells 
of a 48 well plate. Each well contained 1-1.5X106 cells. Overlapping peptides were 
added separately at 1.5µl/500 µl cell suspension and incubated at 370C, 5% CO2 for 
1.5 hours.  
The cells were then taken out and placed in 5 ml FACS tubes. To each tube, 3.5 ml 
TCL media was added. After centrifugation at 400xg for 8 minutes, the cells pellet 
was resuspended with TCL media containing: IL-7 (25 ng/ml), IL-15 (5 ng/ml), IL-21 
(2 ng/ml). This cell suspension was then plated out into wells of a 24 well plate (1 ml 
per well) and incubated at 370C, 5% CO2. On day 3, IL-2 (100 U/ml) was added to 
each well. To maintain the overlapping peptide-specific T cell clones, IL-2 (100 U/ml) 
containing TCL media was added to replace the discarded media twice per week. 
The T cell clones were harvested between day 12 and 14. 
  
Polyclonal T Cell Clones Generation 
 
As many as 2x106 PBMCs were resuspended in 1 ml AIM-V media (Thermofisher) 
supplemented with 7.5% human serum. PBMCs from frozen stock were rested in the 
same media between 2-4 hours before assay setup. A half fraction of the PBMCs 
(1x106) were taken to be pulsed with peptides at a final concentration of 5 µg/ml. 
They were incubated in 37ºC for 1 hours. Frozen samples required flicking every 30 
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minutes to avoid clumping. Then, they were washed with RPMI twice and were 
added back to remaining half of the sample.  
Next, the mixture of peptide-pulsed PBMCs and their other half were resuspended 
in IL-7 (10 ng/ml) containing AIM-V media and plated out into 24-well plate. The 
plates were incubated 37ºC, 5% CO2. Feeding was done at day 3 with 10 ng/ml IL-7 
containing AIM-V media. At day 7 the cells were re-stimulated with autologous 
irradiated (3000 rad) peptide-pulsed PBMCs. The wells that showed significant 
growth would be analysed further with limiting dilution single cell cloning. 
B95.8 LCL generation of TGCT patient B cells for autologous antigen 
presentation 
 
B95.8 is an EBV-tranformed B cell line. As much as 4 ml supernatant from at least 
3 days unfed B95.8 culture was removed and spun down at 900 rpm for 5 minutes. 
In separate tube, at least 5x106 PBMCs were resuspended in wash media. Patient 
PBMCs from frozen stock were washed twice with wash buffer to eliminate the 
toxicity effect of DMSO, then rested for 1 hour in 37ºC. Next, the PBMCs were 
centrifugated in 400xg for 5 minutes. Supernatant was discarded. 
B95.8 supernatant was then filtered onto the cell pellet using 0.45 µm syringe filter 
then FCS was added dropwise. This was incubated in 37ºC overnight. The following 
day this mixture (PBMCs diluted in viral supernatant) was spun down at 350xg for 5 
minutes and supernatant was discarded. The cell pellet resulted from this step was 
resuspended in 2 ml CSA medium then plated out into 2 wells of a 24 well plate. The 
PBMCs were considered to be converted into LCLs completely when the colour of 
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the diluting media changed from red to yellow. Normally it occurred after 2 weeks of 
incubation. When the cells seemed too thick, they were split into another well in the 
same plate and topped up with LCL media. 
Next, the LCLs were transferred into 25 cm2 flask and media was refreshed twice a 
week. These LCLs were used as antigen presenting cells for both polyclonal and 
limiting dilution single cell T cell cloning. The remaining LCLs were diluted in 1 ml 
freezing media and transferred into 2 ml cryovial. Each tube received at least 5X106 
cells and stored in liquid nitrogen after being kept overnight at -80ºC via controlled 
cooling of 1ºC per minute.  
Tumour Necrotic Factor Alpha (TNF-α) Capture 
 
PBMCs were divided into 2 fractions: ⅓ part to be pulsed with specific peptide 
(patient dependent) and ⅔ part to be rested. A single peptide with a final 
concentration of 10ug/ml was added to the ⅓ fraction and incubated in 37ºC for 30 
minutes. These peptide-pulsed cells were then added back to the rested cells. A 
single peptide at a final concentration of 10 µg/ml was used to pulse ⅓ of PBMC and 
incubated at 37°C for 30 minutes. After being washed twice, the peptide-pulsed 
PBMC were mixed with the remaining cells. Antibody anti-human TNF-α-APC 
(eBioscience) and TNFα-Processing Inhibitor (TAPI-0) (Enzo Life Sciences) were 
added at a final concentration of 0.5µl/0.5ml and 0.5µg/0.5ml, respectively. Following 
incubation at 37°C/5% CO2 for 4 hours, cells were washed once with MACS buffer 
and centrifuged at 400xg for 5 minutes. Cells were prepared for flow cytometric 
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analysis as follows: Cell viability was first marked by adding 100 µl live/dead fixable 
molecular probe solution (Life Technologies) and inccubated at RT for 10 min and 
washed with MACS buffer. Next, surface staining was performed with antibodies 
listed in Table 2-5. Cells were incubated on ice for 1 hour prior to flow cytometric 
analysis. 
Table 2-5. TNF-α-capture assay antibody details 
Antibody anti 
human- 
Fluorochrome Clone Manufacturer Volume/
reaction 
(µl) 
CD4 FITC RPA-T4 Biolegend 5 
CD8 PerCP/Cy5.5 SK1 Biolegend 2.5 
CD3 PE/Cyanine7 UCHT1 Biolegend 5 
FcR Block   Biolegend 5 
Total volume    17.5 
  
HLA Type Identification 
 
In my thesis I was interested to assess donor HLA status in relation to specific alleles 
that are associated with presentation of immunodominant peptides. As such, 
genomic DNA was extracted from cell pellet using DNeasy Blood and Tissue Kit 
(Qiagen). The purity of extracted DNA was measured in ND-100 spectrophotometer. 
About 140 ng DNA per sample was prepared for HLA-type identification. The 
amplification primers were adopted from Bunce et al (1995) and purchased from JPT 




Table 2-6. Primer pairs for HLA typing of patient PBMC 
Antigen (HLA-
type) 
Forward Primer Sequence: 5’-3’ Reverse Primer Sequence: 5’-3’ Product 
Size (bp) 
A1 CGA CGC CGC GAG CCA GAA AGC CCG TCC ACG CAC CG 629 
A2 GTG GAT AGA GCA GGA GGG T CCA AGA GCGCAGGTCCTCT 489 
A3 AGC GAC GCC GCG AGC CA CAC TCC ACG CAC GTG CCA 628 
A11, 6601 ACG GAA TGT GAA GGC CCA G GAG CCA CTC CAC GCA CCG 552 
A1, 11, 36, 80, 
3402 TAC TAC AAC CAG AGC GAG GA CCA CGT CGC AGC CAT ACA TT 300 
B7 (inc. B703), 
B8101 GGA GTA TTG GGA CCG GAAC TAC CAG CGC GCT CCA GCT 619 
B8 GAC CGG AAC ACA CAG ATC TT CCG CGC GCT CCA GCG TG 606 
B44 
GGC CGG AGT ATT GGG ACG A GTC GTA GGC GTC CTG GTC 
546/481 
CGC CAC GAG TCC GAG GAA CGT CGT AGG CGT ACT GGT C 
DR7 CCT GTG GCA GGG TAA GTA TA CCC GTA GTT GTG TCT GCA CAC 231 
DQ6 GGA GCG CGT GCG TCT TGT A 
TGC ACA CCG TGT CCA ACT C 
249/140 
TGC ACA CCC TGT CCA CCG  
Cw7 CCG CGG GTA TGA CCA GTC CAG CCC CTC GTG CTG CAT 1062 
Control Primer TGC CAA GTG GAG CAC CCA A GCA TCT TGC TCT GTG CAG AT 796 
 
PCR amplifications were performed through the following cycling parameters: 1 
minute at 96ºC, 5 cycles of 25 seconds at 96ºC, 45 seconds at 70ºC, 45 seconds at 
72º, followed by 21 cycles of 25 seconds at 96ºC, 50 seconds at 65ºC, 45 seconds 
at 72ºC, followed by 4 cycles of 25 seconds at 96ºC, 60 seconds at 55ºC and 120 
seconds at 72ºC. Touchdown PCR was not used. The primers were designed such 
that these temperatures were ideal for all primers. Next, the PCR amplification 
results were run on 1.5% agarose gel and visualized in UV-Transilluminator using 







In order to evaluate the response specificity of polyclonal T cell cones, IFN-γ ELISA 
was performed. As much as 75-100 µl of 2 weeks old polyclonal T cell clones were 
taken and transferred into 5 ml FACS tubes. They were washed with 3 ml wash 
buffer and spun down twice at 400xg for 5 minutes each. In separate tubes, 
autologous previously cryopreserved PBMCs were also prepared. When they were 
taken from frozen stock, they were rested immediately after thawing at 37ºC 5% CO2 
for about an hour top in 2 ml of GM media. Next, cells were washed twice and 
irradiated at 40 Gy. After being washed once with wash buffer and resuspended in 
2 ml of sterile GM, the irradiated cognate PBMCs were pulsed with corresponding 
peptide/peptide mix at a final concentration of 10 ng/ml at 37ºC 5% CO2 for 2 hours. 
We spared some for negative control in which the irradiated PBMC was not pulsed 
with peptides.   
The peptide-pulsed irradiated PBMCs were added to the corresponding clones with 
a ratio of 1:10. After being mixed, they were washed once with wash buffer and 
resuspended in 200 µl GM per peptide to be plated out in duplicate into 96 well V-
bottom plates. Each well was treated with peptide at a final concentration of 5 ng/ml 
accordingly and incubated at 37 ºC 5% CO2 overnight. Meanwhile, 96 well ELISA 
plate was coated with IFN-γ capture antibody (clone 1-D1K; Thermofisher) in coating 
buffer overnight at 4ºC. 
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The following morning, the coated ELISA plate was washed 6 times with PBS-T 
(0.05% Triton™X-100 in 1x PBS) and blocked with 5% BSA-containing PBS-T for 2 
hours. The blocking agent was removed by washing 6X times using PBS-T. The V 
bottom plate containing stimulated cells was spun down at 90xg. The supernatant 
was gently taken and pipetted into the ELISA plate. To measure the concentration 
of captured IFN-γ, several tubes for standards were prepared with a defined 
concentration of IFN-γ: 25 µg/ml; 12.5 µg/ml; 6.25 µg/ml; 3.125 µg/ml; 1.56 µg/ml; 
0.78 µg/ml; 0.39 µg/ml; 0.195 µg/ml; 0.098 µg/ml; 0.049 µg/ml; 0.024 µg/ml and 0 
µg/ml. From each tube, 100 µl was pipetted into ELISA plate. Then, the plate was 
incubated in the dark at RT for 4 hours. The plate was washed 6 times with PBS-T 
and then stained with 50 µl of diluted Biotinylated-IFN-γ (mAB-7-B6-1; 1:1000; 
Thermofisher). The plate was incubated in the dark at RT for 1 hour. The plate was 
washed 6 times with PBS-T and 100ul/well of SA-HRP (1:1000; Thermofisher) was 
added to each well, and incubated at RT for 1 hour. The plate was washed 10-times 
with PBS-T followed by the addition of 100ul of TMB substrate. The plate was 
incubated for 15minutes then 100ul of Stop solution (1M HCl acid) was added to 
each well. Absorbance was measured at 450nm in a microplate reader (BioRad). 
Statistical Analysis 
 
Prior to the main significance test, the normality of each dataset is evaluated through 
Saphiro-Wilk’s test. Normally distributed data is confirmed when the Saphiro-Wilk’s 
test results in nonsignificance among the 3 compared data. This will be further 
analysed with one way ANOVA with Tukey’s multiple test to check if there is 
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significance emerges per each comparison. Kruskal-Wallis with Dunn’s multiple test 
is, otherwise, used to obtain significance from dataset that are not normally 
distributed. Outliers are also identified and omitted to see if these affect significance. 
If they do, data are re-analysed post outlier-cleanse using one way ANOVA with 





CHAPTER III. IMMUNE CELL POPULATION IN TGCT PATIENT 
COHORT 
 
Demography of Testicular Germ Cell Tumour (TGCT) Patient Cohort 
 
A total of 57 patients with histopathologically-confirmed TGCT screening results 
were recruited and further discriminated, according to their characteristics into 2 
major groups: seminoma and nonseminoma as listed in the Table 3-1. 
Table 3-1. Patient characteristics 
Testicular Germ Cell 
Tumour (TGCT) Type 
Stage n  Histopathological 
Characteristic 
Seminoma 
IA 28 pT1N0M0 
IB 7 pT3N0M0 
IIA 2 pT2N1M0 
IIB 3 pT3N2M0 
IIC 2 pT1N3M0 
IIIC 1 TxN2M1b 
Total 43 patients 
Nonseminoma  
IA 1 pT1N0M0 
IB 4 pT3N0M0 
IIA 1 pT2N1M0 
IIB 2 pT3N2M0 
IIIA 1 pT2N2M1a 
IA 1 pT1N0M0 
IIB 1 pT3N2M0 
IA 2 pT1N0M0 
IB 1 pT3N0M0 
Total 14 patients 
 
Seminoma groups comprised of 43 patients (75.44%) and nonseminoma comprised 
of 14 patients (24.56%). Stage IA seminoma dominated the overall cohort. This 
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constituted about 49.12% (28 out of 57) cases under our investigation. Stage IB 
seminoma made up a quarter lower cases than stage I (12.28%, 7 out of 57).  Stage 
IB nonseminoma followed as the top 3 with 4 out of 57 (7.02%) of our TGCT cohort 
belonged to the group. There were 5 patients showed distinctive histopathological 
features that were attributed for the exclusion of them from the typical nonseminoma. 
Among those, 2 were categorized as embryonal carcinoma at stage IA and IIB with 
one patient each stage and the remaining 3 were mixed-germ cell tumor at stage IA 
and IB with 2 and 1 patient, respectively. Stages in our study spanned from stage IA 
to IIIC. Stage IV was not observed.   
Enumerated on the day of initial blood collection, patients age in seminoma group 
ranged from 26-69 years old with median value of 44 [IQR 33, 55] whereas 
nonseminoma group demonstrated slightly younger age which ranged from 20-39 
years old with median value of 28 [IQR 24.75, 34.25]. To detect significances of 
these shown differences,  Kruskal-Wallis with Dunn’s multiple test, significance at 
p<0.05 was performed and this resulted in a statistical confirmation that overall 
patients with nonseminoma were younger than patients with seminoma (p-
value=0.00007). These ages were not stage-associated since our patients with the 
more advanced stage were not the eldest in the respective groups.  
As control we recuited 13 males who on the day of blood collection were physically 
healthy. Their ages ranged from 23-43 years old with media value of 32 [IQR 29, 
34.5]. This age distribution is not significantly different with those seen for 
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nonseminoma. But when compared with the age range in seminoma, significance is 
obtained with p-value is 0.006.  
Phenotypic analysis of the peripheral immune repertoire in patients with 
testicular cancer 
 
Given the excellent clinical outcomes in patients with testicular cancer, even in the 
setting of metastatic disease, I was keen to begin my research with an analysis of 
the baseline immune repertoire of patients with testicular cancer. This work was 
stimulated by previous findings that such patients demonstrated some unususal 
features within their T cell profile (Pearce et al, 2017). It has been seen that patients 
with testicular cancer have an  increased proportion of T cells within the memory 
pool with an equivalent  reduction in the proportion of naive cells. It had been shown 
that within healthy donors the proportion of naïve (CD45RA+CCR7+) cells 
represented 56% and 51% of the CD4+ and CD8+ repertoires respectively. In 
contrast, in the patient group these had been reduced  by 25–40% to values of 38% 
and 30%. The proportion of CD4+ effector memory cells was also increased from 
23% within healthy donors to 32% within TGCT patients (p = 0.0028). CD8+ TEM 
cells were also markedly increased in the patient group, by around 35%, from 32% 
within healthy donors to 45% within the patient group (p = 0.0284).  Similar findings 
were also observed with the CD8+ effector memory subgroup.  
These data had suggested that tumor development is associated with the 
generation of a large pool of memory T cells in the peripheral repertoire. Importantly, 
this increment had been shown to be corrected by surgery or chemotherapy and 
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therefore suggests that the T cells may be shortlived. One possible explanation for 
these findings, and an interpretation that was of great interest to me in my studies, 
was that these might represent tumour-specific T cells that are circulating within the 
blood and are primed to kill malignant cells within the periphery. 
To date my work had focused on T cells, a major subset of the adaptive immune 
system. I was also keen to assess if testicular cancer had any influence on the innate 
immune system as this had not been assessed in previous studies. Innate immune 
system is the first line of defense to combat and control bacterial infections but is 
now appreciated to play an important role in the control of malignant disease . As 
such I included innate-like T cells and NK cells in my study. 
In order to undertake this work I went on to develop a flow cytometry panel that 
allowed evaluation of the magnitude and proportion of major immune cells in TGCT 
patients in comparison with healthy donors. Relatively little work has been done on 
this topic in previous studies. Formalin Fixed Parrafin-Embedded (FFPE) archive 
analysis of tumour-inflitrating lymphocytes (TIL) employing immunohistochemistry 
(IHC) has recently been undertaken by Fankhauser et. al (2015). They 
demonstrated that PD-L1 (Programmed Death Ligand-1) was expressed by 73% 
and 64% of seminoma and nonseminoma samples respectively. Interestingly, PD-
L1 positive stromal cells were only present within the seminoma subgroup. However 
I was not able to find any reports of flow cytometric analysis in this setting. Flow 
cytometry allows analysis of simultaneous expression of a wide range of membrane 
proteins. My aim was to utilize this information to gain novel insights into the immune 
repertoire of patients with testicular cancer. 
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Flow cytometric analysis of peripheral blood patients with testicular cancer 
 
Blood samples were obtained from patients with testicular cancer and age-matched 
samples were analysed either fresh or frozen. Blood was collected at the time of 
diagnosis and before any chemotherapy had been given. Frozen PBMC were 
incubating in RPMI 1640 at 37 ͦ C for 1 hour prior to staining. Cells were then stained 
with antibodies against a range of membrane proteins prior to flow cytometric 
analysis.  
TGCT samples were classified into 2 groups, as either seminoma (34 samples) or 
nonseminoma (13 samples) according to histopathology records. The 
nonseminoma group included embryonal carcinoma, mixed germ carcinoma and 
teratoma. Blood from 16 healthy donors (HDs), which was age-matched with the 
TGCT population, was used as a control group (Table 3-2). The gating strategy used 
in the analysis is illustrated in Fig. 3-1.  
Table 3-2. Age Range of Patients and healthy donors 
Groups of Samples Sample Size (n=) 
Age (years) Median [IQR 
Q3, Q1] 
Seminoma 34 44   [IQR 32,56] 
Nonseminoma 13 25   [IQR 23,35]  
















Fig. 3-1. Representative gating strategy to identify immune cell subpopulations in TGCT patients. 
Firstly, singlets were obtained on the basis of FS INT (X Axis) and FS PEAK (Y Axis). Secondly, viability dye was used to exclude 
dead cells from further analysis and live CD45+ lymphocytes were selected. Thirdly, CD45+ lymphocytes were further analysed 
and divided into distinct (bottom row from left to right) CD3- CD56+ NK cells, CD19+ CD56- B cells and CD3+ T cells to further 




T cells are the dominant subpopulation in both healthy donors and patients 
with testicular cancer 
 
As expected, T cells were found to be the major immune subset within peripheral 
blood in both the control and patient groups. Initial analysis focused on the 
distribution of the broad immune subsets of T cells, B cells and NK cells within each 
donor. A subset of CD45+ cells that did not comprise any of these subsets, and is 
most likely to represent myeloid cells, was also defined.  
The distribution of each cell subset did not reveal any major visual differences within 
the three groups (Fig. 3-2). There was a suggestion of a potential relative increase 
in the B cells and CD45+ subsets and in order to assess this I next compared the 







Fig. 3-2. Major immune cell populations within the TGCT patient and healthy donor 
cohorts 
In the three groups immune cells are largely consist of T- (red),  NK- (blue), and B-cells 
(green), respectively. The purple subgroup represents cells that are CD45+ but are not NK, 
T or B-cells. Each fraction of the defined immune cell types is presented as a percentage 






Fig. 3-3. Summary of overall immune cell populations in seminoma, nonseminoma 
and healthy donors 
Immune cell populations in the three groups comprise of T cells (red), NK cells (blue), B 
cells (green) and other CD45+ cells (purple). 
 
As shown in Table 3-3, in the healthy donor cohort T cells represent the largest 
immune cell population at  69.6% [IQR 62.03%, 72.62%]. Within the seminoma 
group this value is somewhat reduced to 64.5% [IQR 46.54%, 72.24%] of immune 
cells and falls further to 58% [IQR 40.20%, 71.60%] in nonseminoma patients. This 
decrease frequencies of T cells in seminoma and nonseminoma patients compared 
with HD, however, are  insignificant with adjusted p-values of 0.210 and 0.050, 












Observed in the 
PBMCs 
Mean Median [IQR Q1, Q3] 






64.5% [IQR 46.31%, 72.20%] 
13.5% [IQR 9.2%, 21.9%]  
9.9% [IQR 5.8%, 13.7%] 






58% [IQR 40.2%, 71.6]   
15.2% [IQR 7.24%, 26.1%] 
13.5% [IQR 8.85%, 21.3%]  






69.6% [IQR 62.%, 72.6]   
15.4% [IQR 12.4%, 18.1%] 
6.09% [IQR 3.37%, 8.95%] 
 
The total NK cell proportion within HD was measured at 18% [IQR 12.98%, 23.07%] 
but was somewhat lower in seminoma and nonseminoma respectively at 13.2% 
[IQR 10.16%, 19.70%] and 16.8% [IQR 8.76%, 21.86%] (Table 3-3). No significance 
is obtained from the comparisons of these three groups (p-values > 0.999) (Kruskal-
Wallis with Dunn’s multiple comparison test, significance at p<0.05).    
Interestingly, compared to HD the percentage of B cells in patients with seminoma 
and nonseminoma was statistical significantly increased (Table 3-3). The p-values 
observed for these comparison are 0.049 and 0.004, respectively (one way ANOVA 
with Tukey’s multiple test, significance at p<0.05). This may suggest that there may 
be a peripheral humoral response as a part of the adaptive immune response 
against testicular cancer. This is an area that has not been thoroughly investigated 
to date and represents an important area for future study.  
In addition, an increase in the CD45+ subset was also seen in the patient group. 




possible that they may comprise cells such as myeloid-derived suppressor cells 
whose numbers have been demonstrated to be increased in many patients with 




Fig. 3-4. Distribution of major T cell subpopulations in patients with testicular cancer. 
T cell populations were delinated according to expression of αβ-TCR, γδ-TCR and CD56 
(NKT). The frequencies above are enumerated as a total of the CD3+ pool.   
 
αβ T Cells are the most dominant fraction within the T cell population 
 
T cells were found to be the most common cell subset within the immune repertoire 
and I next went on to examine the subsets of T cells within this group. In particular 
I examined the relative proportion of cells that expressed the αβ-TCR or γδ-TCR 
and also enumerated the NKT subpopulation through co-expression of CD56 and 




αβ-T cells are the predominant cellular subset among all the three groups. On 
average they are approximately 20 fold more numerous than γδ-T-cells. In 
seminoma, the median value for the αβ-T cell fraction is 93.9%% [IQR 90.3%, 
96.7%] whereas in nonseminoma the value is 93.3% [IQR 90.29%, 96.58%] and the 
percentage in healthy donors is 94.2% [IQR 89.65%, 97.34%]. All these values are 
not significant with all observed p-values >0.999 (Kruskal-Wallis with Dunn’s 
multiple comparison test, significance at p<0.05).  
γδ-T cells are not increased in the blood of patients with testicular cancer 
 
γδ T-cells encompass a well-conserved population of innate lymphocytes whose 
structures and functions are largely heterogenous. During tumour progression, they 
participate in diverse immune responses. The cells lately have emerged as an 
interesting field of study to develop immunotherapy (Wu et al., 2017). In human, γδ- 
T cells contribute to the immune response against a subset of tumours of 
haematological and epithelial origin (Hannani et al., 2012). An antibody against 
the γδ TCR was used to define the presence of this subset in flow cytometric 






Fig. 3-5. γδ-T cells are detected in seminoma and nonseminoma cohorts with a 
frequency similar to those in HD 
In the left panel γδ-T cells are demonstrated as γδ-TCR-expressing CD3+ T cells. The 
right panel indicates the percentages of γδ- T cells within the CD3+ repertoire. Two 
populations of cells are observed by intensity of TCRgd staining. Values were analysed 
statistically through Kruskal-Wallis with Dunn’s multiple comparison to adjust the 
observed p-values (Graph Prism 8). (Non-significant =ns).  
 
In our samples, γδ- T cells in seminoma, nonseminoma and HD are detected at 
median values of 2.95% [IQR 1.16%, 3.95%], 4.13% [IQR 1.81%%, 6.04%] and 
1.90% [IQR 1.03%, 4.07%] respectively. Although the median and quartile values 
appear to show a 2 fold and 1.5 fold increase in the nonseminoma and seminoma 
groups when each is compared with HD, these differences  are not significant. 
These comparison yield p-values of 0.192 and 0.845, respectively. Likewise, γδ- T 




at the level of 0.299 (one way ANOVA with Tukey’s multiple comparison, 
significance at p<0.05). Despite these statistical insignificance, nonseminoma tend 
to upregulate more γδ-TCR. One notable observation was the relative heterogeneity 
in the percentage of γδ cells within the three groups, as indicated in the pattern of 
distribution within the violin plots. The relative importance of these interesting cells 
in either the development or control of cancer thus needs considerably more 
investigation ( Zhao et al., 2018).  
The relative frequency of total NKT cells is not altered in patients with 
testicular cancer 
 
Carrying phenotypic characteristic of both T cell and NK cell, NKT cells emerged as 
a unique cell subset. Their potential role in cancer development and control was 
noted almost 15 years ago by Tachibana et al who demonstrated that colorectal 
cancer patients with high NKT-cell infiltration had higher overall and disease-free 
survival rates (Tachibana et al., 2005).  
NKT cells are mainly restricted by CD1d and whilst some populations express a 
conserved TCR there are also many cells that express a diverse TCR repertoire. In 
my analysis I defined NKT cells by a CD3+CD56+ phenotype. CD56+ is widely 
expressed on NKT cells and has been used to assess their profile in previous 
studies. Alternative approaches could have been to use a CD1d tetramer or 
potentially antibody staining against the conserved Va24-Vb11 heterodimer on 




CD3+CD56+ NKT cells in seminoma, nonseminoma and HD were observed at 
median and quartile values of 3.02% [IQR 1.10%, 4.25%], 2.53% [IQR 0.84%, 
4.95%] and 2.00% [IQR 0.98%, 7.01%] respectively (Fig. 3-6). NKT cell frequencies 
are therefore not altered in testicular cancer (p-values >0.999) (Kruskal-Wallis with 
Dunn’s multiple test, significance at p<0.05). Some outliers are detected in 
seminoma and healthy donors whose NKT cell frequencies exceed normal 
distribution of the analysed data. In seminoma, the outliers are identified in IN 28, 
IN 22, IN 23 and IN 25 with NKT cell frequencies at the levels of 12.9%, 19%, 20.7% 
and 21%, respectively. Healthy donors with ID HD-4 and HD-14 have NKT cell 
percentages of 21.1% and 22.4%, respectively, which become the outliers. If these 
outiers are removed, the p-values yielded by frequency comparison between 
seminoma and nonseminoma, seminoma and HD and nonseminoma and HD, 









Fig. 3-6. NKT cells are present in PBMCs of seminoma and nonseminoma cohorts 
In the left panel, flow cytometry analysis demonstrates that NKT cells are defined as CD45+ 
lymphocytes which positively co-express CD56 and CD3. In the right panel, NKT cells of 
each examined group are plotted as percentages of total T cells (CD3+). Asterisk denotes 
omission of detected outliers. After outliers are excluded from the affected dataset, 
seminoma and healthy donors have a total of 30 and 16 remaining individual data to be 
further analysed. Statistical significance is obtained by performing Kruskal-Wallis with 
Dunn’s multiple test and re-testing with one way ANOVA with Tukey’s multiple test after the 
outliers are depleted from the dataset. No significance is observed from the three 
comparisons either through Kruskal-Wallis or one way ANOVA analysis.   
 
A total of 6 outliers are detected. Of those, 4 outliers are from seminoma where 3 of 
which are at stage I and one is at stage II TGCT. Both, therefore, did not have 
metastatic disease. The remaining 2 outliers are found in HD. It worth noting that 
compared to other members in the corresponding dataset, the outliers are 




aging although to confirm this further evalution a much larger sample size is 
required. 
The percentage of circulating B cells is increased in patients with TGCT 
 
The relative importance and contribution of B cells to the adaptive immune response 
against cancer has been somewhat less well investigated in comparison to tumour-
specific T cell responses. B cells constitute approximately 15% of peripheral blood 
leukocytes and can be defined by a range of different markers such as CD19 or 
CD20. 
I used a combination of CD45+ and CD19+ to define B cells in my flow cytometry 
panel. CD19 is a biomarker for normal and neoplastic B cells and acts to regulate 
the intrinsic B cell signaling threshold through modulation of B cell receptor-
dependent and independent signaling. 
The median proportion of B cells within the peripheral immune repertoire in the 
seminoma and nonseminoma samples was 9.93% [IQR 5.84%, 13.55%] and 13.5% 
respectively [IQR 6.85%, 21.34%]. There was no statistically significant difference 
observed between these numbers (p-value=0.24). In contrast, the values are higher 
than those seen in HD where the median value was 6.1% [IQR 3.37%, 8.95%]. The 
p-values for seminoma vs HD and nonseminoma vs HD were seen to be 0.049 and 





I next went on to assess if this difference might represent an alteration in the relative 
proportion of naive or memory B cells. In particular, expression of CD27 was used 
as a marker of B cell memory (Fig. 3-7). Interestingly the proportion of memory B 
cells in the three groups was very similar at a mean frequency around 2-3% of the 
CD45+ pool. This failure to see any difference in the frequency of memory B cells 
in seminoma, nonseminoma and HD suggests that the increased proportion of B 
cells in the patient group must belong to another subset of B cells, potentially the 
naïve repertoire. As such it is difficult to interpret the significance of the increased 
proportion of non-memory B cells in the blood of the patient group. It might 
potentially imply that this simply reflects a stable residual population that is 
increased due to a numerical decrease in other leukocyte subsets or it may reflect 
a systemic activity from the tumour in releasing naïve B cells from the bone marrow 






Fig. 3-7. The relative percentage of B cells and memory B cells within patients with 
testicular cancer or healthy donors 
The individual values for percentage of total B cells or B memory cells is presented as 
percentage of a total CD45+ Lymphocytes.The median of each group is marked by longer 
dashed-lines in black while the quartile values (lower quartile Q1 and upper quartile Q3) are 
represented by shorther lines. Colours in red, green and blue represent seminoma, 
nonseminoma and HD, respectively. The median and the quartile values are determined 
Statistical significance is obtained by performing ANOVA with Tukey’s multiple test after the 
dataset is confirmed to be normally distributed through Saphiro-Wilk test (Graph Prism 8).  
 
Further, I assessed if there is a disparity in the memory B cell proportion in both 




cells are CD45+ cells which co-express CD19 and CD27. In seminoma, the relative 
proportion is measured at a median level of 27.1% [IQR 21.40%, 32.85%] while in 
nonseminoma the median is observed at a level of 27% [IQR 15.33%, 44.28%]. As 
reference group, healthy donor group demonstrates a higher level proportion of 
memory B cell compared to that of both seminoma and nonseminoma. The median 
in the group is 39% [IQR 27%, 50.18%].  
Compared to values within healthy donors, the proportion of memory B cells in 
seminoma and nonseminoma patients are significantly lower with observed p-values 
of 0.003 and 0.046, respectively (Fig. 3-8). Neither age nor stage is seen to be a 
determinant of this profile. The patients with the highest proportion of B cell memory 
in seminoma and nonseminoma were diagnosed with stage IA and aged 59 and 34 
years old, respectively. Both are not the oldest within the corresponding groups. The 
pattern of B cell memory proportion in HD is, likewise, not correlated with age 
because the donor whose the cell frequency is the highest was relatively young, 






Fig. 3-8. The relative proportion of memory B cells in the total B cell repertoire in 
seminoma, nonseminoma and healthy donors.  
The individual values for proportion of memory B cell is presented as percentage of the cells 
in the total B cell repertoire. These memory B cells are phenotyped as CD27-expressing 
CD19+ CD45+ lymphocytes. The data distribution within each group is demonstrated as 
median (marked by longer dashed-lines), lower quartile Q1 (marked by shorter dashed-lines 
below the median lines) and upper quartile Q3 (marked shorter dashed-lines above the 
median lines). Each dataset is confirmed to be normally distributed through Saphiro-Wilk 
test hence statistical significance is conducted via one way ANOVA with Tukey’s multiple 
test, significance at P<0.05. Both seminoma and nonseminoma demonstrate significant 
lower proportion of memory B cell compared to healthy donor’s as indicated by double and 










The percentage of invariant MAIT Cells is not altered in patients with testicular 
cancer  
 
Mucosa-associated invariant T (MAIT) cells are a class of innate-like T cells that are 
involved primarily in mucosal immune responses. The cells were identified relatively 
recently and are recognized phenotypically by their co-expression of TCR Vα7.2 
and CD161 (Garner et al., 2018).  The median percentage of MAIT cells (expressed 
as a percentage of the T cell pool) in seminoma, non-seminoma and HD was found 
to be 1.55% [IQR 0.61%, 3.35%], 1.22% [IQR 0.76%, 2.55%] and 2.77% [IQR 
1.05%, 4.71%] respectively. P-values exceed 0.999, 0.695 and 0.527 when MAIT 
frequencies are compared between seminoma vs nonseminoma, seminoma vs HD 
and nonseminoma vs HD, respectively. These are all non significant (Fig. 3-9). 
There are 5 outliers identified from seminoma group whose MAIT cell frequencies 
range from 5.940%-8.893%. To assess if these outliers alter significance of the 
analysed dataset, these values were excluded from the analysis and the remaining 









Fig. 3-9. The percentage of expression of MAIT cells within patients with testicular 
cancer and healthy donors 
The percentage of MAIT cells was defined by co-expression of CD161 and TCR Vα7.2 as 
shown in the left hand panel.  This proportion was then calculated as a percentage of the 
total αβ-T cell population. The data within each study group is shown individually with their 
respective median and quartiles (lower quartile Q1 and upper quartile Q3). Pre-normality 
test (Saphiro-Wilk test), significance is determined by performing Kruskal-Wallis with Dunn’s 
multiple test and yield no significance. Since some outliers are detected in seminoma group, 
the dataset are re-analyzed by one way ANOVA with Tukey’s multiple test after the outliers 
are excluded. The statistical significance emerges from the comparison of MAIT cell 
frequency in seminoma and HD post outliers exclusion (p-value=0.023) (Graph Prism 8). 
(Non-significant = NS).  
 
As many as 5 outliers are detected in seminoma group. The highest frequency of 
MAIT is shown by a patient whose age was 44 and diagnosed with stage IIB 




IA. This implies that, unlike NKT, MAIT frequency is reflective upon cancer stage 
instead of age.  
I further wondered if these outliers affect significance among the 3 assessed groups. 
Therefore I conducted outliers data cleanse and re-analyzed the dataset with one 
way ANOVA. This exclusion results in significant frequency difference between 
seminoma and HD, suggesting that, in normal data distribution, MAIT frequency is 
significantly reduced in seminoma (p-value = 0.023). Moreover, the level of such 
decrease might be positively proportional to the stage. Although this still needs 
further confirmation, this early finding is seen to be in agreement with a study 
conducted by Walker et al., that revealed MAIT frequency was negatively correlated 
with aging (Walker et al., 2014). The study involved patients with severe infectious 





The distribution of peripheral NK cell subsets is markedly altered in patients 
with TGCT 
 
Based on the co-expression intensity of surface molecules CD56 (neural cell 
adhesion molecule (NCAM) 2) and CD16 (FcγRIII) , NK cells in human  are classified 
into two major populations being that CD56dimCD16bright which accounts for about 
90% of circulating NK cells and CD56brightCD16dim which comprises the remaining 
10% (Poli et al., 2009). Of these two, CD56bright NK cells predominate in lymph nodes 
and sites of inflammation (Chan, et al., 2007). While CD56bright NK cells are generally 
considered to be more responsive towards cytokine stimulations, CD56dim 
populations are broadly known to be more cytotoxic (Zamai et al., 2007).   
In order to generate IFN-γ, the CD56bright NK population generally requires 2 signals.  
One of these almost always includes IL-12. The second can be IL-1, IL-2, IL-15 or 
IL-18, or the binding of an NK-activating receptor such as CD16 (FcγRIIIa) or 
NKG2D (Caligiuri, 2008). In the context of cytotoxicity, NK cells are more tentative 
and form transient contacts inducing less profound Ca2+ mobilization and 
cytoskeletal polarization. T cells, in contrast to NK cells, form stable contact with 
target cells (Chiang et al., 2013). 
NK cells express a vast repertoire of germ-line encoded inhibitory- and activating- 
receptors for target recognitions. Among these receptors, CD16--a low affinity 
binding Fc receptor, has been thought to be the key. It was demonstrated by 




differential loss of CD16 expression in a target-cell dependent manner (Tsukerman 
et al., 2014).  
My data shown above had revealed that the absolute percentage of total NK Cells 
did not differ between patients with testicular cancer and normal controls. I next 
analysed the relative contribution of different NK subsets based on the pattern of 
CD16 and CD56 expression. This approach allowed delineation of 5 different NK 
cell subsets (Fig. 3-10). 
 
Fig. 3-10. Subset analysis of NK cells as defined by the pattern of CD16 and CD56 
expression 
NK cells were defined as CD3- and then gated according to relative expression of CD16 (X 
Axis) and CD56 (Y axis). In this way five distinctive NK cells could be obtained, termed 






These 5 NK subgroups were assigned according to the level of expression of CD16 
and CD5 at the cell surface: 
1. Population A: CD56BrightCD16Neg 
2. Population B: CD56BrightCD16Pos 
3. Population C: CD56DimCD16Pos 
4. Population D: CD56DimCD16Intermediate 
5. Population E: CD56DimCD16Neg 
My data demonstrated that there are three populations in which marked differences 
are observed in relation to their expression in patient or control groups (Fig. 3-11). 
This was observed most strikingly in population E (CD56DimCD16Neg) which was 
markedly more common in patients with seminoma (p-value<0.0001) and 
nonseminoma (p-value=0.003) compared with HD. This is normally a relatively rare 
NK cell phenotype in normal donors and its functional role is uncertain. Population 
D (CD56DimCD16Intermediet) was also enriched in both the seminoma (p-
value<0.0001) and nonseminoma patients (p-value<0.0007).  
Populations D and E were increased in the patient group at the expense of 
population C (CD56DimCD16Pos) which was markedly reduced in seminoma (p-
value=0.0003) and nonseminoma (p=0.0065). Population C is the classic cytotoxic 
NK phenotype that dominates the peripheral repertoire in healthy donors. These 
data would suggest that the presence of cancer may act to suppress the expression 




E subgroups.  CD16 is a powerful activation marker on NK cells and mediates 
antibody directed cytotoxicity. As such these data indicate that peripheral NK 






Fig. 3-11. The distribution of NK cell subsets is markedly altered in patients with testicular cancer 
(Upper Panel) In the context of CD16 expression, CD56 (NK) cells distinct themselves as five populations being that 
CD56BrightCD16Neg  (blue bar), CD56BrightCD16Post (red bar), CD56DimCD16Pos (yellow), CD56DimCD16Intermediate  (green bar), 
CD56DimCD16Neg (purple bar). The percentages plotted on each are enumerated as a total of CD3- lymphocytes and represent 
average of each population. (Bottom row) Three out of the five population exhibiting statistically significant dynamics: 
CD56DimCD16Pos (yellow), CD56DimCD16Neg (purple bar) and CD56DimCD16Intermediate. No significance is observed when seminoma 
is compared with nonseminoma. However, when each of them is compared with the HD, statistical significancies emerge. 







Despite the excellent clinical prognosis of TGCT, there has been relatively little 
investigation of potential tumour-specific immune responses in this tumour subtype. 
Despite this, PD-1- and CTLA-4 checkpoint-based immunotherapy are beginning to 
be introduced into patient management (Seidel et al., 2018).  
In order to guide introduction of these approaches it will be important to stratify 
treatment according to the immunophenotype of individual patients. Ideally this 
would be undertaken by analysis of the primary tumour and assessment of 
immunological features on the tumour, TIL and stromal populations. However, this 
is a challenging ambition at the current time and is difficult to perform on patients 
with enough time to optimize treatment pathways. As such, I undertook a study of 
the major phenotypic feature of peripheral blood in patients with TCGT. I 
examined the relative proportion of each fraction of immune cells observed within 
PBMCs in patients with either seminoma or non-seminomatous lesions and 
contrasted these results with those seen in healthy donors. Several studies are 
now indicating that the immunophenotype of blood samples can be used as an 
important correlate of clinical outcome in patients with cancer (Krijgsman et al., 
2019).  
My data demonstrated that the major subsets of immune cells within PBMCs of 
cancer patients were T, NK- and B cells. No gross changes in the overall 
proportion of T and NK cells were observed in comparison to healthy donors 




further. In contrast, I did detect an increase in the relative proportion of B cells in 
the patients with TCGT. B cells were defined CD19+ lymphocytes and this is a 
broad lineage marker that does not discriminate between B cell subsets. As such, 
I also included CD27 in my panel as this is a reliable marker of memory B cells. 
This revealed that the proportion of memory B cells was similar in all three groups, 
suggesting that modulation of antigen-experienced B cell subsets was not the 
important factor. This suggests that a population of CD19+CD27- B cells is 
relatively increased in the patient group. At this stage it is not clear what this 
population might represent although consideration should be given to the 
immunosenescent IgG+IgD-CD27- subset that is increased in association with 
ageing (Buffa et al., 2011). At this stage there is no evidence that CD19+CD27+ 
cells are recruited into tissue. Further analysis should use an extended B cell 
immune phenotype in order to assess the functional significance of this observation.  
γδ T cells are now of considerable interest in cancer immunology (Nussbaumer & 
Koslowski, 2019). However, a broad overview of the global γδ repertoire did again 
not reveal any differences between the patient and control groups. These cells can 
mediate inflammatory or immunosuppressive responses against tumour tissue 
(Legut et al., 2015) and may also provide help for B cell differentiation. Moreover, 
the cells are able to control levels of imunoglobulin and influence autoantibody 
production (Born et al., 2017). Further interrogation of γδ T cells in TCGT will require 
analysis of the different subgroups of cells and would necessitate incorporation of 




NKT cells are a relatively minor component of the immune repertoire but it is 
believed that they can have profound effects on the rest of the immune system. NKT 
cells are specific for lipid which is presented on the surface of CD1d, a non-classical 
member of the HLA gene family. The rationale for ‘lipid-sensing’ by the immune 
system is not entirely clear but it is now believed that NKT cells play an important 
role in determining both the ‘quantity and quality’ of the immune response to antigen  
(Terabe & Berzofsky, 2018). Having said that, no differences in NKT cell proportion 
were observed in my study.  
I also examined the profile of MAIT cells in my panel. These cells express a 
conserved T cell receptor encoced from the TCR α chain Vα7.2-Jα33 which can be 
paired many different members of the TCRVβ repertoire. Antigenic specificity 
appears to be directed towards the MR1 protein and a characteristic feature of these 
cells, and one that is useful for laboratory investigation, is that CD161 is expressed 
on the majority of the population. The frequency of MAIT cells in seminoma, 
nonseminoma and HD exhibited no statistical differences between groups.  
As described in the Introduction, Natural Killer (NK) cells play a pivotal role in the 
control of transformed cells and NK cell evasion is emerging as a hallmark of many 
tumours, especially in metastatic disease (Lorenzo-Herrero et al., 2019).   Similar to 
the findings in relation to T cells, there were no differences observed in the 
proportion of total NK cells between the three groups of subjects. However NK cells 
encompass considerable heterogeneity and I therefore went on to assess the 




Here I discovered significantly reduced expression of CD16 on CD56dim (NKdim) 
population in seminoma and nonseminoma patients compared with HD. CD56dim NK 
cells are normally highly cytotoxic and this is strongly mediated through Ab-
mediated cell cytotoxicity (ADCC) via expression of the Fc receptor CD16 
(FcγRIIIa). Indeed, ADCC is clinically important as a primary mechanism of 
therapeutic antibodies and binding of Fc receptors has been shown to be critical for 
their activity in vivo (Srpan et al., 2018). As such the loss of CD16 would be expected 
to significantly compromise their functional activity.  
Although the origin and function of the CD56dim CD16−/dim NK population is unclear 
the population is widely thought as a highly heterogenous population comparising 
of both maturing and target cell-activated cells. A similar population of 
CD56dimCD16Neg cells has been observed in pateints with advanced melanoma and 
here is was also reported that this population is markedly increaed in the tumour 
microenvironment. Importantly, cytotoxic activity remained strongly associated with 
retention of the CD56dimCD16Pos subset (Vujanovic et al., 2019). 
Amand et al reported that a CD56dimCD16dim population appears to be a relatively 
immature population of NK cells with a lower level of CD57 and increased NKG2A 
in comparision to CD56dimCD16bright subsets (Amand et al., 2017). They may 
represent an intermediate population between the dominant CD56dimCD16bright and 
CD56brightCD16neg  subsets but at this stage the pathway for differentiation of these 




transit of NK subsets and in future work I would have wished to have examine this 
repertoire in more detail  (Wang and Reinherz, 2012). 
One of the limitations of my study is that I was not able to investigate the number or 
phenotype of T regulatory cells. These cells act as an important determinant of 
cancer outcome and would represent an important area for future investigation 
(Jørgensen et al., 2019). Also I was not able to assess how these changes were 
influenced by disease stage and this could be assessed in future studies. 
Overall, my findings in this chapter show that no differences were observed in the 
overall broad phenotype of T cell subsets within peripheral blood in patienst with 
testicular cancer. In particular, analysis of αβ and γδ subsets, as well as MAIT and 
NKT subsets did not reveal significant differences. In contrast, the proportion of 
CD27-  B cells was increased in the patient group. The most profound changes were 
observed in relation to the distribution of NK cell subsets where I detected a 
significant increase in the proportion of CD56dim cells that had downregulated or lost 
CD16.  
Future studies on immune phenotyping should focus on more detailed 
characterization of immune subsets, including multiparametric CyTOF or flow 
cytometry analysis, potentially combined with analysis of sequence data from 
antigen receptors. My data indicate that the peripheral immune system is 
significantly altered in patients with testicular cancer although the mechanisms 








CHAPTER IV. THE PROFILE OF IMMUNE CHECKPOINT PROTEIN 
EXPRESSION ON PBMC IN TGCT PATIENT COHORT  
 
Although surgery and chemotherapy are highly effective in the management of 
testicular cancer it is important to remember that this is not effective in every case 
and many men die of their disease each year. As such it is important that we continue 
to aim to develop new treatments for testicular cancer that can achieve cure in every 
case. In addition, approaches such as immunotherapy may prove to be less toxic 
than chemotherapy and so may act to reduce morbidity within the patient cohort 
(D’Souza et al., 2015).  
It is unclear why TGCT are so curable by chemotherapy and what lessons may be 
learnt from this in relation to immunotherapy. Of interest, inactivation of the p53 
signalling pathway is observed in almost all solid tumours but p53 is not typically 
mutated in TGCT. As such, the ability of drugs such as cisplatin to mediate excellent 
levels of cell death may reflect effective induction of apoptosis pathways. Taken 
together, these considerations indicate that TGCT can also act as a model system 
in which to assess optimal molecular determinants of chemotherapy sensitivity in 
solid tumours (Boublikova et al., 2014). However, modulating common epithelial 
tumours to obtain the genetic profile of TGCT is currently beyond the scope of gene 
therapy.  
Cancer immunotherapy is aimed primarily at either reinforcing an endogenous anti-




immunocompetent cells in those setting where such a response is not apparent. In 
the latter case either autologous or third-party immune effector cells are expanded 
in vitro and then infused into the patient (Minato & Honjo, 2016).  
Two main approaches that are often considered in cancer immunotherapy are 
passive and active immunotherapy. Passive immunotherapy is principally aimed at 
enhancing the existing anti-tumour responses through the administration of 
immunological agents such as monoclonal antibodies, cellular products or cytokines. 
In contrast, active immunotherapy attempts to generate a long-lasting immune 
response to destroy the tumour cells. This strategy can be implemented through 
approaches such as immunomodulation or vaccination (Zhang & Chen, 2018).   
Immunological products including cytokines (IFN-α and IL-2), monoclonal antibodies 
(for instance trastuzumab, bevacizumab and ipilimumab) and anticancer cell -based 
therapy (as in the case of Sipuleucel-T) have received regulatory approval either as 










Table 4-1. Implemented Passive and Active Immunotherapy 

















● Chimeric antigen 
receptors (CARs) 




Immune checkpoint blockade 
 
The immune micro-environment within a tumour mediates integration of multiple 
interactions between tumour cells and reactive cells, including lymphocytes, antigen 
presenting cells (APCs) and stroma (Rabinovich et al., 2007). The development and 
activity of the host immune response against tumour tissue will reflect the net 
balance of inhibitory and stimulatory signals. A further concept that has emerged has 
been that of activating and inhibitory ‘immune checkpoints’ that maintain immune 
homeostasis and preventing auto-immune disease by limiting effector lymphocyte 
responses. Tumours, however, may co-opt immune-checkpoint pathways. As a 
consequence, T cell-mediated anti tumour immunity may be supressed and this 
leads to the promotion of tumour growth (Pardoll, 2015). 
Immune checkpoint inhibitors are a novel class of drugs that are designed to 
enhance immune response by competitively binding the inhibitory checkpoint 




blockade has been recently seen as one of the most promising approach to activate 
anti-tumour immunity (Pardoll, 2016). Weakening the inhibitory checkpoint activity 
can boost inflammatory immune responses and improve patient outcomes in a wide 
range of tumour settings (Kareva, 2018). CTLA-4, PD-1, T-cell immunoglobulin and 
mucin domain containing protein 3 (Tim-3) and lymphocyte activation gene-3 (LAG-
3) are prototypic checkpoint proteins and antibodies that block their interactions are 
already in clinic or pre-clinical development. Triggering the activation of these 
markers by engagement with their ligands on tumour cells is believed to cause 
hyporesponsiveness and eventually tumour-specific T cell exhaustion. The first 
successful therapy was the anti-CTLA-4 antibody ipilimumab which was introduced 
for the treatment of metastatic melanoma in 2011 (Savoia et al., 2016). This marked 
the beginning of a new era for cancer immunotherapy. Subsequently, 
pembrolizumab and nivolumab, two antibodies that block PD-1, were found to have 
remarkable activity in a wide range of cancer settings (Alsaab et al., 2017). 
Squamous cell lung cancer and melanoma are particularly susceptible to disruption 
of the PD-1:PD-L1 interaction and this may reflect that fact that these tumours have 
been exposed to high mutagenic challence in the environment in the form of smoking 
and sunlight. Atezolizumab is an antibody that can block the major ligand of PD-1, 
PD-L1, and is finding a role in bladder cancer (Inman et al., 2017).  
Despite this success, checkpoint inhibition is also associated with side effects in 
many tissues which reflect overactive ‘auto-immune’ processes. These may require 




On the basis of these observations, it is of paramount importance to exactly know 
which inhibitory checkpoint pathway(s) can be harnessed by the different tumour 
types. I have therefore developed an antibody panel called the ‘Checkpoint Panel’ 
which would allow me to examine by flow cytometry the simultaneous expressions 
of five major checkpoint inhibitors, namely PD-1, TIGIT, Tim-3, CTLA-4 and LAG-3, 
on peripheral blood cells from patients with testicular cancer.  
Table 4-2. Checkpoint-Blockade-Based Cancer Immunotherapy 
Target Drug name Cancer Type Current Status 
PD-1 Nivolumab Melanoma, lung cancer FDA approved 
Multiple cancers Phase I-III 
Pembrolizumab Melanoma FDA approved 
Multiple cancers Phase I-III 
MED10680 Multiple cancers Phase I 
AMP-224 Multiple cancers Phase I 
Pidilizumab Multiple cancers Phase I-II 
PD-L1 Atezolizumab Multiple cancers Phase I-III 
MED14736 Multiple cancers Phase III 
Avelumab Multiple cancers Phase I-III 
BMS-936559 Multiple cancers Phase I 
CTLA-4 Ipilimumab Melanoma FDA approved 
Multiple cancers Phase I-III 
Tremelimumab Multiple cancers Phase I-III 
LAG-3 IMP321 Multiple cancers Phase I 
BMS-986016 Multiple cancers Phase I 






Programmed Death-1 (PD-1) 
 
The PD-1 immunoinhibitory receptor is a type-1 transmembrane protein that belongs 
to the CD28 family (Dong et al., 2017). This is typically expressed by 
activated immune cells including T cells, B cells and myeloid cells (Nowicki et al., 
2017). It may also be present on  some tumour cells  (Kareva, 2018). PD-1 is 
delineated as a protein with capability of promoting apoptosis and inhibiting 
proliferation. Glucose metabolism and cytokine signalling in antigen-specific T cells 
are also correlated with checkpoint protein expression. PD-1 engagement also 
appears to reduce apoptosis of regulatory T cells, further increasing the 
immunosuppressive state of the microenvironment (Gianchecchi & Fierabracci, 
2018). 
PD-1 suppresses cellular activation and the cytoplasmic tail has two tyrosine 
residues which may undergo phosphorylation. PD-1 binds to either PD-L1 (CD274) 
or PD-L2 (CD273) which display moderate homology and whose differential role is 
not entirely confirmed. Genetic evidence from PD-1 deficient T cells suggests that 
PD-L1 and PD-L2 may also bind to a still unknown co-stimulatory receptor that is 
expressed on T cells (Pardoll, 2015). 
PD-L1 and PD-L2 are expressed on a range of cells, including lymphoid and non-
lymphoid populations, and their expression is increased by inflammatory mediators 
such as IFN-γ (Dong et al., 2017). This is thought to represent one potential 




PD-1:PD-L1 interaction is very important in immune homeostasis and PD-1-deficient 
mice can develop auto-immunity, splenomegaly and expanded lymphoid tissues 
(Mak & Saunders, 2006). 
TIM-3 (T Cell Immunoglobulin and Mucin-domain containing-3) 
 
T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) is a negative 
regulator of T cell activation and expressed on many immune cells, namely NK cells, 
macrophages (Sakuishi et al., 2013), T cells, regulatory T cells (Tregs), dendritic 
cells (DCs), B cells and mast cells (He et al., 2018). Tim-3 is also expressed on 
regulatory T cells and it is of interest that this is seen most strongly within the tumour 
bed rather than in peripheral sites (Yan et al., 2013). . 
Tim-3 is a type I membrane protein and consist of 302 amino acids. Its basic 
structure encompasses an extracellular IgV domain, a single transmembrane 
domain, a C-terminal cytoplasmic tail (Monney et al., 2002)  and a glycosylated 
mucin domain with varying length . Despite the absence of either an ITIM and ITAM 
inhibitory signalling motif, Tim-3 has 5 tyrosine residues in its cytoplasmic tail which 
may undergo phosphorylation (Meyers et al., 2005). In the absence of ligand binding 
Bat3 and Lck are recruited to this tail and this promotes T cell signalling. In contrast, 
when Tim-3 binds to a ligand Bat3 is released, Fyn becomes recruited and T cells 
are suppressed (Granier et al., 2017). There are four ligands that can bind to Tim-3 
including galectin-9 (Gal-9) (Zhu et al., 2005), HMGB1 (Fonslow et al., 2013), 




2017) and phosphatidylserine (Weber & Zhou, 2017) . The first identified ligand was 
Gal-9 which binds to the carbohydrate motif on Tim-3 (Zhu et al., 2005). PtdSer 
binding promotes antigen cross presentation by DCs (Trahtemberg & Mevorach, 
2017). Nucleic acid released by dying cancer cells are bound by HMGB1 leading 
attenuation of the innate immune responses (Fonslow et al., 2013). The most recent 
ligand characterized was Ceacam-1 whose co-expression with Tim-3 functions as a 
negative regulator of T cell-mediated immune responses. The interaction between 
Ceacam-1 and Tim-3 can be either cis or trans, and both allow T cell immune 
tolerance (Du et al., 2017). 
Expression of Tim-3 is highly associated with T-cell exhaustion that leads to anti-
tumour immunity inhibition. Blocking this checkpoint molecule allows T cells increase 
their cytokine production, mainly int the form of IFN-γ. It is therefore enhancing T 
cell-mediated cancer immunity.  In in vitro and in vivo models, the presence of Tim-
3+ CD8+ T cells were seen to be correlated with PD-1 expression (He et al., 2018). 
Dual expression of Tim-3 and PD-1 is characteristic of highly exhausted CD8+ T 
cells and dual blockade against PD-1 and Tim-3 appear synergistic in boosting T cell 
function (Zhou et al., 2011). This does suggest that the molecules have non-
redundant functions (Anderson et al., 2016)and this has been shown in vitro (He et 
al., 2018). Currently, the application of one monoclonal antibody against Tim-3 
(MBG453) to patients with advanced malignancies (NCT02608268) is being 
investigated in phase I-II clinical trial. Yet, no clinical results are reported (Marin-




T Cell Immunoglobulin and ITIM Domain (TIGIT) 
 
TIGIT also known as WUCAM, Vstm3 or VSIG9 is a member of the poliovirus 
receptor (PVR)/nectin family, a subset of the immunoglobulin superfamily (Marin-
Acevedo et al., 2018;  Manieri et al., 2017). TIGIT expression is restricted to 
lymphocytes and is seen on a range of cells, including effector, follicular helper and 
regulatory subsets (Catakovic et al., 2017). 
TIGIT indirectly increases the production of immunoregulatory cytokines like IL-10, 
and on the other hand inhibits the production of IFN-γ and IL-17a, therefore acting 
to suppress DC maturation (Li et al., 2014). There are two dominant agonists for 
TIGIT, the poliovirus receptor (PVR;CD155) and nectin-2 (PVRL2; CD112), which 
are quite widely expressed (Yu et al., 2009). High level expression of TIGIT has been 
seen in many populations of tumour infiltrating lymphocytes (Li et al., 2019). 
T cell functions, generally, are regulated by inhibitory receptors via 3 main 
mechanisms: (1) cell-intrinsic modulation through intracellular signalling domain of 
the receptor (Attanasio & Wherry, 2016), (2) indirect effects resulted from 
competition among T cells and costimulatory receptors for shared ligands on APCs 
(Chen & Flies, 2013), and (3) function modulation of the ligand-expressing cells 
(Escors, 2011). Interestingly, in 2014 Johnston et al. discovered that TIGIT’s 
immunomodulatory effects were CD226-dependent. TIGIT is shown to affect  CD226 




ligand, representing a novel mechanism through which inhibitory receptors can elicit 
their immunomodulatory effects (Johnston et al., 2015).  
Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) 
 
The interaction between CD80 or CD86 on dendritic cells, and CD28 on T cells, is a 
key ‘second signal’ that facilitates activation of the effector cell during a primary 
immune response (Beyersdorf et al., 2015). CTLA-4 is a fascinating protein that is 
expressed on activated T cells and has exceptionally high affinity for CD80/CD86. 
As such it can act to physically pull CD80 off the surface of the dendritic cell and 
suppress T cell activation. Ipilimumab is a monoclonal antibody that binds to, and 
blocks, CTLA-4 and has been shown to have efficacy in  the treatment of metastatic 
melanoma (Savoia et al., 2016). This is attributed by its ability to improve the strength 
and breadth of primary immune responses, presumably against tumour antigens. 
LAG-3 (Lymphocyte Activation Gene-3) 
  
LAG-3 (CD223) is a co-inhibitory receptor that suppresses T cell activation . n 
physiological condition, it presents to maintain the immune homeostasis. It is 
expressed on many immune cells but the downstream processes involved in  LAG-3 
signalling are currently unclear (Andrews et al., 2017) . LAG-3  expresses four IgG 
loops and as such is somewhat similar to CD4, but there is only around 20% amino 
acid homology and LAG-3 has an additional loop (Drake & Drake, 2011). This may 
assist it in binding to MHC-II with greatly increased affinity and subsequently 




The application of LAG-3-targeted immunotherapy started with a LAG-3/Ig fusion 
protein (IMP321) and there are now many such reagents in development (Isakov, 
2018). 
To our best knowledge, the inhibitory checkpoint pathway most commonly 
associated with TGCT is PD-1/PD-L1, seen on around 60-70% of tumours 
(Fankhauser et al., 2015). PD-L1 expression can also be seen on stromal cells 
although interestingly this was seen only in seminomas. As such PD-L1 may 
represent an interesting target in clinical treatment. This study employed IHC 
technique on archive FFPE TGCT tissues. I used a different method in which flow 
cytometry was used to detect and quantify the simultaneous expression of the five 
checkpoint proteins mentioned above. This is important to gain some understanding 

















Fig. 4-1. Gating strategy to assess the expression of checkpoint proteins 
First, cells were gated for singlets on the basis of FS PEAK (Y Axis) and FS INT (X Axis). Second, live CD45 cells were obtained. 
Third, live CD45+ cells were gated on the basis of the expressions of CD3.  Next, cells were gated for the expression of CD4 or 
CD8. Finally, checkpoint expression was measured on the two major T cell subsets. Checkpoint markers examined in this study 




Our sample cohort consisted of peripheral blood samples from patients with 
seminoma (n=37) or non-seminoma (n=14) and also healthy donors (HD) (n=16). I 
presented my data as a median followed by quartile values. Statistical significance 
was determined using Kruskal-Wallis with Dunn’s multiple test, significance at 
p<0.05. To allow me to measure the simultaneous expression of more than one 
checkpoint marker on a cell surface, in addition to conventional quadrant gating 
strategy I also performed a Boolean gating scheme by which as many as 32 different 
expression combinations could be obtained by consolidating five checkpoint markers 
for each T cell subset. I therefore had a total of 64 expression combinations. 
Furthermore, single expression of a checkpoint protein has been defined in this 
chapter as a cell that expressed only one checkpoint marker and not the others. For 
example, PD-1-expressing T cells refers to a population consisting of PD-1+/TIGIT-
/Tim-3-/CTLA-4-/LAG-3-  T cells (either CD8+ or CD4+), and so forth. To enable this, 
Boolean gating scheme was used. This approach provided many advantages 
especially in the sense of multiple-probes/fluorochromes-stained-cell enumeration 
since they could be discriminated thoroughly according to their expression patterns.   
PD-1 alone is expressed at a low level on CD4+ and CD8+ T cells within 
peripheral blood  
 
PD-1 has been the most studied checkpoint in the context of cancer immunotherapy 
in TGCT. As discussed earlier, PD-L1 has been shown to be expressed within 
seminoma tumours and I had therefore anticipated that PD-1+ T cells might be 




from 25 HD and 42 non-small cell lung cancer (NSCLC) patients found selective 
increase on CD4+ in the patient group (Zheng et al., 2016).  
 
Fig. 4-2. The magnitude of single expression of PD-1 observed in seminoma and 
non-seminoma in comparison with healthy donor. 
 
However, my data showed otherwise (Fig. 4-2). Indeed, PD-1 alone was expressed 
at low frequency on both CD4+ and CD8+ T cells, at a median level of around 3-4% 
and a broad distribution between donors. Of note, whilst the data within the CD4+ T 
cell subset appeared to be normally distributed, we found some extreme outliers in 
relation to CD8+ T analysis. In particular one donor in the seminoma group had a 
frequency of 35% PD-1+ CD8+ T cells. This might be associated with the age and 




years old. Furthermore, the patient was diagnosed with stage IIIC where the stage 
is the most advanced within the entire dataset.   
One of our HD also displayed an exteremely high expression of PD-1 that reached 
a level of 26%. But this feature seems to be irrelevant with the age as the particular 
donor was only 25 years old. This abrogates my initial assumption that in 
physiological condition, PD-1 expression may positively correlated with age.  
Further studies will be required to investigate the relationship between PD-1 
expression and clinical data such as tumour stage, grade and metastases.  
Single expression of TIGIT is observed on many CD8+ T cells within peripheral 
blood 
 
I next went on to assess the expression of TIGIT on peripheral T cells. The 
frequencies of CD8+ T cells expressing ‘TIGIT alone’ in seminoma, non-seminoma 
and HD were 32.3% [IQR 23.8, 39.8], 25.3% [IQR 19.3%, 29.8%] and 31.1% [IQR 
18%, 34.7%], respectively (Fig. 4-3). TIGIT expression of CD4 cells was somewhat 
lower, typically around 12-14% and did not vary between groups.  
Indeed, TIGIT was the checkpoint protein that was expressed most strongly by most 
cells within my analysis. The frequency of TIGIT expression is approximately 2.5 
times greater than that of PD-1 in both T cell subsets in all the groups and this 





Fig. 4-3. Profile of single TIGIT expression on T cells within peripheral blood 
TIGIT is expressed by many cells within the CD8+ (left)  and CD4+ (right) T cell subsets. 
The frequency differences among the 3 investigated groups are not statistically significant 
(Kuskal-Wallis with Dunn’s multiple test, significant at p<0.05).  
 
However, even though TIGIT was the most frequent expressed checkpoint in 
seminoma, non-seminoma and HD, no significant differences were observed 
between the three groups. The high percentage of TIGIT+ CD8+ T cells in HD 
suggests that TIGIT might be a marker of senescence/exhaustion. I initially assumed 
that this might be attributed by age. In order to address this, I picked top 5 highest 
TIGIT-expressing patients in seminoma and correlated this expression with their 
corresponding age and stage. The highest TIGIT-expressing patient (68.5%) aged 




features of metastases were observed and aged 56 years old, expressed TIGIT 
almost a half lower (39.6%). Likewise, a patient who was 54 years old with stage IB 
seminoma showed 5% lower expression of TIGIT in CD8 population than a 49 year 
old-patient with stage IB. Similar trends were also observed in nonseminoma and 
HD. Therefore, speculation that TIGIT expression might be age- and stage-affected 
is weakened. A bigger size of sample is necessary for further investigation. Song et 
al (2018) have recently evaluated TIGIT expression in PBMCs collected from HD of 
different ages by flow cytometry and found results that were comparable to my data. 
In addition, they also reported that older donors had a higher frequency of TIGIT+ T 
cells compared with younger donors (Song et al., 2018). However, the majority of 
these TIGIT+ CD8+ T cells also expressed other inhibitory receptors including PD‐1. 
Furthermore, they exhibited features of exhaustion such as downregulation of CD28 
and high susceptibility to apoptosis. It is possible that TIGIT+ CD8+ T cells are 
undergoing an early stage of T‐cell immunosenescence, a phenotype associated 
with loss of the ability of self‐renewal and long‐term survival (Kasakovski et al., 
2018). 
The profile of single Tim-3 expression on peripheral blood T cells 
 
I further went on to determine the profile of Tim-3 expression on T cells within the 3 
cohorts. Tim-3 expression was found to be much lower compared to PD-1 and TIGIT 
with median values that were below 1% of the T cell pool. However, here for the first 
time I observed statistically significant differences between the findings in the control 






Fig. 4-4. The pattern of single Tim-3 expression on peripheral blood 
Tim-3 expression is significantly increased on CD8+ T cells from patients with non-
seminoma tumours compared to the other two groups. Within the CD4+ cell subset  this 
value is increased in nonseminoma compared to HD.  
 
In particular, Tim-3 expression on CD8+ T cells from the seminoma, nonseminoma 
and HD groups are the levels of  0.27% [IQR 0.19%, 0.75%], 0.64% [IQR 0.40%, 
1.25%] and 0.35% respectively. Expression frequency on the CD4+ T cell subset 
was 0.06% [IQR 0.04%, 0.10%], 0.09% [IQR 0.06%, 0.13%] and 0.03% [IQR 0.02%, 
0.06%] in these groups respectively [IQR 0.13%, 0.47%]. As such the frequency of 
expression of this checkpoint marker on CD8+ T cells is 4 to 10-fold higher compared 
with the values on CD4+ T cell. At this stage it is not clear if this represents the fact 




exposure or if this checkpoint protein has a differential mechanism of action on CD4+ 
and CD8+ subsets.  
In the CD8+ T cell subset, I saw two comparisons that generated statistical 
significance while in CD4+ cell subset only a comparison turned out to be significant. 
Significances in CD8+ T cell subset were obtained from non-seminoma vs HD with 
p-value of 0.002 (Kruskal-Wallis with Dunn’s multiple test, p<0.05). Within the CD4+ 
T repertoire, Tim-3 is strikingly enhanced in non-seminoma compared to HD with p-
value=0.015 (Kruskal-Wallis with Dunn’s multiple test, p<0.05).  
By exhausting T cells, Tim-3 weakens anti-tumour immunity. Tim-3+ CD8+ T cells 
exhibit dysfunctional STAT5 and p38 signalling. Blocking of Tim-3 pathway can 
improve cancer immunity because interferon-gamma (IFN-γ) will be generated more 
by T cells (Li et al., 2018). The expression of Tim-3+ CD8+ T cells seems to be 
having some correlation with PD-1 expression in both in vitro and in vivo models. It 
can inhibit the effector T cell proliferation and reduce cytokine production such as 
interleukin-2 (IL-2) (Carter et al., 2002).   
At this stage it is not clear why Tim-3 would be increased on T cells from non-
seminomatous tumours but not the seminoma subtype. It is certainly true that this 
category of tumours have a worse clinical outcome and it is possible that the 






The pattern of co-expression of PD-1 and TIGIT on peripheral blood T cells 
 
I next went on to measure the pattern of co-expression of PD-1 and TIGIT on PBMC 
from TGCT patients and HD (Fig. 4-5). The frequencies of PD-1/TIGIT co-expression 
on CD8+ T cells were observed at median levels of 10.2% [IQR 6.57%, 13.40%], 
7.90% [IQR 5.97%, 15.30%] and 10.8% [IQR 3.45%, 13.805] in seminoma, non-
seminoma and HD cohorts, respectively. This co-expression frequency was also 
quantified in the respective CD4+ T cell subsets at 4.65% [IQR 3.48%, 7.02%], 
4.42% [IQR 2.81%, 6.03%] and 6.30% [IQR 3.48%, 7.64%] respectively.  As such, 
the level of PD-1/TIGIT co-expression was typically around 2-fold higher on CD8+ T 
cells compared to the CD4+ subset.  
These data show that the frequency of cells that shows co-expression of PD-1 and 
TIGIT was larger than PD-1 single expression. However, when compared with TIGIT 
single expression, PD-1 and TIGIT co-expression was observed at slightly lower 
frequencies.  
In 2018, co-expression of PD-1 and TIGIT was investigated by Li et al (2018). They 
carried out fluorescence measurements on archived FFPE of Nodular Sclerosis 
Classical Hodgkin’s Lymphoma (NSCHL) tissues. Their results showed that the 
majority of T cells (68%) in NSCHL had co-expression of TIGIT and PD-1, while 
single positivity for TIGIT and PD-1 was seen in only 14% and 5% respectively. The 
remaining 13% T cells had neither TIGIT nor PD-1 expression (Li et al., 2018). These 




observations. However, it was important that I had been able to include control 
samples in my analysis and this showed that there was no additional increment in 
the proportion of T cells that exhibited PD-1 and TIGIT co-expression within the 
cancer patients.  
An important consideration is that I chose to focus my studies on the percentage of 
cells that were positive for cytokine expression. On reflection, it is clear that it would 
also have been valuable to measure the mean fluorecence intensity (MFI) of cytokine 










Fig. 4-5. Co-expression of PD-1 and TIGIT on peripheral blood cells from patients with testicular cancer and healthy 
donors 
(Left panel) Gating strategy to determine and quantify the frequencies of PD-1/TIGIT-expressing T cells. (Right panel) Data of 
PD-1/TIGIT-expressing T cell is presented individually with median and quartile values (upper and lower quartiles) for each group. 




The profile of single CTLA-4 expression on peripheral blood T cells 
 
The next checkpoint protein that I examined was CTLA-4, a protein which binds 
strongly to CD80/86 and competes with CD28 to suppress T cell activation. The 
pattern of single CTLA-4 expression on peripheral blood was rather low and 
indeed somewhat similar to that observed for Tim-3. In particular, CTLA-4 was 
expressed by either CD8 or CD4 at low frequencies. However, a major difference 
here was that expression was increased on CD8+ and CD4+ T cells in samples 
from patients with both seminoma and non-seminomatous tumours (Fig. 4-6). 
 
Fig. 4-6. The pattern of CTLA-4 expression on T cells within peripheral blood 
CTLA-4 expression frequency is significantly increased in seminoma and non-seminoma 
groups compared to HD in both CD8+ and CD4+ T cell subset. 
 
The percentage of CTLA-4+ CD8+ T cells in patients with seminoma, non-
seminoma and in HD respectively were 0.45% [IQR 0.21%, 0.63%], 0.46% [IQR 




cell subset, the comparable CTLA-4 expression frequencies were 0.31% [IQR 
0.21%, 0.60%], 0.37% [IQR 0.18%, 0.70%] and 0.15% [IQR 0.09%, 0.19%] 
respectively. As such the frequencies of CTLA-4 expression on CD8+ and CD4+ 
T cells appear to be broadly comparable. In the CD8+ population, the increase of 
CTLA-4 yielded p-values of 0.003 and 0.021 for the comparisons of seminoma 
vs HD and nonseminoma vs HD, respectively (Kruskal-Wallis with Dunn’s 
multiple test, p<0.05). For the CD4+ population, the frequencies of CTLA-4-
expressing cells in seminoma and nonseminoma resulted in p-values of 0.0005 
and 0.005 when each was compared to HD (Kruskal-Wallis with Dunn’s multiple 
test, p<0.05). No statistical significance was observed between seminoma 
compared to nonseminoma. 
The profile of single LAG-3 expression on peripheral blood T cells 
 
Finally, I next investigated the expression of LAG-3 on the peripheral blood 
samples. LAG-3 was the least expressed checkpoint marker, with individual 
frequencies that varied from very low to undetectable in the majority of  samples. 
However overall expression was higher on CD8+ T cells from both tumour groups 
compared to the control subjects (Fig. 4-7). A similar profile was observed for the 
CD4+ subset in relation to the seminoma samples. It should be noted that there 
were occasional outliers in both these groups. In particular, LAG-3 was 
expression on 1.4% of CD8+ T cells from one donor whilst another donor showed 
a value of 9.4% on the CD4+ subset. Despite these outliers it was clear that these 
did not distort the overall statistical analysis. 






Fig. 4-7. The pattern of LAG-3 expression on T cells within peripheral blood 
LAG-3 is expressed at low levels by both CD8+ and CD4+ T cells in HD. Overall 
expression is increased on blood from patients with either seminoma or nonseminoma. 
Statistical significance is obtained by both T cell populations in seminoma compared to 
healthy donor with p-values are 0.006 and 0.043 for CD8+ and CD4+, respectively 
(Kruskal-Wallis with Dunn’s multiple test, significance at p<0.05).  
 
The pattern of LAG-3 expression is therefore similar to that observed with Tim-3 
and CTLA-4 and rather distinct from that observed with PD-1 and TIGIT. In 
seminoma, nonseminoma and HD, the LAG-3 molecule is expressed by 0.421% 
[IQR 0.132, 0.980%], 0.411 [IQR 0.166, 0.644] and 0.104% of T cells [IQR 0.078, 
0.368] respectively. Despite the small frequency demonstrated by each tested 
group, the number of LAG-3-expressing CD4+ T cells in seminoma was higher 
than HD. On the other hand, no significance was observed in the comparison of 
LAG-3 expressing CD4+ T cell frequencies in nonseminoma and HD. This 




expression, potentially to avoid immune surveillance. This pattern is also seen for 
CD8+ T cells where LAG-3 is significantly upregulated within seminoma (p-
value=0.006).  
Owing to some outliers detected in datasets of seminoma and HD, I wondered if 
these contributed to the observed significances. I further carried on outliers 
cleanse and re-analyzed data using one way ANOVA with Tukey’s mutilple test.  
The significance were not affected by the outlier omission (p-value=0.002) 
suggesting that outliers did not perturb significance in the particular comparison 
(seminoma vs HD).  
In particular, with PD-1 and TIGIT expression, there was no difference in 
expression between the tumour groups and the HD. As such there is no indication 
to consider PD-1 and TIGIT as markers of T cells exhaustion due to the testicular 
tumour. In contrast, LAG-3 joins Tim-3 and CTLA-4 as a potential marker of T cell 
exhaustion within this patient cohorts. LAG-3 expression has not previously been 
investigated on PBMC from TGCT patients. A relevant study on LAG-3 was 
conducted by He et. al (2017) who observed LAG-3 expression on a subset of 
TILs from 36 patients with NSCLC. LAG-3 was here overexpressed on TILs in 
nonadenocarcinomas compared to adenocarcinomas and acted as a marker of 
poor clinical outcome (He et al., 2017). In contrast to the results from He’s group 







TGCT is an interesting model for studying the role of immune response in 
relationship with anti-tumour treatment. The tumour demonstrates superior 
clinical responses to therapy compared to virtually all other subtypes of cancer. 
A deep and integrative understanding on how this good prognosis is mediated 
after treatment may help in the design of anti-tumour therapeutic approaches for 
many patients.  The expression of checkpoint proteins on immune cells is now 
appreciated to play a major role in the regulation of tumour-specific immune 
responses (Zappasodi et al., 2018). In particular, checkpoint proteins on T cells 
within the tumour microenvironment has been associated transcriptional and 
metabolic alterations that induce a profile of ‘exhaustion’, with  incremental loss 
of effector function. PD-1 is the canonical exhaustion marker. PD-1 is briefly 
expressed on T cells after activation but when this expression is sustained it it felt 
to be a reflection of exhaustion due to persistent antigen exposure. This 
phenotype extends to overexpression of other inhibitory receptors including Tim-
3, Lag-3, CTLA-4, and TIGIT (Thommen & Schumacher, 2018). In this chapter I 
analysed the expression of a range of important checkpoint proteins on peripheral 
blood T cells from patients with testicular cancer.  
I chose to assess the expression of five different checkpoint proteins that are 
representative of the most important proteins associated with tumour-specific 
responses. The pattern of expression on the tumour and control samples varied 





It should be noted that this analysis was performed on peripheral blood samples 
and not directed on tumour infiltrating lymphocytes within the testicular tumour. 
This was done as it had proven very difficult to obtain samples of tumour biopsy 
from men undergoing orchidectomy. In addition, it remains valid to assess 
peripheral responses as these have been shown to correlate with local analysis 
in some  (Desgrandchamps et al., 2018), but not all studies (Kwiecien et al., 
2019). Nevertheless, I did anticipate that my findings in relation to the degree of 
checkpoint expression would be rather less marked than observed on TIL 
populations.  
One advantage of using peripheral blood samples is that I was able to incorporate 
the use of healthy donor control samples. These were age-matched with the 
samples from TGCT patients and this is an important consideration as the 
expression of checkpoint proteins on peripheral blood lymphocytes can increase 
during aging.   
A number of interesting findings were obtained from my results. Firstly, it was 
somewhat surprising that the expression of PD-1 did not differ between the 
patient and control groups. PD-1 is the most heavily studied checkpoint protein 
and checkpoint therapy that targets the PD-1:PD-L1 interaction is the most 
effective therapy at the current time. My results did reveal a wide range of PD-1 
expression levels on both the control and patient groups. The determinants that 
regulate the heterogeneous expression of PD-1 on T cells within the blood are 
not yet known but could include factors such as chronic viral infection or 
inflammation. It was remarkable that two donors expressed PD-1 on over 15% of 




Expression of TIGIT was also heterogeneous in both patient and control groups 
but again no associations were observed between this profile and the TGCT 
diagnosis. Cells with single TIGIT expression were more common than those with 
PD-1 and represented around 30% and 15% of the CD8+ and CD4+ T cell 
repertoires respectively. TIGIT was also expressed in association with PD-1 on a 
considerable number of peripheral T cells. This was enumerated at around 10% 
of the CD8+ T cell pool and 5% of the CD4+ pool. A similar phenotype h as been 
found in previous studies and shown to reflect a population with senescent 
phenotype (Song et al., 2018). Importantly, this phenotype increases with age 
although my data show that considerable numbers of these cells are already 
present in young to middle aged donors (20-50 years).  
In relation to TCGT my results become somewhat more interesting for analysis 
of Tim-3, CTLA-4 and LAG-3.  In particular, expression of these markers was 
shown to vary in patients with cancer compared to the control group, although 
the pattern of expression was different in each case.  
Tim-3 was unusual in the sense that higher expression levels were observed on 
CD8+ and CD4+ T cells in patients with non-seminomatous tumours. In contrast 
there was no such increase in seminoma. Our previous work had shown that 
cancer testis-specific responses were particularly marked in patients with 
seminoma and as such I was anticipating that exhaustion might be particularly 
strong in the seminoma subgroup. Nevertheless, the non-seminomatous group 
of patients do have an impaired clinical outcome and it will be of interest to see if 
this is related to T cell exhaustion. The importance of Tim-3 in cancer 




applied to mark immune responses following nivolumab therapy (Kato et al., 
2018). 
The expression of CTLA-4 and LAG-3 was found at only low levels in all the 
samples However, this was clearly increased in the patient subgroups. In 
particular, CTLA-4 was increased on both CD4+ and CD8+ T cells in patients with 
either seminoma or non-seminomatous tumours. LAG-3 showed a slightly 
different profile and was increased only in the seminoma subgroup.  LAG-3, Tim-
3 and PD-1 co-expression is increased on peripheral T cells in patients with 
ovarian cancer and further supports the potential importance of my results 
(Rådestad et al., 2019). 
These data reveal that the pattern of peripheral T cell checkpoint expression is 
heterogeneous in patients with testicular cancer. The findings suggest that PD-1 
and TIGIT may not be the most valuable markers in which to define a ‘tumour-
specific checkpoint phenotype’ within peripheral blood in TCGT patients. Indeed, 
the relatively high expression of these markers may simply reflect physiological 
regulation of immune function and potentially also a component of aging-
associated immunosenescence. However, other groups have shown that PD-1 
expression is increased on peripheral T cells in some solid tumours and so there 
may be a tumour-specific association in this regard (Zgodzinski et al., 2019). 
In contrast, CTLA-4 and LAG-3 may represent valuable markers with which to 
identify relatively rare populations of ‘exhausted’ cells within blood. This might 
even allow the isolation of tumour-reactive cells from the vascular compartment 




carcinoma (Huang et al., 2019). It will be interesting in future work to assess the 
pattern of co-expression of the Tim-3, CTLA-4 and LAG-3 checkpoint proteins. 
This might reveal a particularly powerful and specific ‘cancer-associated’ 
phenotype. Unfortunately, these cells were too rare for detection in my own 





CHAPTER V. THE PATTERN OF CYTOKINE PRODUCTION BY 
PERIPHERAL T CELLS IN TGCT PATIENT COHORT 
 
Cancer is a very common clinical problem in modern society and as such it is 
clear that the immune system is not capable of controlling the proliferation of 
transformed cells in all cases. The mechanisms by which tumours can escape 
immune control are a major topic in clinical research. This includes the 
development of antigen-loss variants and the inactivation of antigen 
processing/presentation pathways through which the T cells lose their ability to 
recognize tumour cells (Garrido et al., 2016).  It is imperative that auto-immune 
responses are avoided over the lifecourse and as such vertebrates have evolved 
a range of mechansism to generate immune tolerance to ‘self’ proteins. As 
tumour antigens are often subtle modifications of self protein this means that 
tumour-specific T cell responses are often weak. Evidence of immune escape is 
seen in many tumour subtypes. This has been used to support the model of 
immune surveillance as a mechanism to control cancer development (Roufaiel et 
al., 2015). 
As a major effector arm of the immune responses, cytokine production has a 
profound impact on the nature of the subsequent immune response. 
Immunological dogma suggests that the immune system facilitate Th1 and Th2 
CD4+ polarization in which different CD4+ cells can respond to antigen 
stimulation by generating cytokines such as IFN-γ and TNF-α, or IL-4 and IL-13 
respectively (Mosman et al, 1989) . It is now clear that there is a broad spectrum 




may modulate their cytokine responses over time and exhibit ‘plasticity’ in their 
functional response.  
Given my previous work on the phenotype and checkpoint protein expression on 
T cells within the blood of patients with testicular cancer I was interested to 
assess the functional response of these cells in comparison to healthy donors. 
Specifically, I undertook an analysis of cytokine production from peripheral blood 
CD4+ and CD8+ T cells following stimulation with PMA/Ionomycin.  
Assessment of cytokine responses in peripheral blood samples from 
patients and donors 
 
PMA/Ionomycin was used as it is a potent mitogen and is generally 
acknowledged to be the optimal method for stimulation of T cells prior to 
assessment of cytokine production (Crawford et al., 2014). PMA activates protein 
kinase C, whilst ionomycin is a calcium ionophore, and stimulation with these 
compounds ‘bypasses’ TCR engagement and leads to activation of several 
intracellular signaling pathways, resulting in T cell activation and production of a 
variety of cytokines (Ai et al., 2013).  
Blood samples at the time of diagnosis were available from 31 patients with 
seminoma, 15 with non-seminomatous malignancy and 13 age-matched healthy 
donors (for details of donors see Chapter III). PBMC from patients and gender-
matched controls were stimulated with PMA/ionomycin for 4 hours in the 
presence of protein transport inhibitor, followed by ICC staining. A non -stimulated 
control which contained only protein transport inhibitor was used to examine 




performed using antibodies to assess type-1 (IFN-γ), type-2 (IL-10 and IL-13), 
and type-17 (IL-17a and IL-21) cytokine responses.  
IFN-γ production is conserved within T cells from the patient group 
 
Interferons were originally described as a group of  molecules with a similar 
function, that of inducing  an immediate defensive response against viral 
infections. In the mid-1960s, type II IFN or IFN-γ was identified on the basis of its 
antiviral activities (Lee & Ashkar, 2018). However it is now known to play a much 
more important role as a more general proinflammatory molecule. It promotes all 
aspects of the Th1 immune response, while suppressing Th2 and Th17 
responses (Martinez et al., 2008).  In this study, I found that IFN-γ was the 
predominant cytokine produced by both CD4+ and CD8+ T cells regardless of 
disease status.  
Without PMA/Ionomycin stimulation, the median proportion of IFN-γ-producing 
CD8+ T cells in seminoma was only 0.12% [IQR 0.05%, 0.79]. With stimulation, 
this increased to 35% [IQR 22%, 50%] (left panel, Fig. 5-2). In patients with non-
seminoma tumours the proportion of IFN-γ+ CD8+ T cells without and with 
stimulation were measured at 0.13% [IQR 0.06%, 0.23%] and 44% [IQR 23.54%, 
52.88%] (left panel, Fig. 5-2) respectively. Comparative values in the HD cohort 
were 0.042% [IQR 0.02%, 0.10%] and 44% [IQR 30.78%, 63.14%] (left panel, 
Fig. 5-2).  
Similarly to CD8+ T cells, IFN-γ was the predominant cytokine produced by CD4+ 
T cells in all groups although the frequency was much less compared to CD8+ T 




of CD4+ T cells prior to stimulation compared to 12% [IQR 6.25%, 21.31%] 
following stimulation. In nonseminoma, these values increased from 0.08% [IQR 
0.02%, 0.31%] to 7.9% [IQR 4.02%, 14.38%] after stimulation. Levels of 
spontaneous secretion were 0.05% in the HD cohort [IQR 0.02%, 0.09%] 
compared to 14% [IQR 3.27%, 27.35%] following stimulation.  
These data show that IFN-γ levels following stimulation were in the range of 
fifteen to seventy-five fold higher compared to baseline production. It is known 
that the level of spontaneous cytokine production is very low within circulating T 
cells and so these results are comparable with other datasets. However it was 
noteworthy that the level of spontaneous IFN-γ production was around 3 fold high 
in both the CD4+ and CD8+ T cell subsets in the patient group. This raises the 
possibility that there are low levels of pre-activated T cells in patients with 
testicular cancer which may potentially represent tumor-specific clones.  
Despite this, my data suggest that the proportion of IFN-γ-producing T cells 
following stimulation does not differ between patients with different types of TGCT 





Fig. 5-1. IFN-γ production by CD4+ and CD8+ T cells following PMA/Ionomycin stimulation of PBMC from testicular cancer 
patients and healthy donors  
PBMC from patients and gender-matched controls were stimulated with PMA/ionomycin for 4 hours in the presence of protein transport 
inhibitor, followed by ICC staining. Graphs represent IFN-γ-producing T cells as a proportion of total CD8+ (top) and CD4+ (bottom) T 
cells from seminoma patients (left, n=31), nonseminoma patients (middle, n=15) and healthy donors (right, n=13). Each tick along the X 





Fig. 5-2. Summary of IFN-γ production by CD8+ and CD4+ T cell subsets following 
PMA/Ionomycin stimulation 
Comparison between the proportion of CD8+ and CD4+ T cells producing IFN-γ following 
PMA/Ionomycin stimulation in seminoma patients (n=31), nonseminoma patients (n=15) 
and healthy donors (n=13). Data analysed statistically using Kruskal-Wallis with Dunn’s 
multiple test, significance at p< 0.05. 
 
By analyzing the dataset using Kruskal-Wallis and further post-hoc testing with 
Dunn’s multiple test, no significance emerges from the comparisons of the 
increment of IFN-γ-producing T cell number in the healthy donor and the two 
subtypes of TGCT (all p-values exceed 0.05) (Fig. 5-2).  This suggests that there 
is no intrinsic impairment in pro-inflammatory T cell function. Since Th1/Tc1 
immunity is often associated with anti-tumour responses, this may contribute to 
the excellent clinical outcome of this disease. 
A subset of CD8+ T cells from patients with TCGT demonstrates 
spontaneous secretion of IL-17a  
 
CD4+ Th17 cells secrete IL-17a, which has been shown to have both anti-
tumourigenic and pro-tumourigenic roles and hence may play an important role 




(Tc17)  have also been described (Yen et al., 2009) yet little is know of their 
functional relevance in the cancer setting. Here, we examined spontaneous and 
mitogen-stimulated production of IL-17a by CD4+ and CD8+ T cells from TGCT 
patients and healthy controls.  
The frequency of spontaneous IL-17a production by CD4+ T cells between 
seminoma (0.43% [IQR 0.11%, 0.43%]), nonseminoma (0.17% [IQR 0.09%, 
0.39%], and healthy donors (0.16% [IQR 0.07%, 0.31%]) was low and not 
significantly different (right panel, Fig. 5-4). The frequency of IL-17a producing 
CD4+ T cells following stimulation was 0.86% [IQR 0.28%, 1.85%] in seminoma, 
0.48% [IQR 0.22%, 0.86%] in nonseminoma and 0.62% [IQR 0.26%, 2.86%] in 
HDs (Fig. 5-3). 
In general, the proportion of CD8+ T cells producing IL -17a was far lower than 
that observed from CD4+ T cells (left panel, Fig. 5-4). Interestingly, there was a 
significantly higher proportion of CD8+ T cells producing IL-17a without prior 
stimulation in vitro in both the seminoma (p<0.001) and nonseminoma (p<0.05) 
patients compared to healthy controls. However this difference between groups 
was lost following functional stimulation and there was no difference in the 
proportion of CD8+ T cells producing IL-17a following PMA/Ionomycin treatment 
between seminoma, nonseminoma and healthy donors. Our results show that IL-
17a is produced by a higher proportion of CD4+ T cells compared to CD8+ T cells 
in health and disease although a small proportion of CD8+ T cells demonstrate 





Fig. 5-3. IL-17a production by CD4+ and CD8+ T cells following PMA/Ionomycin stimulation of PBMC from testicular cancer 
patients and healthy controls 
PBMC from patients and gender-matched controls were stimulated with PMA/ionomycin for 4 hours in the presence of protein transport 
inhibitor, followed by ICC staining. Graphs represent IL-17a-producing T cells as a proportion of total CD8+ (top) and CD4+ (bottom) T 





Fig. 5-3. Summary of the IL-17a production patterns by CD4+ and CD8+ T cells in 
TGCT and HD. 
The production of IL-17 was assessed in response to mitogen challenge. No significant 
differences were observed between the groups (one way ANOVA with Tukey’s multiple 
test, significance at p<0.05) (Graph Prism 8). 
 
As demonstrated in Fig. 5-4, without receiving non-specific stimulation of 
PMA/Ionomycin, both CD8+ and CD4+ T cell populations in both subtypes of 
TGCTs are able to produce IL-17a at higher frequencies compared with HDs. 
Some outliers are identified in every tested group but their omissions do not alter 
significance values. Adjusted p-values remain below P<0.05, suggesting that, 
despite as individual data they are higher than 1.5 Q3 of their respective datasets, 







Fig. 5-4. Summary of the proportion of T cells that exhibit spontaneous release of 
IL-17a from testicular cancer patients and healthy donors 
Comparison is made of spontaneous production of IL-17a by CD8+ and CD4+ T cells 
from seminoma patients, nonseminoma patients and healthy donors. Data analysed 
statistically using Kruskal-Wallis with Dunn’s multiple test; *p-value=0.028, **p-
value=0.009.  
 
Production of IL-21 by CD4+ T cells is increased in seminoma patients  
 
IL-21 is a member of the γc family of cytokines and is produced by various CD4 
T cell subsets including follicular helper T (Tfh) cells and Th17 cells (Leonard et 
al., 2019). In addition, CD8 T cells have been shown to secrete IL-21 under 
certain conditions such as during chronic viral infections. IL-21 is able to regulate 
the function of various T cell subsets including Tregs, Th1 and Th2  cells and may 
therefore play an important role in balancing pro- and anti-tumour responses. 
In my study I found that IL-21 was produced by CD4+ T cells from healthy donors 
at a frequency of 1.02% [IQR 0.21%, 1.50%] of total CD4+ T cells following 
PMA/Ionomycin stimulation (Fig. 5-6). Spontaneous IL-21 production was 
detected at a very low frequency of around 0.08% [IQR 0.03%, 0.53%]. 




patients [IQR 1.18%, 3.06%]) demonstrating a small but significant increase 
compared to healthy controls (p<0.001) (Fig. 5-7). There was no significant 
difference between nonseminoma and healthy donors suggesting this is a 
phenomenon restricted to seminoma patients. A similar trend towards increased 
expression of IL-21 from CD8+ T cells in patients with seminoma was observed 



















Fig. 5-4. IL-21 production by CD4+ and CD8+ T cells following PMA/Ionomycin stimulation of PBMC from testicular cancer 
patients and healthy controls. 
PBMC from patients and gender-matched controls were stimulated with PMA/ionomycin for 4 hours in the presence of protein transport 
inhibitor, followed by ICC staining. Graphs represent IL-21-producing T cells as a proportion of total CD8+ (top) and CD4+ (bottom) T cells 





Fig. 5-5. Pattern of IL-21 production by CD8+ and CD4+ T cells following 
PMA/Ionomycin stimulation of PBMC from testicular cancer patients and healthy 
controls 
Comparison of IL-21 production by CD8+ and CD4+ T cells from seminoma patients , 
nonseminoma patients and healthy donors. Normality distribution of each dataset is 
performed via Shapiro-Wilk test. Since the data distribution in CD8+ T cell panel (left 
panel) is confirmed to be normal, one way ANOVA with Tukey’s multiple test is used to 
detect any significance from each comparison. Data distribution in CD4+ T cell (right 
panel), in contrast, is not normally distributed and thus is statistically analysed using 
Kruskal-Wallis with Dunn’s multiple test; significance at p< 0.05. 
 
This pattern of IL-21 production is similar to that seen for IL-17a where 
downregulation was observed in some patients across the 3 assessed groups. It 
is noteworthy that IL-21 can induce IL-17 production whereas generation of Th17 
cells is attenuated by blocking IL-21. IL-21 is known to activate STAT3 and its 
ability to induce Th17 differentiation is abrogated in the absence of STAT3 (Jin & 





Fig. 5-7. Spontaneous production of IL-21 by CD8+ and CD4+ T cells in PBMC from 
testicular cancer and healthy donor is detected at very low level and shows no 
significance among the 3 evaluated groups. 
Spontaneous production of IL-21 by CD8+ and CD4+ T cells from TGCT patients in 
comparison to that of HDs. Due to all datasets are not normally distributed, statistical 
analysis is performed by using Kruskal-Wallis with Dunn’s multiple test, significance at 
P<0.05. This analysis results in insignificant differences of spontaneous IL-21 production 
among the 3 tested groups. 
 
As illustrated in Fig. 5-7, spontaneous release of the cytokine is also detected, 
albeit the levels are much lower than that seen for IL-17a. No significance is 
produced any group comparison either by CD8+ or CD4+ T cell population. This 
suggests that IL-21 is not a strong feature for immune response against the 
disease. 
A subset of CD4+ T cells from testicular cancer patients spontaneously 
produce immunosuppressive IL-10 
 
I next evaluated the production of IL-10, a major immunosuppressive factor 
critical for the induction of tolerance through inhibition of Th1 immune responses 
and T cell cytotoxic activity. IL-10 hinders the proliferation, cytokine production 




activity in transplant rejection. IL-10 may act either via direct or indirect 
mechanisms to mediate immune suppression (Dennis et al., 2013). 
As expected, my data showed that stimulation with PMA/Ionomycin induced IL-
10 production predominantly by CD4+ T cells from healthy and cancer patients 
(Fig. 5-8). Intriguingly, the frequency of spontaneous IL-10 production from CD4+ 
T cells was statistically greater in seminoma patients (0.43% [IQR 0.13%, 0.775]; 
p<0.01) and nonseminoma patients (0.37% [IQR 0.11%, 0.60%]  p<0.05) 
compared to healthy donors (0.11% [IQR 0.05%, 0.26%]). No difference was 
observed between seminoma and nonseminoma (right panel, Fig. 5-9). However 
there was no significant difference in the profile of PMA/Ionomycin -induced 
production of IL-10 by CD8+ T cells between any of the 3 subject groups (left 





Fig. 5-8 Spontaneous and mitogen-induced IL-10 production by CD4+ and CD8+ T cells from testicular cancer patients and 
healthy controls 
PBMC from patients and gender-matched controls were stimulated with PMA/ionomycin for 4 hours in the presence of protein transport 
inhibitor, followed by ICC staining. Graphs represent IL-10-producing T cells as a proportion of total CD8+ (top) and CD4+ (bottom) T cells 





Fig. 5-9. Summary of IL-10 production by CD8+ and CD4+ T cells from testicular 
cancer patients in comparison with healthy controls following the PMA/Ionomycin 
stimulation. 
 
Fig. 5-10 Summary of spontaneous release of IL-10 by CD8+ and CD4+ T cells from 
testicular cancer patients in comparison with healthy controls 
Comparison of spontaneous production of IL-10 by CD4+ T cells from seminoma 
patients, nonseminoma patients and healthy donors. Data analysed statistically using 
Kruskal-Wallis with Dunn’s multiple test, significance at p<0.05.  
 
Some outliers are detected in the spontaneous production of IL-10, mainly within 
the seminoma group. There are 4 seminoma-derived outliers in the CD4+ subset 




other hand, CD8+ subsets in 4 patients with seminoma produced extremely high  
levels of IL-10, ranging from 0.5%-0.77%, compared with those seen for the 
remainders. A nonseminoma ‘outlier’ gave a value of 1.830% of IL-10-producing 
CD4+ and a HD contributed a value of 0.114% IL-10-producing CD8, also an 
outlier (left panel, Fig. 5-10). All these outliers in the seminoma group were at 
stage I whereas an outlier in the non-seminoma group was from a 26 years-old 
patient with stage IIB. It is intriguing that this spontaneous IL-10 production tends 
to increase by age in the CD4 subset when the disease was diagnosed at early 
stage (IA). In descending order, IL-10-producing CD4+ T cells are seen in the 
patients aged 59 (2.373%), 55 (2.200%), 28 (2.086%) and 26 (1.575%) (right 
panel, Fig. 5-10). This trend, however, is not observed in CD8 subset.  
IL-13 production was seen only in CD4+ T cells and was similar between all 
groups 
 
Finally I went on to examine the profile of IL-13 production from CD4+ T cells 
following PMA/Ionomycin stimulation. IL-13 is one of the Th2 cytokines that has 
similar effects on an immune response to IL-4. Recent studies have revealed that 
IL-13 plays a critical role in many aspects of immune regulation (Terabe, Park 
and Berzofsky, 2004), and hence may play a role in tumour immune evasion. 
IL-13 levels were undetectable without mitogenic stimulation and were also only 
observed in the CD4+ T cell subset. When the profile of IL-13 production by CD4+ 






Fig. 5-11. Summary of IL-13 production by CD8+ and CD4+ T cells following 
PMA/Ionomycin stimulation of PBMC from testicular cancer patients and healthy 
controls 
Comparison of IL-13 production by CD4+ T cells from seminoma patients , nonseminoma 
patients and healthy donors. Data analysed statistically using Kruskal-Wallis with Dunn’s 
multiple test, significance at P<0.05. 
 
 
Fig. 5-12. Spontaneous production of IL-13 by CD8+ and CD4+ T cells in PBMC 
from testicular cancer patients and healthy controls 
Comparison of IL-13 production by CD4+ T cells from seminoma patients , nonseminoma 
patients and healthy donors. Data analysed statistically using Kruskal-Wallis with Dunn’s 








My previous work had shown that subtle but clear differences were observed in 
the phenotype of peripheral T cells in patients with testicular cancer. Whilst these 
are of interest, their main importance would relate to how they modulate the 
function of the immune system in the patient group. T cell function can be 
assessed in a number of ways including proliferative response, cytokine 
production and cytotoxic activity. In this chapter I chose to focus on the pattern of 
cytokine production by peripheral  T cells as these are established as key 
regulators of immune activity in malignant disease.  
I opted to stimulate T cells with PMA/Ionomycin and one consideration was that 
this acts through bypassing TCR stimulation. Indeed, PMA/Ionomycin is used 
routinely to study T cell activation and proliferation as it works in a T cell receptor-
independent way. It does this by mimicking the phospholipase C-driven activation 
of PKC with the subsequent  increase of cytosolic Ca2+, PMA/Ionomycin activates 
the transcription factors: nucelar factor of activated T cell (NFAT1)-1, NF-κB and 
activator protein-1 (AP-1). This results in  downstream gene expression. Under 
different circumstances, these agents can either activate T cells or initiate 
activation-induced cell death (AICD) in lymphocytes (Han, et al., 2013). One 
consideration for future studies is that impairment of T cell receptor signalling is 
sometimes observed in patients with malignant disease and so parallel studies 
that incorporate the use of CD3 and CD28-mediated T cell activation would 




I chose to select a range of pro- and anti-inflammatory cytokines within my 
intracellular cytokine analysis. This included IFN-γ, IL-17a and IL-21 as well as 
the anti-inflammatory cytokines IL-10 and IL-13. A further decision that I made, 
and which in retrospect proved to be very valuable, was to measure the level of 
spontaneous cytokine production whenever these were at a detectable level.  
IFN-γ was the most abundantly produced cytokine from T cells in all three groups 
although no differences were observed between healthy donors and the patient 
groups. This indicates that T cells are broadly functional for Th1 responses and 
may potentially contribute to the impressive clinical responses seen in this group 
during chemotherapy.  
The pattern of IL-17a production was intriquing as higher levels of spontaneous 
cytokine production were observed from CD8+ T cells in patients with testicular 
cancer. The role of Th17 cells in cancer development is not yet defined but they 
have been suggested to potentially play either a pro- or anti-tumourogenic 
mechanism in different scenarios. As such the interpretation of this finding is 
unclear at this stage. Spontaneous cytokine production has not been investigated 
in any great detail in previous reports and is somewhat difficult to interpret as the 
number of cells that demonstrate this pattern is very small and large patient 
groups need to be studied. A similar trend was detected in the profile of 
spontaneous IL-21 production in CD4+ T cells which were significantly more 
common in patients with seminoma, but not non-seminoma. 
In relation to anti-inflammatory cytokines, IL-13 and IL-10 were both identified 




was of most interest, and this IL-10 expression by CD4+ T cells in seminoma and 
nonseminoma was significantly enriched compared to that of HD.  
Overall my findings show that peripheral T cells from patients with testicular 
cancer display a full range of cytokine responses following stimulation with 
mitogens in vitro. This profile is compatible with the clinical phenotype of patients 
with this disorder as they are not known to display any excess susceptibility to 
infection, inflammatory or auto-immune disease. However, blood from patients 
with testicular cancer did show increased numbers of T cells that display 
background levels of ‘spontaneous’ cytokine production without the need for 
mitogenic stimulation. This may reflect evidence of ongoing low level immune 
activation and may potentially represent evidence of a tumour-specific immune 
response. I was able to detect increased spontaneous production of both pro- 
and anti-inflammatory cytokines and as such it is not clear what the net effect of 
this profile would be. 
The use of intracellular cytokine analysis necessitates permeabilisation of the cell 
membrane and therefore the cell is rendered non-viable for further downstream 
analysis. This is a shame as my research indicates that a pattern of spontaneous 
cytokine production may represent a marker of immune activation and could 
potentially offer a tool for the detection and isolation of tumour-reactive T cells. 
Taken together, the results from my first three chapters suggest that the 
peripheral immune repertoire of patients with testicular cancer does demonstrate 
evidence for immune activation and this may reflect an ongoing tumour-specific 




approach to identify these rare cells, even in the absence of knowledge regarding 








CHAPTER VI. STUDY OF THE IMMUNE RESPONSE AGAINST 
CANCER/TESTIS ANTIGENS IN TGCT PATIENT COHORT  
 
As described earlier, the clinical outcome for patient with seminoma is very good 
and this may partially reflect the induction of an immune response against the 
tumour.  
In the next phase of my thesis I undertook a study to attempt to identify the 
antigenic target of T cells that might be involved in the immune response against 
testicular cancer. In particular, I obtained blood from patients with seminoma and 
undertook an analysis of the immune response against proteins from the MAGE 
family of cancer testis antigens. This work built on previous studies from the 
laboratory although these had exploited ELISPOT analyses as a means to 
identify immune responses (Pearce et al, 2017). Although ELISPOT is a very 
sensitive technology with which to identify T cell responses it does not allow 
downstream isolation of antigen-specific T cells, or the examination of multiple 
cytokines simultaneously. As such, I sought to utilise the application of 
Intracellular cytokine staining in order to identify peptide-specific responses. 
I chose to focus on immune responses against MAGE-A1, MAGE-A3 and MAGE-
A4 as these were identified as the major immunodominant proteins in the 
publication by Pearce et al, 2017. A limitation of my study was that I was not able 
to confirm expression of these proteins within the tumour sample of the patients 
studied. This was a shame, as histological sections of tumour would be available 
within the histopathology archives, but we did not have ethical permission to 




In particular, PBMC were collected from patients with testicular germ cell tumours 
(TGCT) and stimulated with overlapping peptide libraries followed by intracellular 
cytokine staining (ICC). Spontaneous immune responses were defined by the 
release of cytokines. In order to allow the potential identification of a wide range 
of functional T cell responses I undertook analysis of a range of cytokine 
responses including IFN-γ, TNF-α, IL-2 and GM-CSF. In addition, the expression 
of CD107a was identified in order to assess the cytotoxic activity of cells in 
response to antigen stimulation. IFN-γ and TNF-α are the two major cytokines 
produced by Th1 and NK cells and these therefore served as the primary focus 
of interest.  
Blood samples were taken from patients with seminoma at the time of diagnostic 
orchidectomy. These were an unselected subset of samples that had been 
analysed in previous chapters. PBMC were then isolated by density 
centrifugation and stimulated separately with 3 different peptideMix™ of MAGE-
A1, MAGE-A3 or MAGE-A4. Each peptide mix contained 75 peptides spanning 
the whole amino acids sequence. Each individual peptide was 15 amino acids 
(aa) long and an 11 aa overlap was incorporated between each peptide. Peptide 
mixes were purchased in the form of powder which was then dissolved in DMSO 
into the appropriate concentration as described in Materials and Methods 
(Chapter II). A formulation of DMSO alone was used as a negative control for cell 
stimulation. It was anticipated that the magnitude of the CTAg-specific response 
would not be intense and I therefore felt it necessary to incorporate a positive 
control for peptide stimulation. In this regard I used a peptide pool of CEFT. CEFT 




Cytomegalovirus, Epstein-Barr virus, Influenza (flu) virus and Clostridium tetani 
(Tetanus) which are restricted by a range of different HLA class I and class II 





Fig. 6-1. Gating analysis for identification of peptide-specific T cells 
Cells were initially gated on the singlets where clumped/doublet cells are excluded. This enables evaluation of cytokine expression on 
individual cell basis. FS INT (X Axis) and SS INT (Y Axis) gating was used to identify lymphocytes. CD3 expression was used to identify T 
cells. Further, the cells are divided into 2 primary subsets: CD8+ T cells and CD4+ T cells whose cytokine productions (IFN-γ, TNF-α, IL-2 





IFN-γ expression allows the identification of MAGE-A family specific T cells 




Blood samples were available from 9 patients with seminoma and 4 with other 
subtypes of testicular tumour. These were stimulated with the MAGE-A1 
overlapping peptide library as previously described. 
One sample from patients with seminoma (IN24) showed an increase of IFN-γ 
production in the CD8+ T cell subsets following stimulation with the peptide pool. 
The incremental magnitude of the cytokine response was 0.10% following 
challenge with MAGE-A1 overlapping peptides although there was also a high 
baseline level of 0.26%. Despite this, the clear increment in cytokine production 
observed following stimulation with the MAGE peptides was taken to represent a 
positive response. IN09 also demonstrated an enhanced level of IFN-γ 
production from CD8+ T cells after MAGE-A1 stimulation but this was very small, 
an increment of only 0.006% from the baseline level of 0.135% to 0.141%, and 
so was discounted. 
IFN-γ production was also observed in CD4+ T cell subsets. For instance, in  
sample IN41 this increased by nearly two fold from 0.015% to 0.037%. No such 
CD4+ response was observed in IN24 which had demonstrated a peptide-specific 
CD8+ response. The other six samples in the seminoma group, IN36, IN29, IN32, 
IN33, IN21 and IN12, did not respond to peptide stimulation within either the 






Fig. 6-2. IFN-γ responses of CD4+ and CD8+ T cells from patients with seminoma 
and non-seminoma tumours following stimulation with MAGE-A family peptide 
pools 
PBMC were isolated from 9 patients with seminoma and 4 patients with non-seminoma 
tumours. These were stimulated with overlapping peptide pools from MAGE-A1/A3/A4 
proteins. Cytokine-positive cells were then identified by expression of IFN-γ as a 
percentage of total CD8+ (left) or CD4+ (right) T cells. 
 
In the non-seminoma group, MAGE-A1 overlapping peptide stimulation did 
induce selective production of IFN-γ from CD8+ T cells in two samples, IN08 and 
IN37. In particular, the baseline cytokine production levels from these samples 
were 0.062% and 0.084% respectively but this increased to 0.13% and 0.27% 
following peptide stimulation (left panel, Fig. 6-2). CD4+ responses did not appear 




Sample IN19 also demonstrated a cytokine response in both the CD4+ and CD8+ 
T cell subsets against peptide stimulation with MAGE-A1. In particular, the 
frequency of CD8+ cytokine-producing cells was 0.19% compared to 0.04% in 
the unstimulated population. A similar response was observed in the CD4+ pool 
from this sample where the frequency of responding cells was 0.17% with a 
baseline of only 0.082% (right panel, Fig. 6-2). Overall, the results show a low 
frequency of T cell response to MAGE-A1 stimulation.  
MAGE-A3 Responses 
 
Unlike the MAGE-A1 overlapping peptide stimulation whereby responses were 
detected in 3 seminoma and 3 non-seminoma patients, the MAGE-A3 
overlapping peptide stimulation resulted in fewer responding patients. In the 
seminoma group, responses were demonstrated by sample IN36 where IFN-γ+ 
CD8+ T cells were detected at the frequency level of 0.11% (left panel, Fig. 6-2). 
This value is 3.5 fold higher than that seen in the unstimulated control. The CD4+ 
T cells in this sample did not seem to produce the cytokine post-stimulation. The 
other samples in the seminoma cohort did not show an apparent increase on IFN-
γ-production either from their CD8+ T cells or their CD4+-counterparts. In the 
non-seminoma group, a positive response was seen with sample IN19 where the 
baseline value of  0.053% within CD8+ T cells was increased to 0.218% following 
MAGE-A3 overlapping peptide stimulation. This specific response was in fact 
even higher than that of MAGE-A1 stimulation (0.19%) (left panel, Fig. 6-2). CD4+ 
T cells in sample IN36 and IN19 also responded upon stimulation although their 
responses were weaker than that of their respective CD8+ T cells. IFN-γ-




value was 0.218% (right panel, Fig. 6-2). The baseline levels were 0.021% and 
0.082% in IN36 and IN19, respectively (left panel, Fig. 6-2). MAGE-A3 
overlapping peptide could enhance the production of IFN-γ by CD4 approximately 
2-folds higher in IN36 and 3-folds higher in IN19. The remaining samples 
appeared to be irresponsive to the MAGE-A3 stimulation. 
MAGE-A4 Responses 
 
Another MAGE-family antigen I employed to induce specific responses from the 
seminoma and non-seminoma samples was MAGE-A4. Patient IN21 showed a 
modest CD8+ T cell IFN-γ response of 0.145% compared to unstimulated control 
(0.073%). In contrast, no CD4+ T cell response to MAGE-A4 was detected in this 
patient. 
Patient IN14 had the greatest IFN-γ response to any MAGE antigen in our cohort 
which was against MAGE-A4. As marked by the purple triangle, upon stimulation, 
IFN-γ-producing MAGE-A4 specific CD8+ T cells were observed at a frequency 
of nearly 1 in 100 (0.96%) CD8+T cells (left panel, Fig. 6-2). Interestingly, this 
patient did not demonstrate responses to the other MAGE antigens investigated 
in this study.  
The higher percentage of IFN-γ responses in patients with non-seminomatous 
tumours was something of a surprise based on our previous report. Although, the 
higher percentage of responses in IN19 might be due to seminoma tissue 
contained within this mGCT subtype. However, patient IN14 was found to be 
diagnosed with pure embryonic carcinoma that would not contain seminomatous 




levels of MAGE-A antigens by each individual tumour is required to determine if 
responses are being evoked specifically by the tumour or normal testicular germ 
cells. 
TNF-α expression increases the sensitivity of identification of MAGE-A 
family specific T cells  
 
My studies to this time had used only IFN-γ as the cytokine readout for a peptide-
specific response. TNF-α is an additional cytokine that is produced in Th1 
immune responses and in order to increase the potential sensitivity of detection I 
next went on to examine the TNF-α response to MAGE stimulation (Fig. 6-3).  
TNF-α production was found to be a more sensitive approach to the detection of 
MAGE-specific T cells compared to IFN-γ.  In particular, cytokine responses were 
detectable in the majority of samples except in sample IN33, IN12 (seminoma 
group) and IN37 (non-seminoma) where the background production of TNF-α 
was greater than that observed following challenge by either MAGE-A1, A3 or A4 
overlapping peptides.  
In some samples, the TNF-α production seemed to be consistent with the IFN-γ 
response. For example, in IN24 the frequency of IFN-γ-producing CD8+ T cells 
was measured at 0.1% when stimulated by MAGE-A1 overlapping peptides and 
a similar increment was observed through detection of the TNF-α-specific 
immune response (left panel Fig. 6-3). Similarly, in sample IN36 the antigen-
specific IFN-γ and TNF-α cytokine responses were 3.5- and 2.3-folds higher than 




A particularly strong and TNF-α selective immune response was made following 
MAGE-A3 overlapping peptide stimulation of sample IN09. Here the frequency of 
TNF-α-producing CD8+ T cells was 0.5% above background (left panel, Fig. 6-3) 
whilst the CD4+ response showed an increment of 0.73% (right panel, Fig. 6-3). 
Interestingly, this profile was not reflected in a similar magnitude of IFN-γ 
production. 
 
Fig. 6-3. TNF-α responses of CD4+ and CD8+ T cells from patients with seminoma 
and non-seminoma tumours following stimulation with MAGE-A family peptide 
pools 
PBMC were isolated from 9 patients with seminoma and 4 patients with non-seminoma 
tumours. These were stimulated with overlapping peptide pools from MAGE-A1/A3/A4 
proteins. Cytokine-positive cells were then identified by expression of TNF-α as a 
percentage of total CD8+ (left) or CD4+ (right) T cells. 
 
The pattern of cytokine production did not correlate with a use of a specific MAGE 




response to stimulation from MAGE-A1 or MAGE-A3 but IFN-γ was only 
generated through use of the MAGE-A3 library. Likewise, CD8+ T cells in sample 
IN14 consistently responded to MAGE-A4 stimulation only with an increment of 
0.36% above background (left panel, Fig. 6-3).  
Simultaneous production of IFN-γ and TNF-α (further termed as IFN-γ/TNF-α) 
was observed most clearly in sample IN24 which demonstrated a strong CD8+ T 
cell response to stimulation with all three MAGE peptide pools (Fig. 6-4). IN14 
also demonstrated increasing frequency of IFN-γ/TNF-α-producing CD8+ T cells 
although interestingly this was only seen following MAGE-4 stimulation (Fig. 6-
4). A similar pattern of co-expression was also detected from sample IN09 in both 
the CD8+ and CD4+ T cell compartments. However, apart from these three 
samples there was no clear consistent profile of IFN-γ/TNF-α response to MAGE 




















Fig. 6-4. Examples of dual cytokine secretion of CD8+ T cells following MAGE antigen stimulation 
Flow cytometry plots showing dual secretion of TNF-α and IFN-γ in CD8+ T cells from patients IN14 and IN24. IN14 exhibited a large CD8+ 






Fig. 6-5 . Overall profile of dual IFN-γ and TNF-α production by CD4+ and CD8+ T 
cells from patients with seminoma and non-seminoma tumours following 
stimulation with MAGE-A family peptide pools 
PBMC were isolated from 9 patients with seminoma and 4 patients with non-seminoma 
tumours. These were stimulated with overlapping peptide pools from MAGE-A1/A3/A4 
proteins. Cytokine-positive cells were then identified by expression of both IFN-γ and 
TNF-α as a percentage of total CD8+ (left) or CD4+ (right) T cells. 
 
IL-2 is not produced by T cells following stimulation by MAGE-A peptides  
 
IL-2 is a critical cytokine in T cell survival and differentiation and IL-2-responsive 
T cell subsets have extremely diverse characteristics including proinflammatory 
and anti-inflammatory biological roles. Moreover, IL-2 inhibits the differentiation 
of Th17 and Tfh cells such that IL-2 acts as an important regulator of T cell lineage 
commitment. In addition, the levels of IL-2 signalling can help to define the 




lived effector cells whilst lower levels promote the differentiation of memory T 
cells (Ross & Cantrell, 2018).     
I next decided to use IL-2 production as a further marker of peptide-specific 
immune response. However, no significant IL-2+ T cell response was observed 
in any of the samples that were analysed (Fig. 6-6). Of note, donor IN41 
expressed quite high levels of spontaneous IL-2 production but these were 
suppressed following stimulation with antigen. These data indicate that IL-2 is not 
a useful marker for the detection of MAGE-specific T cells. Furthermore, this 
raises interesting questions regarding the physiological status of the MAGE-
specific T cells. Previous work from our laboratory had shown that MAGE-specific 
T cell response were not sustained following treatment for testicular cancer 
(Pearce et al, 2017). IL-2 is an important autocrine survival signal and as such 
this may go some way towards explaining why these clones do not persist into 











Fig. 6-6. IL-2 responses of CD4+ and CD8+ T cells from patients with seminoma and 
non-seminoma tumours following stimulation with MAGE-A family peptide pools 
PBMC were isolated from 9 patients with seminoma and 4 patients with non-seminoma 
tumours. These were stimulated with overlapping peptide pools from MAGE-A1/A3/A4 
proteins. Cytokine-positive cells were then identified by expression of IL-2 as a 
percentage of total CD8+ (left) or CD4+ (right) T cells. 
 
GM-CSF production can be used to identify occasional MAGE-specific T 
cell responses and is independent of Th1 cytokine responses 
 
The next cytokine that I investigated as a potential readout for MAGE-specific T 
cell response was GM-CSF. Although GM-CSF is primarily considered as a 
haemopoietic growth factor is also has a role in immune modulation. GM-CSF is 
produced by a subset of T cells following activation  (Shi et al., 2006)and may be 
associated with the simultaneous production of IFN-γ (Sheng et al., 2014). This 




believed to play a critical role to the maturation of dendritic cells (Shi et al., 2006). 
In addition to this function, GM-CSF, just recently, was reported to contribute in 
the mycrobacterial infection control. This was mediated by NKT cell subsets 
(Rothchild et al., 2017). 
The frequency of GM-CSF+ T cells that was detected after MAGE stimulation 
was relatively low compared to the profile that had been seen following TNF-α or 
IFN-γ detection (Fig. 6-7).  Moreover, we found that the GM-CSF+ T cell response 
did not   coincide with simultaneous production of TNF-α or IFN-γ. For instance 
patient IN24, whose TNF-α and IFN-γ were highly upregulated following antigen 
stimulation, did not secrete GM-CSF. No GM-CSF response was observed in 
donor IN14 following MAGE-A4 stimulation. However an interesting pattern was 
observed in donor IN09 who demonstrated a strong GM-CSF+ response within 
both the CD8+ and CD4+ T cell subsets following MAGE challenge. 
These findings show that GM-CSF is produced by a small subset of T cells 
following MAGE stimulation. However, this does not correspond to the subset 
that produces Th1 cytokines. The strong GM-CSF specific response that was 
observed in donor IN09 is of particular interest. This would represent an important 
area for future study if such T cells could be isolated and analysed in downstream 







Fig. 6-7. GM-CSF responses of CD4+ and CD8+ T cells from patients with 
seminoma and non-seminoma tumours following stimulation with MAGE-A family 
peptide pools  
PBMC were isolated from 9 patients with seminoma and 4 patients with non-seminoma 
tumours. These were stimulated with overlapping peptide pools from MAGE-A1/A3/A4 
proteins. Cytokine-positive cells were then identified by expression of GM-CSF as a 
percentage of total CD8+ (left) or CD4+ (right) T cells. 
 
CD107a upregulation identifies MAGE-A specific CD8+ T cells that fail to 
secrete inflammatory cytokine 
 
In addition to cytokine production, cytotoxic activity is also a critical determinant 
of T cell function. Therefore I next went on to examine the upregulation of surface 
CD107a expression following peptide stimulation. CD107a expression is a 
reliable marker for cell degranulation which is a prerequisite of T cell mediated 
cytotoxicity. As such it is used widely as a surrogate for target cell killing which is 




CD107a expression was observed on CD8+ T cells from patients IN24, IN29 and 
IN12 within the group of patients with seminoma. These values were measured 
at 0.42%, 1.7% and 1.7% respectively after MAGE-A1 stimulation although there 
were also considerable baseline responses at 0.25%, 1.4% and 1.1%, (left panel, 
Fig. 6-8).  
The strongest CD107a response was observed in donor IN14 who was within the 
nonseminoma group. Here the CD8+ T cell subset exhibited a near 2% increase 
in surface CD107a expression following stimulation with MAGE-A4, with very little 
spontaneous upregulation (Fig. 6-8). Interestingly, we also detected a large 
CD107a response of around 1.75% and 1% from baseline from CD8+ and CD4+ 
T cells, respectively, from patient IN19. As such this suggests that there are both 









Fig. 6-8 . CD107a surface upregulation on CD4+ and CD8+ T cells from patients 
with seminoma and non-seminoma tumours following stimulation with MAGE-A 
family peptide pools. 
PBMC were isolated from 9 patients with seminoma and 4 patients with non-seminoma 
tumours. These were stimulated with overlapping peptide pools from MAGE-A1/A3/A4 
proteins. Cells undergoing degranulation were identified by surface expression of 
CD107a and data represented as a percentage of total CD8+ (left) or CD4+ (right) T 
cells. 
 
Combined, these data suggest that CD107a expression is able to detect MAGE-
A responsive T cells and that this occurs independently of the profile of 
inflammatory cytokine production. This indicates that there is only a modest 
overlap in the profile of T cells that can secrete Th1 cytokines and also 
degranulate in response to challenge with MAGE peptides. For example, MAGE-
A4 specific T cells within donor IN14 augmented both TFN-α (Fig. 6-3) and IFN-




this are not entirely clear but may reflect T cells that have differentiated to exhibit 
differential functional capacity or potentially cells with relative ‘exhaustion’ of the 
cytotoxic or cytokine response.  
Combinatorial assessment with multiple cytokines and CD107a expression 
represents a potentially optimal approach to detect MAGE-specific T cell 
responses 
 
In order to provide an overview of my results I next went on to compare and 
contrast the profile of cytokine response and CD107a expression within the 
overall cohort (Table 6-1). A qualitative assessment was used to define the 
cytokine responses as either weak (+, response between 0.02% to 0.1%) or 
strong (+++, response greater than 0.1%). Each response was presented as 
normalized response where the frequency of each assessed cytokine post 
stimulation was deducted by that of pre stimulation (considered as background 
noise). 
Overall these data show considerable heterogeneity in the different functional 
responses both within and between donors. Unfortunately I was not able to 
isolate, expand and define the potential MAGE-specific responses that I detected 
with this approach and so it must be considered that not all of these responses 
represent genuine MAGE-specific T cells. The development of approaches that 
permit this confirmation represents an important ambition for future studies.  
Overall my results do demonstrate the need to examine multiple cytokine 
responses, as well as a degranulation marker, in order to optimize identification 




cytokine production (IFN-γ and TNF-α-production) and degranulation (CD107a) 
as discussed above.  
One of the most convincing responses were observed in donors IN19 where IFN-
γ producing CD8+ T cell increased up to 4 times from baseline following MAGE-
A3 stimulation whilst the TNF-α response to MAGE-A1 was also strong. MAGE-
A1 overlapping peptides also generated a markedly high induction of CD107a 
expression, although spontaneous degranulation was also high in this patient. A 
more consistent effector response was found in IN14 whereby CD8+ T cells 
increased production of both IFN-γ and TNF-α, as well as upregulation of CD107a 
following MAGE-A4 stimulation. This suggests that immune responses 
demonstrated by IN14 was more robust and as such this would represent a strong 
candidate for subsequent isolation of MAGE-A4-specific CD8+ T cells in 





Table 6-1. Qualitative Measurement of T cell responsiveness against MAGE-A overlapping peptides 
Samples ID T Cell subset  
MAGE-A1 MAGE-A3 MAGE-A4 




CD8  +++  +++  +++  +++  +    +++        +++   
CD4                         
IN36 
CD8  +++        +  +    +        + 
CD4  +        +               
IN29 
CD8  +      +++  +      +++  +       
CD4  +        +               
IN32 
CD8  +        +        +       
CD4                         
IN33 
CD8                         
CD4  +        +        +       
IN09 
CD8      +                   
CD4  +++        +++        +++    +   
IN21 
CD8                +         
CD4  +                +       
IN12 
CD8        +++        +++         
CD4                         
IN41 
CD8  +                       
CD4  +++                +++       
IN08 
CD8  +  +                     
CD4    +              +       
IN37 
CD8    +++                +++     
CD4        +        +++         
IN19 
CD8  +++  +++    +++    +++      +++  +     
CD4  +++  +  +  +++    +        +     
IN14 
CD8                  +++  +++  +++  +++ 
CD4                         




Despite the relatively small size of my patient cohort (n=13) I was able to detect 
potential CTAg-specific T cell responses in the peripheral blood of TGCT patients 
using ICC staining. The three most convincing such responses, based on TNF-α, 
IFN-γ or CD107a expression, were observed in one seminoma patient (IN24) and 
two patients with nonseminomatous diseases (IN14 and IN19). The frequency of 
MAGE-specific responses is similar to that observed in previous work from our 
laboratory (Pearce et al, 2017) but the distribution of the positive results in relation 
to the tissue diagnosis was unexpected as we have previously shown that antigen-
specific T cells were focussed within patients with seminoma. This is discussed more 
fully below. 
Attempts to define the minimal immunodominant peptide epitope within the 
MAGE protein 
 
The work above had shown that MAGE-specific T cell responses were indeed 
present in a subset of patients with TCGT and that intracellular cytokine secretion 
was an appreciate methodology for their detection. However, this response was 
detected against a peptide library that covered the whole of the MAGE protein. As 
such it does not give any indication as to the nature of the peptide epitope that 
underlies this response. As such, in the final part of my thesis I attempted to define 
this minimal epitope using T cells from donors IN14 and IN24 that represented 
nonseminomatous TGCT (pure embryonal carcinoma) and seminoma, respectively. 
This work involved defining the HLA allele status of these donors and then the use 




that share the same short sequence. The ultimate aim was then to define the minimal 
9-mers peptide sequence within the 15-mers peptide that were used in the 
overlapping pool.   
Assessment of the HLA genotype of donors IN14 and IN24 
Immunogenic peptide epitopes are presented to αβ-T cells bound to an HLA class I 
or class II molecule. Different HLA alleles present a different spectrum of peptide 
sequences and as such knowledge of the patients HLA sequence can help to localist 
the potential sequence of the immunogenic epitope. As such , in initial work I 
undertook analysis to define the HLA alleles within donors IN14 an d IN24, HLA 
typing was performed by PCR using primer sequences adopted from Bunce, et al 
that detect common HLA class I and II alleles (Bunce et al., 1995) .  
As many as 14 different alleles were examined including: A1 (Lane 1); A2 (Lane 2); 
A3 (Lane 3); A11, 6601 (Lane 4); A1,11, 36,80, 3402 (Lane 5); B7 (including B703) 
B8101(Lane 6); B8 (Lane 7); B35, 18, 78, 1522 (Lane 8); B44 (Lane 9); DR7 (Lane 
10); DR53 (Lane 11); DQ6 (Lane 12); CW7 (Lane 13) and CW0702,0703 (Lane 14). 
The results from this HLA typing approach are shown in Fig. 9. From these data 
patient IN14 was defined as expressing HLA-A11, HLA-B44, HLA-B35 and HLA-
DR53 whilst IN24 was typed as HLA-A1, HLA-A2, HLA-DR7 and HLA-DQ6 positive. 
This information could then be used in the potential definition of individual peptide 






Fig. 6-9. HLA genotyping of patients IN14 and IN24 
PCR products were separated by gel electrophoresis on a 1.5% agarose gel. HLA-DRB1 
primers were added to each sample as a positive PCR control (+Co). A 100bp DNA ladder 
was used (far left lane) to confirm size of positive bands.  
 
Screening of MAGE peptide libraries to define minimal MAGE epitopes  
 
I next sought to define the T cell epitopes that were responsible for the positive T 
cell response in donors IN14 and IN24 following stimulation with the complete MAGE 
library. In order to do this we obtained two pools of 15-mers long peptides that 
spanned the entire sequences of MAGE-A1 and MAGE-A4. Unfortunately 3 peptides 
(p38, p50 and p51) were found not to dissolve in DMSO and so were excluded from 
the assay (Table 6-2).  
The peptides were then utilized in a peptide matrix on 96 well plates such that each 
peptide was contained within two different pools. Through this approach it should 




present in two different pools, both of which should exhibit a functional response 
(Table 6-2 and Table 6-3). 
Table 6-2. MAGE-A1 Peptide Matrix Pool (IN24) 
 
Table 6-3. MAGE-A4 Peptide Matrix Pool (IN14) 
 
In order to obtain the best possible chance to detect a positive response, and also 
to ‘cross-check’ individual assays, I elected to use intracellular cytokine detection of 
IFN-γ and TNF-α, as well as CD107a expression, as functional assays for response. 
As shown in Fig. 6-10, relatively weak IFN-γ responses were observed following 
stimulation of PBMC from the donor.  
MAGE-A1
1 2 3 4 5 6 7 8 9
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2 10 11 12 13 14 15 16 17 18 B
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The results of assessment from donor IN14, who was diagnosed with pure 
embryonal carcinoma, were somewhat difficult to interpret. Peptide pool M elicited 
strong functional responses across all three readouts. However, there was no clear 
positive signal from any other pool that shared individual peptides. Peptide pool B 
did increase production of TNF-α as well as CD107a expression and therefore I 
elected to target peptide 14, the only ‘shared’ peptide between these pools, as 
potentially containing the minimal epitope.  Unfortunately, the use of the peptide 
matrix with PBMC from donor IN24, a patient with seminoma, did not reveal any 
specific responses and so I was unable to pursue this further.  
Peptide 14 has an amino acid sequence of EVPAAESAGPPQSPQ. Most peptide 
epitopes that bind HLA class I are 9 amino acids long and therefore I synthesized 7 
individual peptide epitopes that commenced at sequential positions in the 15mer. 
For instance, peptide 1 was EVPAAESAG, peptide 2 was VPAAESAGP and so on.  
I then used individual 9-mer peptides in a TNF-α intracellular assay to assess 
responses for against each peptide (Fig. 6-11).  
 
PBMCs from IN14 were stimulated with peptide-pulsed lymphoblastic cells lines 
(LCLs) generated from two healthy donors who each shared two alleles with the 
patient: HLA-A24/B44 and HLA-A11/B35. These were chosen as the patient has 
been ‘tissue typed’ as expressing all four of these alleles. The strongest response 
was observed following challenge with peptide 5 when it was presented by HLA-




CD8+ pool. The same peptide does not induce cytokine production when pulsed 
onto HLA-A11+/B35+ LCL. 
I next went on to try to define if the peptide 5 sequence of AESAGPPQS would be 
predicted to bind to HLA-A24 or HLA-B44. Use of NetMHC 
(www.cbs.dtu.dk/services/NetMHC/Pan) revealed that it should indeed bind to HLA-
B44 although with relatively weak binding. As such AESAGPPQS seems 
encouraging for further investigation and may represent a novel peptide epitope from 
MAGE that is restricted by HLA-B44. Unfortunately at this stage the number of donor 
PBMCs that I had available for further analysis was limited and I was unable to 





Fig. 6-10. Cytokine and degranulation levels following stimulation with MAGE-A peptide matrices 
Responses to peptide matrices using IFN-y (left), TNF-a (middle) and CD107a (right) as readouts following stimulation with 





Fig. 6-11. TNF-α production by PBMC from donor IN14 against 7 individual 9-mer 
peptides derived from the peptide 14’s 15-mers 
PBMC were stimulated with LCL that had been pulsed with individual 9-mer peptides. 
The TNF-α production in response to stimulation was then measured after 4 hours.  
Missing bars indicate no observable TNF-α productions after the T cellsbeing 
stimulated with corresponding 9-mer peptides.  
 
Next, we attempted to determine the HLA-I restriction of peptide 
EEVPAAESAGPQSPQ using polyclonal T cell lines we generated. As previously 
determined, IN14 was HLA-A11, A24, B35, B44 positive, and so we used allogeneic 
LCLs from healthy donors whose HLA-I shared one common allele. The HLA types 
of our donors were identified as: 
1. A2/A11/B7/B8 : shared A11 allele in common 
2. A3/A23/B7/B44: shared B44 allele in common 
3. A2/A68/B35/B49: shared B35 allele in common 
4. A1/A24/B52/B61: share A24 allele in common 




We peptide-pulsed the LCLs with peptide pools consisted of seven peptides (each 
was 9-mers long) spanning the entire amino acid sequence of 
EEVPAAESAGPQSPQ. Those peptides were: EEVPAAESA, EVPAAESAG, 
VPAAESAGP, PAAESAGPQ, AAESAGPQS, AESAGPQSP and ESAGPQSPQ. 
Each group of peptide pulsed LCLs were irradiated at 40Gy, and used to stimulate 
polyclonal T cells specific (assumingly) for the 15-mer peptide to help determine 
what particular epitope the CD8+ T cells responded to. We then did restimulations 
with peptide-pulsed LCL at day 7 and day 14. At day 21, we performed limiting 
dilution T cell cloning of these polyclonal populations. Cloning was performed with 
irradiated peptide pulsed LCL A allele group (bearing LCL A11 and LCL A24) and 
LCL B allele group (bearing LCLB35 and B44). We plated cells at 3 and 0.3 cells 
per well. After second restimulation and we observed some potential growth, and 
therefore perfomed IFN-γ ELISA to measure the clones’ capability of secreting IFN-
γ following stimulation with the seven 9-mers peptides spanning 
EEVPAAESAGPQSPQ.  
We detected a single response whereby clone 5 in the 0.3 cells/well cloning assay 
secreted IFN-γ above baseline with the A1/A11 LCLs (Fig. 6-12). Unfortunately, I 
attempted to bulk up clone 5 to further elucidate the exact peptide to which the clone 







Fig. 6-12. Peptide screening to determine HLA-restriction of CD8+ T cell clones from 
IN14. 
T cell clones were tested for peptide specificity following peptide-pulsed LCL co-culture, and 
IFN-γ was measured by ELISA. Peptide pulsed LCLs with matched HLA-A alleles (top) and 
HLA-B alleles (bottom) were tested in clones derived from limiting dilution cloning with 0.3 














The first three chapters in my thesis have focused on characterization of the 
peripheral T cell immune response in patients with testicular cancer.  This had 
shown evidence of low level T cell activation within this patient sub-group, 
supporting the previous work from our group that this group of patients do indeed 
show T cell responses against cancer testis antigens.  However, in my final chapter 
I elected to undertake a further screening of these peripheral blood samples against 
CTAG family members. 
A major focus of my chapter was to investigate the potential use of the intracellular 
cytokine assay (ICC) for the detection of peptide responses as our previous work 
had used ELISPOT analysis.  Despite the high sensitivity that renders it as a widely 
used tool to assess tumour specific and vaccine-induced T cell responses, ELISPOT 
has its own disadvantages.  Firstly, it is difficult to distinguish between CD4 and CD8 
T cell responses. Secondly, it does not allow for the simultaneous cytokines 
production measurement. And the third disadvantage is that the T cells used for this 
method are not recoverable thus limits the scope of analysis. With a main 
consideration to overcome those mentioned disadvantage, I performed intracellular 
cytokine (ICC) staining and used appropriate age-matched controls.  This approach 
is also a sensitive one. In addition to the sensitivity, it allows delineation of CD4 and 
CD8 subset as well as additional phenotypic sub-groups. However, like the 
ELISPOT does, it does have some weaknesses. Firstly, it necessitates a lot more 




running cells are at least 500,000, which is 5 folds higher than that required to 
conduct ELISPOT analysis. Secondly, it does not allow isolation of viable cells for 
downstream cloning. However, cytokine capture systems are available to 
compensate this limitation. The capture system basically functions to  facilitate the 
selection of cytokine-positive T cells for subsequent cell culture.   My aim was to use 
these systems subsequent to detection of positive responses. 
My results show that cytokine secretion is indeed a viable approach to detect CTAg-
specific T cells.  I chose to focus on the MAGE protein family, as this has previously 
been shown as an immunodominant CTAg family member within this setting.  In 
particular three overlapping peptide pools spanning the whole sequences of  MAGE-
A1, A3 and A4 were used.  These proteins are highly homologous but do show 
reasonable amino acid variation. 
Although compared to ELISPOT, ICC does not seem to be highly sensitive, but I 
was able to detect responses in around one third of donors.  In order to increase 
sensitivity, I detected a range of cytokines following stimulation but, not surprisingly, 
the Th1 cytokines of IFN-γ and TNF-α were found to be the most sensitive in this 
regard.  Indeed, TNF-α appeared to identify a greater proportion of responsive T 
cells compared to (IFN-γ) and this phenotype has been observed in other situations.  
It was noteworthy that no IL-2-positive T cells were identified and this may be 
relevant to our previous observation that MAGE-specific T cells are not long lived.  






Since cytokine secretion is only one functional assay, I also therefore included 
CD107a expression in my analysis.  This is considered to be a robust correlation for 
cytotoxic function.  The correlation between cytokine and CD107a responses was 
moderate but it did allow me to identify 2 donors in which consistent and convincing 
responses were detected across both of these functional readouts.  I then went on 
to assess these donors in more detail. 
The ultimate aim of my work in this chapter was to identify novel peptide epitopes 
from within the MAGE proteins. Several MAGE immunodominant epitopes have 
been characterized but these are restricted by individual HLA alleles and are 
therefore limited in their potential within immunotherapy trials (Yao et al, 2016; Yu 
et al, 2012).  One of the ambitions of my research group has been to use patients 
with testicular cancer as ‘reservoir’ for mapping MAGE-specific T cells and I 
therefore undertook a more detailed assessment of the epitope-specificity of these 
two donors.  I utilized a well described technique of peptide matrices to try and 
identify the dominant 15-mer peptides.  This appeared to work in one of the donors 
(IN14) whose responses toward MAGE-A4 was deemed to be specific and 
consistent. After conducting the peptide matrices test where the entire sequence of 
MAGE-A4 was chopped off into 15-mers with 11 amino acid overlapped, I Fig.d out 
that 15-mers with a sequence of EVPAAESAGPPQSPQ was able to stimulate 
cytokine productions at relatively higher frequency compared to that seen for other 
peptide pools. I then chose to breakdown this 15-mer peptide into individual 9 amino 
acid peptide fragments in order to assess the specific peptide that gave the optimal 




HLA-B44 or HLA-A24.  In silico analysis showed that it did exhibit moderate binding 
affinity for HLA-B44 and therefore this peptide does represent a genuine new 
candidate as a MAGE-A4 specific peptide.   
In future studies it will be important to evaluate peptide specific responses patients 
who express the HLA-B44 allele at various stages of disease, including presentation 
with testicular cancer, and these results are awaited.  One proviso is that not all 
epitopes presented by HLA class I are 9 amino acid long and peptide lengths 
between 8 and even 12 amino acids are certainly potential possibilities.  However, I 
was unable to perform further assessment of this possibility due to the expense of 
generating such a large pool of peptides and a limiting number of patient’s PBMCs.  
Indeed, one of the lessons learned from this chapter was that the number of T cells 





CHAPTER VII. DISCUSSION 
 
Testicular cancer is the most common tumour amongst young men and is increasing 
in incidence within the Western world.  The aetiological factors that drive this 
disorder are currently unclear although the condition is more common in men of 
Caucasian origin. The clinical outcomes for men with testicular cancer are now 
excellent. This is partly because the surgical removal of the tumour (orchidectomy) 
offers a definitive approach to eliminating the primary tumour, but primarily reflects 
the fact that systemic chemotherapy, most notably with cisplatin, is highly effective 
at eradicating metastatic disease in almost all cases. Indeed, the clinical response 
to chemotherapy can be so effective and rapid that the development of necrotic 
lymph nodes can be a clinical concern and a number of men have to undergo 
surgical removal of lymph nodes.  As such, testicular cancer cannot really be 
considered as a ‘tumour of unmet need’ as the number of men who succumb to this 
diagnosis is now thankfully quite small.  However, it should be noted that not all 
patients do achieve a functional cure hence further comprehensive studies are 
required to reach the cure rate of 100%. In this context, research within my thesis 
has a direct relevance to seeking to improve the outcome of men with this disease. 
However, the major premise of my thesis is that the immune response can play an 
important role in controlling and curing testicular cancer following treatment 
intervention.  At first sight this may appear contradictory, as chemotherapy is clearly 
the agent that mediates highly efficient responses.  However, it is known that 




and the development of tumour-specific immune responses.  Indeed, the use of low 
dose cyclophosphamide as an approach to reduce the number of T regulatory cells 
is an area of very active interest. In addition to the remarkable efficacy of 
chemotherapy in testicular cancer, the anatomical location of this tumour also 
implicates tumour-specific immunity as potentially playing an important role.  In 
particular, the testis is defined as an immune privileged site where, by the Sertoli 
cells-built blood-testis barrier (BTB), the immune system is strictly not allowed to 
invade adluminal compartment of seminiferous tubules, thus the process of 
spermatogenesis is protected. Once this blood-testis barrier is broken, as in the 
case of local tumour, the immune system can enter this compartment and would be 
predicted to generate local immune responses against sperm-based antigens.  The 
systemic dissemination of the response may then be able to control metastatic 
disease, following priming initiated by chemotherapy. 
There remain very few studies of immune response to testicular cancer at the 
current time.  Histological analysis of the immune infiltrate in seminoma has shown 
that T cells dominate the infiltrate and that this is positively correlated with clinical 
outcome.  Indeed, a major ambition of our research group is to interrogate the 
immune response locally within the primary tumour site. I contributed to the 
collection and storage of tumour infiltrated lymphocytes (TILs) from patients with 
primary testicular tumours. However, I did not carry on further with these TILs since: 
1) the samples were uncommon,-- being that the type of TGCT which was teratoma 




2) the samples were of interest yet given at a tiny sizes. This remains an important 
area for future study. 
Previous work from the research group had shown an abnormal profile for the T cell 
repertoire in patients with testicular cancer (Pearce et al, 2017). In particular, an 
increased proportion of memory cells is seen in the blood of patients at the time of 
diagnosis but this disturbance in the memory/naïve ratio was corrected over the first 
3-6 months of treatment.  As such, this indicated a clear disturbance of the T cell 
repertoire at the time of disease presentation.  The first 3 chapters in my thesis were 
undertaken on blood samples from patients with seminoma and non-seminomatus 
tumours and interrogated a range of features. 
At the phenotypic level, there were no major disturbances in the T cell subsets within 
the patient group.  This included cells of the innate arm of the immune system 
including γδ-T cells, MAIT and NKT cells.  To some extent this was not surprising, 
as this phenotypic profile has a very broad scale analysis of the repertoire and more 
finely detailed assessments should be performed in the future.  Our laboratory has 
now obtained access to a CyTOF machine that allows simultaneous assessment of 
35 proteins on the surface of cells.  If I were able to continue my study I would be 
very interested to assess T cell repertoire in patients using this sort of technology.  
Perhaps the most interesting results were seen with NK cells within the periphery 
where there was a clear increase in the number of CD56dim cells that had lost or 
downregulated CD16 expression compared to CD56bright subset. The differentiation 
process of NK cells is not entirely clear and so it is difficult to ascertain if this 




Again, in future studies I would like to assess the phenotype of this population in 
more detail and ideally assess its transcriptional basis using approaches such as 
RNA sequencing.  Furthermore, assessment of the cytotoxic capacity of these cells, 
and the relative impairment of antibody dependent cell cytotoxicity, will be important 
to assess. The relative avidity of the peptide-specific cells would also be valuable to 
assess.  
A somewhat unexpected finding was the increased proportion of B cells in the blood 
of patients at the time of diagnosis.  Unfortunately, a limitation of these studies had 
been the fact that I did not have access to the absolute count of lymphocytes within 
the blood of patients and healthy donors.  As such, I could not compare the absolute 
level of discreet cell subsets. Notwithstanding this limitation, this profile does 
suggest a relative concentration of B cells within  the total CD45+ lymphocytes.  
Somewhat surprisingly, these cells lack CD27 expression and therefore are likely to 
reflect B cells as not undergone antigen experience. There have been very few 
studies of the humoral immune response to testicular cancer and my results suggest 
that this could be a fruitful area of future investigation. One potential explanation is 
that T cells may have trafficked into the tumour and therefore increased the 
proportion of B cells in the periphery. 
In order to undertake more detailed phenotypic analysis I then went on to assess 
the expression of five dominant checkpoint proteins on T cells from the patient blood 
samples.  Checkpoint proteins, most notably PD-1 and CTLA-4, are probably the 
most intensively investigated proteins in biology at the current time. Monoclonal 




patients even those whose cancers are metastased. It has relatively recently been 
shown that combination antibody therapy against PD-1 and CTLA-4 works more 
efficaciously compared to antibody blockade directed at either PD-1 or CTLA-4 
alone.  Despite this, the mechanisms by which this happens have not been totally 
unveiled.  It is thought that antibody blockade releases the ‘brake’ on partially 
exhausted T cells and reinforce them  to facilitates tumour cell recognition and lysis.  
However, PD-1 and PD-L1 are also expressed on many other subsets of the 
immune system and changes in immune regulation may also be equally important. 
My findings show that PD-1 and TIGIT were expressed on a substantial minority of 
T cells within the peripheral blood.  However, this was matched by a similar 
proportion within the control group hence the initial assumption that PD-1 and TIGIT, 
either as single or dual expression, might identify ‘exhausted’ T cells is not valid in 
this case.  This emphasizes the need to include appropriate age matched control 
samples in all studies, such as I was able to obtain.  In contrast, more interesting 
results were found from the use of antibodies against LAG-3, Tim-3 and CTLA-4.  
Here, small populations of checkpoint-positive cells were observed within the patient 
group alone.  This is quite an exciting finding and it suggests that small numbers of 
T cell have undergone relative phenotypic exhaustion within the periphery and these 
may represent an important target for future analysis.  Indeed, if time allows, I would 
like to isolate these cells and assess their properties in substantial detail. 
The third analysis within peripheral blood was to undertake a functional assessment 
of T cells. Here I chose to use a strong mitogenic stimulus, in the form of 




the periphery.  In fact, my findings showed that T cells from patients with testicular 
cancer retained a broad profile of cytokine responses, which were comparable with 
those from healthy donors. This is compatible with the natural history of testicular 
cancer in which there is no clear susceptibility to infection within the patient sub-
group.  One surprising, and slightly unexpected, finding within my analysis was the 
value of assessing the profile of spontaneous cytokine secretion prior to addition of 
the mitogen.  Many investigators elect not to undertake this approach as it is quite 
costly and increases the amount of data analysis.  However, I was able to show that 
low levels of spontaneous production of cytokines such as IL-21 and IL-17, which 
are pro-inflammatory cytokines, as well as IL-10 which represents an anti-
inflammatory cytokine, were observed selectively within T cells from the patient 
group.  This may again represent a small population of activated T cells within the 
patient’s blood and these certainly are possible candidates for representing tumour-
specific T cell responses. 
In my final data chapter I was anxious to undertake functional analysis of T cells 
against cancer testis antigen (CTAg) libraries. Seeking to build on previous data 
from our laboratory, I elected to use intracellular cytokine analysis. The idea here is 
that this would allow me to undertake more detailed phenotypic analysis of the 
nature of the T cells that were responding to MAGE stimulation. Furthermore, I was 
hoping that a cytokine secretion assay could be incorporated such that we would 





My data did show that this approach was feasible for the detection of MAGE-specific 
responses although the sensitivity was probably somewhat lower than what had 
been observed with ELISPOT analysis.  Nevertheless, when I combined TNF-α and 
IFN-γ detection together with a CD107a expression analysis, I was able to detect 
what appeared to be robust MAGE-specific responses within 2 donors.  Interestingly 
I was able to see responses in patients with tumours other than seminoma, 
specifically pure embryonic carcinoma, whereas this had previously not been the 
case in our previous report.  One of the major ambitions of the laboratory is to isolate 
new immunogenic epitopes from the MAGE family of proteins which could 
potentially be used as immunogens or vaccines in patients with malignant disease.  
Utilizing the bloods taken from one of my patients, I was indeed able to identify 
candidate peptide from a patient with B44 and I would be delighted if this were able 
to be used in the future as such a product. 
There is a range of future studies that I would like to address if I were able to 
continue this work: 
1.  What is the nature of the T cell immune response to cancer testis antigens? 
 
My own work, and that of the previous report, has shown strong and tantalising 
evidence of T cell responses against cancer/testis antigens and MAGE-A to be 
specific.  However, it is proving to be challenging to isolate functional clones for a 
detailed characterization.  Some of the data from my work suggests that these T 
cells may be short-lived and may perhaps not produce IL-2, a cytokine that would 




approaches to isolate these cells.  Potential opportunities include direct isolation 
from peripheral blood using cytokine secretion followed by sequencing of the T cell 
receptor of responding cells.  This T cell receptor might then be used in a transgenic 
T cell for the treatment of patients during adoptive therapy.  The longevity of these 
cells could potentially also be mapped in vivo by the use of T cell receptor finger 
printing.  It is possible that their half-life is much smaller than would be seen against, 
for instance, virus-specific T cells. 
2. The nature of the humoral response to cancer testis antigens   
 
As discussed above, my work revealed increased proportions of B cells in the blood 
of patients with testicular cancer.  I would now propose to gain evidence of humoral 
responses in the TGCT by assessing their sera. This could feasibly be performed 
with either immunohistochemistry or immunofluorescence staining of testicular 
sections.  Many advances have been made in the isolation of antigen -specific B 
cells with reconstruction of monoclonal B cell products.  These may potentially have 
a use in future immunotherapy. 
3. Does the immune response against cancer testis antigens have any role in 
the control of testicular cancer? 
 
Even if cancer testis antigen-specific T cells are indeed generated in patients with 
testicular cancer, it is not currently clear if they play in role in eradication of the 
disease.  Indeed, one feature that needs to be addressed is that HLA class I is not 
thought to be expressed on tumour cells.  As such, these will not be expected to 




still play an important role, potentially through bystander effects within the micro-
environment. 
4. Can tumour-specific T cell responses that develop within testicular cancer 
be used in other patients with malignant disease? 
 
Interestingly, although testicular cancer tumour cells may not express HLA class I, 
the immune responses that are generated from T cells following invasion into the 
testis may potentially be of benefit in the treatment of other tumours.  In particular, 
if cancer testis antigens are shared on other somatic tumour cells, where HLA class 
I is retained, such T cells, or the potential transfer of genes-encoding their T cell 
receptor, could be a potential future immunotherapy of interest. This is something 
that the group is developing and it will be interesting to follow this over the next few 
years. 
Overall, I have gained substantial experience in investigating this fascinating 
tumour.  Although not a cancer of clinical unmet need, I do believe it represents a 
disease of immunological unmet need and that the key to understanding why this 
tumour responds so well to therapy may offer hope for those patients who have 
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APPENDIX 1. List of 15-mer-containing peptides pools spanning the whole 











MAGE-A1 p1 MSLEQRSLHCKPEEA  
MAGE-A1 p2 QRSLHCKPEEALEAQ  
MAGE-A1 p3 HCKPEEALEAQQEAL  
MAGE-A1 p4 EEALEAQQEALGLVC  
MAGE-A1 p5 EAQQEALGLVCVQAA  
MAGE-A1 p6 EALGLVCVQAATSSS  
MAGE-A1 p7 LVCVQAATSSSSPLV  
MAGE-A1 p8 QAATSSSSPLVLGTL  
MAGE-A1 p9 SSSSPLVLGTLEEVP  
MAGE-A1 p10 PLVLGTLEEVPTAGS  
MAGE-A1 p11 GTLEEVPTAGSTDPP  
MAGE-A1 p12 EVPTAGSTDPPQSPQ  
MAGE-A1 p13 AGSTDPPQSPQGASA  
MAGE-A1 p14 DPPQSPQGASAFPTT  
MAGE-A1 p15 SPQGASAFPTTINFT  
MAGE-A1 p16 ASAFPTTINFTRQRQ  
MAGE-A1 p17 PTTINFTRQRQPSEG  
MAGE-A1 p18 NFTRQRQPSEGSSSR  
MAGE-A1 p19 QRQPSEGSSSREEEG  
MAGE-A1 p20 SEGSSSREEEGPSTS  
MAGE-A1 p21 SSREEEGPSTSCILE  
MAGE-A1 p22 EEGPSTSCILESLFR  
MAGE-A1 p23 STSCILESLFRAVIT  
MAGE-A1 p24 ILESLFRAVITKKVA  
MAGE-A1 p25 LFRAVITKKVADLVG  
MAGE-A1 p26 VITKKVADLVGFLLL  




MAGE-A1 p28 LVGFLLLKYRAREPV  
MAGE-A1 p29 LLLKYRAREPVTKAE  
MAGE-A1 p30 YRAREPVTKAEMLES  
MAGE-A1 p31 EPVTKAEMLESVIKN  
MAGE-A1 p32 KAEMLESVIKNYKHC  
MAGE-A1 p33 LESVIKNYKHCFPEI  
MAGE-A1 p34 IKNYKHCFPEIFGKA  
MAGE-A1 p35 KHCFPEIFGKASESL  
MAGE-A1 p36 PEIFGKASESLQLVF  
MAGE-A1 p37 GKASESLQLVFGIDV  
MAGE-A1 p38 ESLQLVFGIDVKEAD  
MAGE-A1 p39 LVFGIDVKEADPTGH  
MAGE-A1 p40 IDVKEADPTGHSYVL  
MAGE-A1 p41 EADPTGHSYVLVTCL  
MAGE-A1 p42 TGHSYVLVTCLGLSY  
MAGE-A1 p43 YVLVTCLGLSYDGLL  
MAGE-A1 p44 TCLGLSYDGLLGDNQ  
MAGE-A1 p45 LSYDGLLGDNQIMPK  
MAGE-A1 p46 GLLGDNQIMPKTGFL  
MAGE-A1 p47 DNQIMPKTGFLIIVL  
MAGE-A1 p48 MPKTGFLIIVLVMIA  
MAGE-A1 p49 GFLIIVLVMIAMEGG  
MAGE-A1 p50 IVLVMIAMEGGHAPE  
MAGE-A1 p51 MIAMEGGHAPEEEIW  
MAGE-A1 p52 EGGHAPEEEIWEELS  
MAGE-A1 p53 APEEEIWEELSVMEV  
MAGE-A1 p54 EIWEELSVMEVYDGR  
MAGE-A1 p55 ELSVMEVYDGREHSA  
MAGE-A1 p56 MEVYDGREHSAYGEP  
MAGE-A1 p57 DGREHSAYGEPRKLL  
MAGE-A1 p58 HSAYGEPRKLLTQDL  
MAGE-A1 p59 GEPRKLLTQDLVQEK  
MAGE-A1 p60 KLLTQDLVQEKYLEY  
MAGE-A1 p61 QDLVQEKYLEYRQVP  
MAGE-A1 p62 QEKYLEYRQVPDSDP  
MAGE-A1 p63 LEYRQVPDSDPARYE  
MAGE-A1 p64 QVPDSDPARYEFLWG  
MAGE-A1 p65 SDPARYEFLWGPRAL  
MAGE-A1 p66 RYEFLWGPRALAETS  




MAGE-A1 p68 RALAETSYVKVLEYV  
MAGE-A1 p69 ETSYVKVLEYVIKVS  
MAGE-A1 p70 VKVLEYVIKVSARVR  
MAGE-A1 p71 EYVIKVSARVRFFFP  
MAGE-A1 p72 KVSARVRFFFPSLRE  
MAGE-A1 p73 RVRFFFPSLREAALR  
MAGE-A1 p74 FFPSLREAALREEEE  
MAGE-A1 p75 LREAALREEEEGV  
 
APPENDIX 2. List of 15-mer-containing peptides pools spanning the whole 









MAGE-A3 p1 MPLEQRSQHCKPEEG  
MAGE-A3 p2 QRSQHCKPEEGLEAR  
MAGE-A3 p3 HCKPEEGLEARGEAL  
MAGE-A3 p4 EEGLEARGEALGLVG  
MAGE-A3 p5 EARGEALGLVGAQAP  
MAGE-A3 p6 EALGLVGAQAPATEE  
MAGE-A3 p7 LVGAQAPATEEQEAA  
MAGE-A3 p8 QAPATEEQEAASSSS  
MAGE-A3 p9 TEEQEAASSSSTLVE  
MAGE-A3 p10 EAASSSSTLVEVTLG  
MAGE-A3 p11 SSSTLVEVTLGEVPA  
MAGE-A3 p12 LVEVTLGEVPAAESP  
MAGE-A3 p13 TLGEVPAAESPDPPQ  
MAGE-A3 p14 VPAAESPDPPQSPQG  
MAGE-A3 p15 ESPDPPQSPQGASSL  
MAGE-A3 p16 PPQSPQGASSLPTTM  
MAGE-A3 p17 PQGASSLPTTMNYPL  
MAGE-A3 p18 SSLPTTMNYPLWSQS  
MAGE-A3 p19 TTMNYPLWSQSYEDS  
MAGE-A3 p20 YPLWSQSYEDSSNQE  




MAGE-A3 p22 EDSSNQEEEGPSTFP  
MAGE-A3 p23 NQEEEGPSTFPDLES  
MAGE-A3 p24 EGPSTFPDLESEFQA  
MAGE-A3 p25 TFPDLESEFQAALSR  
MAGE-A3 p26 LESEFQAALSRKVAE  
MAGE-A3 p27 FQAALSRKVAELVHF  
MAGE-A3 p28 LSRKVAELVHFLLLK  
MAGE-A3 p29 VAELVHFLLLKYRAR  
MAGE-A3 p30 VHFLLLKYRAREPVT  
MAGE-A3 p31 LLKYRAREPVTKAEM  
MAGE-A3 p32 RAREPVTKAEMLGSV  
MAGE-A3 p33 PVTKAEMLGSVVGNW  
MAGE-A3 p34 AEMLGSVVGNWQYFF  
MAGE-A3 p35 GSVVGNWQYFFPVIF  
MAGE-A3 p36 GNWQYFFPVIFSKAS  
MAGE-A3 p37 YFFPVIFSKASSSLQ  
MAGE-A3 p38 VIFSKASSSLQLVFG  
MAGE-A3 p39 KASSSLQLVFGIELM  
MAGE-A3 p40 SLQLVFGIELMEVDP  
MAGE-A3 p41 VFGIELMEVDPIGHL  
MAGE-A3 p42 ELMEVDPIGHLYIFA  
MAGE-A3 p43 VDPIGHLYIFATCLG  
MAGE-A3 p44 GHLYIFATCLGLSYD  
MAGE-A3 p45 IFATCLGLSYDGLLG  
MAGE-A3 p46 CLGLSYDGLLGDNQI  
MAGE-A3 p47 SYDGLLGDNQIMPKA  
MAGE-A3 p48 LLGDNQIMPKAGLLI  
MAGE-A3 p49 NQIMPKAGLLIIVLA  
MAGE-A3 p50 PKAGLLIIVLAIIAR  
MAGE-A3 p51 LLIIVLAIIAREGDC  
MAGE-A3 p52 VLAIIAREGDCAPEE  
MAGE-A3 p53 IAREGDCAPEEKIWE  
MAGE-A3 p54 GDCAPEEKIWEELSV  
MAGE-A3 p55 PEEKIWEELSVLEVF  
MAGE-A3 p56 IWEELSVLEVFEGRE  
MAGE-A3 p57 LSVLEVFEGREDSIL  
MAGE-A3 p58 EVFEGREDSILGDPK  
MAGE-A3 p59 GREDSILGDPKKLLT  
MAGE-A3 p60 SILGDPKKLLTQHFV  




MAGE-A3 p62 LLTQHFVQENYLEYR  
MAGE-A3 p63 HFVQENYLEYRQVPG  
MAGE-A3 p64 ENYLEYRQVPGSDPA  
MAGE-A3 p65 EYRQVPGSDPACYEF  
MAGE-A3 p66 VPGSDPACYEFLWGP  
MAGE-A3 p67 DPACYEFLWGPRALV  
MAGE-A3 p68 YEFLWGPRALVETSY  
MAGE-A3 p69 WGPRALVETSYVKVL  
MAGE-A3 p70 ALVETSYVKVLHHMV  
MAGE-A3 p71 TSYVKVLHHMVKISG  
MAGE-A3 p72 KVLHHMVKISGGPHI  
MAGE-A3 p73 HMVKISGGPHISYPP  
MAGE-A3 p74 ISGGPHISYPPLHEW  
MAGE-A3 p75 PHISYPPLHEWVLRE  
MAGE-A3 p76 YPPLHEWVLREGEE  
 
APPENDIX 3. List of 15-mer-containing peptides pools spanning the whole 









MAGE-A4 p1 MSSEQKSQHCKPEEG 
MAGE-A4 p2 QKSQHCKPEEGVEAQ 
MAGE-A4 p3 HCKPEEGVEAQEEAL 
MAGE-A4 p4 EEGVEAQEEALGLVG 
MAGE-A4 p5 EAQEEALGLVGAQAP 
MAGE-A4 p6 EALGLVGAQAPTTEE 
MAGE-A4 p7 LVGAQAPTTEEQEAA 
MAGE-A4 p8 QAPTTEEQEAAVSSS 
MAGE-A4 p9 TEEQEAAVSSSSPLV  
MAGE-A4 p10 EAAVSSSSPLVPGTL  
MAGE-A4 p11 SSSSPLVPGTLEEVP  
MAGE-A4 p12 PLVPGTLEEVPAAES  
MAGE-A4 p13 GTLEEVPAAESAGPP 




MAGE-A4 p15 AESAGPPQSPQGASA 
MAGE-A4 p16 GPPQSPQGASALPTT 
MAGE-A4 p17 SPQGASALPTTISFT 
MAGE-A4 p18 ASALPTTISFTCWRQ 
MAGE-A4 p19 PTTISFTCWRQPNEG 
MAGE-A4 p20 SFTCWRQPNEGSSSQ 
MAGE-A4 p21 WRQPNEGSSSQEEEG 
MAGE-A4 p22 NEGSSSQEEEGPSTS 
MAGE-A4 p23 SSQEEEGPSTSPDAE 
MAGE-A4 p24 EEGPSTSPDAESLFR 
MAGE-A4 p25 STSPDAESLFREALS 
MAGE-A4 p26 DAESLFREALSNKVD 
MAGE-A4 p27 LFREALSNKVDELAH 
MAGE-A4 p28 ALSNKVDELAHFLLR 
MAGE-A4 p29 KVDELAHFLLRKYRA 
MAGE-A4 p30 LAHFLLRKYRAKELV 
MAGE-A4 p31 LLRKYRAKELVTKAE  
MAGE-A4 p32 YRAKELVTKAEMLER  
MAGE-A4 p33 ELVTKAEMLERVIKN  
MAGE-A4 p34 KAEMLERVIKNYKRC  
MAGE-A4 p35 LERVIKNYKRCFPVI 
MAGE-A4 p36 IKNYKRCFPVIFGKA 
MAGE-A4 p37 KRCFPVIFGKASESL 
MAGE-A4 p38 PVIFGKASESLKMIF 
MAGE-A4 p39 GKASESLKMIFGIDV 
MAGE-A4 p40 ESLKMIFGIDVKEVD 
MAGE-A4 p41 MIFGIDVKEVDPASN 
MAGE-A4 p42 IDVKEVDPASNTYTL 
MAGE-A4 p43 EVDPASNTYTLVTCL 
MAGE-A4 p44 ASNTYTLVTCLGLSY 
MAGE-A4 p45 YTLVTCLGLSYDGLL 
MAGE-A4 p46 TCLGLSYDGLLGNNQ 
MAGE-A4 p47 LSYDGLLGNNQIFPK 
MAGE-A4 p48 GLLGNNQIFPKTGLL 
MAGE-A4 p49 NNQIFPKTGLLIIVL 
MAGE-A4 p50 FPKTGLLIIVLGTIA 
MAGE-A4 p51 GLLIIVLGTIAMEGD 
MAGE-A4 p52 IVLGTIAMEGDSASE 
MAGE-A4 p53 TIAMEGDSASEEEIW 




MAGE-A4 p55 ASEEEIWEELGVMGV 
MAGE-A4 p56 EIWEELGVMGVYDGR 
MAGE-A4 p57 ELGVMGVYDGREHTV 
MAGE-A4 p58 MGVYDGREHTVYGEP 
MAGE-A4 p59 DGREHTVYGEPRKLL 
MAGE-A4 p60 HTVYGEPRKLLTQDW 
MAGE-A4 p61 GEPRKLLTQDWVQEN 
MAGE-A4 p62 KLLTQDWVQENYLEY 
MAGE-A4 p63 QDWVQENYLEYRQVP 
MAGE-A4 p64 QENYLEYRQVPGSNP 
MAGE-A4 p65 LEYRQVPGSNPARYE 
MAGE-A4 p66 QVPGSNPARYEFLWG 
MAGE-A4 p67 SNPARYEFLWGPRAL 
MAGE-A4 p68 RYEFLWGPRALAETS 
MAGE-A4 p69 LWGPRALAETSYVKV 
MAGE-A4 p70 RALAETSYVKVLEHV  
MAGE-A4 p71 ETSYVKVLEHVVRVN  
MAGE-A4 p72 VKVLEHVVRVNARVR 
MAGE-A4 p73 EHVVRVNARVRIAYP  
MAGE-A4 p74 RVNARVRIAYPSLRE 
MAGE-A4 p75 RVRIAYPSLREAALL  
MAGE-A4 p76 AYPSLREAALLEEEE  
MAGE-A4 p77 LREAALLEEEEGV  
 
